Compounds that inhibit EGFR and ALK and prevent their degradation

Compounds targeting EGFR and ALK for degradation via the ubiquitin-proteasome pathway address drug resistance, enhancing treatment efficacy in non-small cell lung cancer and other cancers.

JP7593998B2Active Publication Date: 2024-12-03BEIJING TIDE PHARMACEUTICAL CO LTD
View PDF 15 Cites 0 Cited by

Patent Information

Application Number
JP2022512798
Authority / Receiving Office
JP · JP
Patent Type
Patents
Current Assignee / Owner
Priority Date
2020-08-20
Filing Date
2020-08-21
Publication Date
2024-12-03
Estimated Expiration
2040-08-21

AI Technical Summary

Technical Problem

Current EGFR and ALK inhibitors face challenges with drug resistance, particularly the EGFR C797S mutation and ALK drug resistance mutations, necessitating the development of new inhibitors to effectively treat non-small cell lung cancer.

Method used

Development of compounds that inhibit EGFR and ALK and induce their degradation through the ubiquitin-proteasome pathway, offering a novel approach to cancer treatment.

Benefits of technology

These compounds provide a potential solution to overcome drug resistance by targeting EGFR and ALK, potentially enhancing treatment efficacy in non-small cell lung cancer and other cancers mediated by these kinases.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure 0007593998000379
    Figure 0007593998000379
  • Figure 0007593998000380
    Figure 0007593998000380
  • Figure 0007593998000001
    Figure 0007593998000001
Patent Text Reader

Abstract

The present invention relates to novel compounds represented by general formula (X), which are capable of inhibiting EGFR and ALK or inducing their degradation, and pharmaceutical compositions containing the compounds, which are used in the treatment of diseases associated with EGFR and ALK kinases, such as cancer. The present invention also relates to the preparation and use of the compounds. TIFF2022546375000291.tif5574
Need to check novelty before this filing date? Find Prior Art

Description

[Technical Field]

[0001] The present invention relates to the pharmaceutical field, more particularly, the present invention provides compounds that can inhibit EGFR and ALK or induce the degradation of EGFR and ALK, as well as methods for preparing and applications thereof. [Background technology]

[0002] Lung cancer is one of the most common malignancies. In 2018, there were 2.1 million new cases of lung cancer worldwide, accounting for 11.6% of all new tumor cases, and 1.8 million deaths, accounting for 18.4% of all tumor deaths. Among these, non-small cell lung cancer (NSCLC) accounted for 80%-85% of the total number of lung cancers. Epithelial growth factor receptor (EGFR) and anaplastic lymphoma kinase (ALK) are common driver genes of NSCLC.

[0003] Approximately 50% of Chinese patients with non-small cell lung cancer (NSCLC) and 11–16% of patients in Western countries harbor EGFR mutations. The most common mutations are exon 19 deletions (del E746-A750) and exon 21 L858R point mutations, accounting for approximately 90% of all EGFR mutations. EGFR small molecule inhibitors are the standard first-line treatment for EGFR-mutated NSCLC and have been widely used in the field of lung cancer treatment. They bind to EGFR competitively with endogenous ligands, inhibiting tyrosine kinase activation and further blocking the EGFR signaling pathway, inhibiting tumor cell proliferation and metastasis, and promoting a series of biological effects, including tumor cell apoptosis.

[0004] The first-generation EGFR small molecule inhibitors, gefitinib and erlotinib, have been used to treat advanced non-small cell lung cancer (NSCLC) with activating EGFR mutations (L858R, del E746-A750). However, patients can develop drug resistance after 10–12 months of treatment with gefitinib and erlotinib. More than 50% of these drug-resistant patients experience secondary EGFR T790M mutations. Afatinib, a second-generation irreversible EGFR inhibitor, is effective in patients with advanced NSCLC with activating EGFR mutations (L858R, del E746-A750), but cannot resolve clinical drug resistance due to the EGFR T790M mutation. Furthermore, afatinib lacks selectivity over wild-type EGFR and is associated with significant toxicity. Osimertinib, a third-generation irreversible inhibitor, overcomes EGFR T790M drug resistance and effectively treats patients with advanced non-small cell lung cancer (NSCLC) with drug resistance due to the EGFR T790M mutation. Osimertinib has shown great success in the clinical treatment of EGFR T790M-associated NSCLC. However, some treated patients develop drug resistance again after 9–14 months of treatment (Nature Medicine, 2015, 21(6), 560–562). Research has shown that 22% of patients with drug resistance experience osimertinib resistance due to the EGFR C797S mutation (JAMA Oncol. 2018;4(11):1527–1534). The EGFR C797S mutation mutates cysteine ​​797 to serine, preventing osimertinib from covalently binding to EGFR, ultimately resulting in drug resistance. Currently, there is no single effective EGFR inhibitor for EGFR C797S in clinical practice, so the development of a new generation of EGFR inhibitors to meet clinical treatment needs is an urgent issue to be resolved.

[0005] Anaplastic lymphoma kinase (ALK) is a receptor tyrosine protein kinase. ALK gene rearrangements, point mutations, and gene amplification can cause carcinogenesis in the body. ALK rearrangements are potent oncogenic drivers, with echinoderm microtubule-associated protein-like 4 (EML4-ALK) and nucleophosmin (NPM-ALK) being the most common types. ALK gene rearrangements cause ALK phosphorylation before dimerization, resulting in the ALK fusion protein remaining activated and activating downstream pathways, leading to excessive cell proliferation and tumor development. In non-small cell lung cancer (NSCLC), 3–7% of patients have ALK gene rearrangements. Small molecule inhibitors targeting ALK are widely used in clinical settings. They bind to ALK competitively with endogenous ligands, inhibiting tyrosine kinase activation and further blocking the ALK signaling pathway, inhibiting a series of biological effects, including tumor cell proliferation and metastasis. Currently, commercially available ALK inhibitors include crizotinib, ceritinib, alectinib, brigatinib, and lorlatinib. However, drug resistance to these inhibitors is inevitable. Common ALK drug resistance mutations include L1196M, G1269A, S1206Y, G1202R, C1156Y, and L1198F. Therefore, the development of new ALK inhibitors is crucial to meet clinical treatment needs.

[0006] The ubiquitin-proteasome system (UPS) is a multi-component intracellular protein degradation system involved in important physiological and biochemical processes, such as cell growth and differentiation, DNA replication and repair, cellular metabolism, and immune response. Protein degradation mediated by the ubiquitin-proteasome pathway is an important mechanism for regulating the levels and function of intracellular proteins and plays a key role in maintaining protein homeostasis in vivo. Inducing degradation of EGFR or ALK via the intracellular ubiquitin-proteasome pathway offers a novel approach to cancer treatment.

[0007] The present invention provides compounds capable of inhibiting EGFR and ALK and / or inducing the degradation of EGFR and ALK, as well as methods for their preparation and applications. Summary of the Invention

[0008] In one aspect, the present invention provides a compound represented by general formula (X), its pharmaceutically acceptable salts, enantiomers, diastereomers, racemates, solvates, hydrates, polymorphs, prodrugs or isotopic variants, and mixtures thereof, for use in the treatment of diseases such as cancer mediated by EGFR and / or ALK kinases. [ka] however, Ring A may be selected from the group consisting of the following, optionally substituted groups: 3-7 Cycloalkyl, 4-8 membered heterocyclyl, C 6-10 aryl, or 5-10 membered heteroaryl, wherein the substituents are selected from the group consisting of halogen, —CN, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 3-7 Cycloalkyl, 4-8 membered heterocyclyl, -P(O)(C 1-6 alkyl)2, -P(O)(C 2-6 alkenyl)2, -OC1-6 Alkyl, -OC 1-6 Haloalkyl, -OC 2-6 Alkenyl, -OC 3-7 Cycloalkyl, -O-4 to 8-membered heterocyclyl, -NH-C 1-6 Alkyl, -NH-C 2-6 Alkenyl, -NH-C 3-7 Cycloalkyl, -NH-4-8 membered heterocyclyl, -C(O)-C 1-6 Alkyl, -C(O)-C 2-6 Alkenyl, -C(O)-C 3-7 Cycloalkyl, -C(O)-4 to 8-membered heterocyclyl, -S(O)2-C 1-6 Alkyl, -S(O)2-C 2-6 Alkenyl, -S(O)2-C 3-7 Cycloalkyl, -S(O)2-4 to 8-membered heterocyclyl, -NHC(O)-C 1-6 Alkyl, -NHC(O)-C 2-6 Alkenyl, -NHC(O)-C 3-7 Cycloalkyl, -NHC(O)-4 to 8-membered heterocyclyl, -NHS(O)2-C 1-6 Alkyl, -NHS(O)2-C 2-6 Alkenyl, -NHS(O)2-C 3-7 cycloalkyl, or -NHS(O)2- 4- to 8-membered heterocyclyl; Ring B is [ka] selected from the group consisting of: [ka] represents a single or double bond; [ka] indicates that the attachment site to the remainder of the molecule may be located at any available site on the ring; Z1 is one or two R Z1or Z1 is absent, Z4 is connected to a C atom of the aromatic ring to which Z1 is bonded, Z2 or Z3, and Z2 and the C atom of the aromatic ring bonded to Z1 are each R W or Z1, Z2 and Z3 are all absent, so that Z4 is connected to one of the C atoms of the aromatic ring to which Z1 or Z3 is bonded, and another C atom of the aromatic ring is bonded to R W Connected to; Z2 is one or two R Z2 is an O, S, N or C atom optionally substituted with; Z3 is one or two R Z3 is an O, S, N or C atom optionally substituted with [ka] represents a double bond, Z2 is an N or C atom and Z3 is an N or C atom; Z4 is N or CR Z4 and; Z5 is N or CR Z5 and; R a , R b and R c are independently H, halogen, -(CH2) 0-5 -OR'', -(CH2) 0-5 -NR''R''', C 1-6 Alkyl, or C 1-6 haloalkyl; or R a , R b and the C atoms to which they are attached, C=O, C 3-7 forms a cycloalkyl or a 4- to 8-membered heterocyclyl; or R a , R c and the C atoms to which they are attached, C 3-7 forms a cycloalkyl or a 4- to 8-membered heterocyclyl; or R a and R c forms chemical bonds; R N1 is H, C 1-6 Alkyl, or C1-6 haloalkyl, preferably H; R Z1 is absent or contains H, CN, halogen, -(CH2) 0-5 -OR'', -(CH2) 0-5 -NR''R''', C 1-6 Alkyl, C 1-6 Haloalkyl, -(CH2) 0-5 -C 3-7 Cycloalkyl, or -(CH2) 0-5 -4 to 8-membered heterocyclyl; or two R Z1 Together with Z1, C=O, C 3-7 forming a cycloalkyl or a 4- to 8-membered heterocyclyl; R Z2 is absent or contains H, CN, halogen, -(CH2) 0-5 -OR'', -(CH2) 0-5 -NR''R''', C 1-6 Alkyl, C 1-6 Haloalkyl, -(CH2) 0-5 -C 3-7 Cycloalkyl, or -(CH2) 0-5 -4 to 8-membered heterocyclyl; or two R Z2 Together with Z2, C=O, C 3-7 forming a cycloalkyl or a 4- to 8-membered heterocyclyl; R Z3 is absent or contains H, CN, halogen, -(CH2) 0-5 -OR'', -(CH2) 0-5 -NR''R''', C 1-6 Alkyl, C 1-6 Haloalkyl, -(CH2) 0-5 -C 3-7 Cycloalkyl, or -(CH2) 0-5 -4 to 8-membered heterocyclyl; or two R Z3 Together with Z3, C=O, C 3-7 forming a cycloalkyl or a 4- to 8-membered heterocyclyl; R Z4 is H, CN, halogen, -(CH2) 0-5 -OR'', -(CH2) 0-5-NR''R''', C 1-6 Alkyl, or C 1-6 is haloalkyl; R Z5 is H, CN, halogen, -(CH2) 0-5 -OR'', -(CH2) 0-5 -NR''R''', C 1-6 Alkyl, C 1-6 Haloalkyl, -(CH2) 0-5 -C 3-7 Cycloalkyl, or -(CH2) 0-5 -4 to 8-membered heterocyclyl; Alternatively, the ring in which Z4 is located is absent; where R w is H, CN, halogen, -(CH2) 0-5 -OR'', -(CH2) 0-5 -NR''R'''', -C 1-6 Alkyl, C 1-6 Haloalkyl, -(CH2) 0-5 -C 3-7 Cycloalkyl, -(CH2) 0-5 -4-8 membered heterocyclyl, C 2-6 Alkenyl, C 2-6 Alkynyl, -(CH2) 0-5 -C 3-10 Halocycloalkyl, -(CH2) 0-5 -C 6-10 Aryl, or -(CH2) 0-5 - 5 to 14 membered heteroaryl; R'' is H, C 1-6 Alkyl, C 1-6 Haloalkyl, or -(CH2) 0-5 -C 3-7 is cycloalkyl; R''' is H, C 1-6 Alkyl, or C 1-6 is haloalkyl; L1 is a chemical bond, -O-, -S(O) p -, -S(O)(=NR * )-, -NR # -, -CR # R # '-, -C a R #R # '-C b R # R # '-, -N=S(O)(R * )-, or -S(O)(R * )=N-; L2 is a chemical bond, -O-, -S(O) p -, -S(O)(=NR * )-, -NR # -, -CR # R # '-, -C a R # R # '-C b R # R # '-, -N=S(O)(R * )-, or -S(O)(R * )=N-; where C a R # R # ' or C b R # R # ' is O, S(O) p , S(O)(=NR * ) or NR # can be replaced by C a R # R # ' or C b R # R # ' is O, S or NR # If replaced by C a R # R # ' or C b R # R # ', another one is S(O) q can be replaced by; E is independently a chemical bond, -C c R # R # '-C d R # R # '-C e R # R# ', [ka] [ka] selected from the group consisting of: where C c R # R # ', C d R # R # ' or C e R # R # ' or C c R # R # ' and C e R # R # 'Both O and S(O) p , S(O)(=NR * ) or NR # can be replaced by C c R # R # ', C d R # R # ' or C e R # R # ' is O, S or NR # If replaced by one or two adjacent Cs, c R # R # ', C d R # R # ' or C e R # R # ', S(O) q can be replaced by; Alternatively, two E units may be -CH2CH2OCH2CH2-, -OCH2CH2CH2CH2-, -CH2CH2CH2CH2O-, [ka] can be formed; where: [ka] represents the attachment site to L1 or L2; H1 and H2 are N or C atoms, H3 is O, S, N or C atom, and H1 and H3, H2 and H3 are not heteroatoms at the same time; H4 and H5 are N or C atoms; H6, H7, H8 and H9 are C or N atoms; p is 0, 1 or 2; q is 1 or 2; R * is H, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Cycloalkyl, C 3-10 Halocycloalkyl, 3-10 membered heterocyclyl, C 6-10 aryl, or 5- to 14-membered heteroaryl; R # H, halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Cycloalkyl, C 3-10 Halocycloalkyl, 3-10 membered heterocyclyl, C 6-10 aryl, or 5- to 14-membered heteroaryl; R # ' is H, halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Cycloalkyl, C 3-10 Halocycloalkyl, 3-10 membered heterocyclyl, C 6-10 aryl, or 5- to 14-membered heteroaryl; Alternatively, R on the adjacent atom # and R #can form chemical bonds, R on adjacent atoms # ' and R # ' can form chemical bonds; Alternatively, R on the same or different atoms # and R # ' is both, =O, C 3-7 Cycloalkyl, 4-8 membered heterocyclyl, C 6-10 aryl or 5-6 membered heteroaryl, wherein C 3-7 Cycloalkyl, 4-8 membered heterocyclyl, C 6-10 Aryl or 5-6 membered heteroaryl is R x and may be substituted with the above-mentioned R x H, CN, halogens, C 1-6 Alkyl, or C 1-6 is haloalkyl; m is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; R s1 is H, CN, halogen, -(CH2) 0-5 -OR'', -(CH2) 0-5 -NR''R''', C 1-6 Alkyl, C 1-6 Haloalkyl, -(CH2) 0-5 -4-8 membered heterocyclyl, C 2-6 Alkenyl, C 2-6 Alkynyl, -(CH2) 0-5 -C 3-7 Cycloalkyl, -(CH2) 0-5 -C 3-10 Halocycloalkyl, -(CH2) 0-5 -C 6-10 Aryl, -(CH2) 0-5 -5 to 14-membered heteroaryl, -C(O)R W , -S(O)R W or -S(O)2R W selected from the group consisting of: s1 is 0, 1, 2 or 3; R' is H, -C(O)-C 1-6 Alkyl, -C(O)-C 1-6 Haloalkyl, -C(O)-C 2-6 Alkenyl, or -C(O)-C6-10 aryl; L is a chemical bond, -O- or -NR-; where R is H or C 1-6 is alkyl; Z is -N= or -C(R4)=; T is a chemical bond, C 2-6 selected from the group consisting of heteroalkylene, 4- to 12-membered heterocyclylene, or 5- to 6-membered heterocyclylene substituted with 5- to 6-membered heterocyclylene; R1 is H, halogen, cyano, C 1-6 Alkyl, C 3-7 Cycloalkyl, 4-8 membered heterocyclyl, C 1-6 Haloalkyl, C 2-6 Alkenyl or C 2-6 alkynyl; Alternatively, when L is -NR-, R and R together with the atoms to which they are attached form an optionally substituted 5- to 6-membered heterocyclyl, wherein the substituents are halogen, oxo, C 1-6 Alkyl, C 1-6 Haloalkyl, mono- or polysubstituted with halogen C 6-10 aryl; R2 is H, halogen, hydroxyl, amino, C 1-6 Alkyl, or C 1-6 is haloalkyl; or R1 and R2 together with the atoms to which they are attached form a 5- to 6-membered heterocyclyl or a 5- to 6-membered heteroaryl; R3 is H, -OC 1-6 Alkyl or -OC 1-6 haloalkyl; R4 is H, halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, -NHC(O)-C 1-6 Alkyl, or -NHC(O)-C 2-6 alkenyl; When each of said groups is H or an H-containing group, one or more of said H atoms may be replaced with a D atom; The alkyl, alkylene, haloalkyl, alkenyl, alkynyl, cycloalkyl, halocycloalkyl, heterocyclyl, aryl, heteroaryl, or groups containing OH, NH, NH, CH, CH, CH in L, E, L, and T may each be one, two, three, or more R s and may be substituted with the above-mentioned R s are independently halogen, hydroxyl, amino, cyano, nitro, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Cycloalkyl, C 3-10 Halocycloalkyl, 3-10 membered heterocyclyl, C 6-10 Aryl, 5-14 membered heteroaryl, C 6-12 Aralkyl, -OR a’ , -OC(O)R a’ , -C(O)R a’ , -C(O)OR a’ , -C(O)NR a’ R b’ , -S(O) n R a’ , -S(O) n OR a’ , -S(O) n NR a’ R b’ , -NR a’ R b’ , -NR a’ C(O)R b’ , -NR a’ -C(O)OR b’ , -NR a’ -S(O) n -R b’ , -NR a’ C(O)NR a’ R b’ , -C 1-6 Alkylene-R a’ , -C 1-6 Alkylene-OR a’ , -C 1-6 Alkylene-OC(O)Ra’ , -C 1-6 Alkylene-C(O)OR a’ , -C 1-6 Alkylene-S(O) n R a’ , -C 1-6 Alkylene-S(O) n OR a’ , -C 1-6 Alkylene-OC(O)NR a’ R b’ , -C 1-6 Alkylene-C(O)NR a’ R b’ , -C 1-6 Alkylene-NR a’ -C(O)NR a’ R b’ , -C 1-6 Alkylene-OS(O) n R a’ , -C 1-6 Alkylene-S(O) n NR a’ R b’ , -C 1-6 Alkylene-NR a’ -S(O) n NR a’ R b’ , -C 1-6 Alkylene-NR a’ R b’ and -OC 1-6 Alkylene-NR a’ R b’ wherein the substituent R s The hydroxyl, amino, alkyl, alkylene, cycloalkyl, heterocyclyl, aryl, heteroaryl and aralkyl mentioned above are independently selected from halogen, OH, amino, cyano, nitro, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkyl hydroxyl, C 3-6 Cycloalkyl, 3-10 membered heterocyclyl, C 6-10 Aryl, 5-14 membered heteroaryl and C 6-12 may be further substituted with one, two, three or more substituents selected from the group consisting of aralkyl; n is independently 1 or 2; R a’ and R b’ are independently H, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkyl-O-, C 1-6 Alkyl-S-, C 3-10 Cycloalkyl, 3-10 membered heterocyclyl, C 6-10 Aryl, 5-14 membered heteroaryl and C 6-12 aralkyl.

[0009] In another aspect, the present invention provides a pharmaceutical composition comprising a compound of the present invention and, optionally, a pharmaceutically acceptable excipient.

[0010] In another aspect, the present invention provides a pharmaceutical composition comprising a compound of the present invention, a pharmaceutically acceptable excipient, and further another therapeutic agent.

[0011] In another aspect, the invention provides a kit comprising a compound of the invention, another therapeutic agent, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

[0012] In another aspect, the present invention provides the use of a compound of the present invention in the preparation of a medicament for treating and / or preventing a disease mediated by EGFR and / or ALK kinases.

[0013] In another aspect, the present invention provides a method for treating and / or preventing a disease mediated by EGFR and / or ALK kinase in a subject, comprising administering to the subject a compound of the present invention or a composition of the present invention.

[0014] In another aspect, the present invention provides a compound of the present invention or a composition of the present invention for use in treating and / or preventing a disease mediated by EGFR and / or ALK kinase.

[0015] In certain embodiments, diseases treated by the present invention include cancers such as, for example, ovarian cancer, cervical cancer, colorectal cancer, breast cancer, pancreatic cancer, glioma, glioblastoma, melanoma, prostate cancer, leukemia, lymphoma, non-Hodgkin's lymphoma, gastric cancer, lung cancer, hepatocellular carcinoma, stomach cancer, gastrointestinal stromal tumor (GIST), thyroid cancer, cholangiocarcinoma, endometrial cancer, kidney cancer, anaplastic large cell lymphoma, acute myeloid leukemia (AML), multiple myeloma, melanoma, mesothelioma, and the like.

[0016] Other objects and advantages of the present invention will become apparent to those skilled in the art from the following specific embodiments, examples, and claims.

[0017] definition chemistry definition Specific functional groups and chemical term definitions are explained in more detail below.

[0018] When a numerical range is recited, it includes each value and subrange within the range. For example, "C 1-6 "Alkyl group" refers to C1, C2, C3, C4, C5, C6, C 1-6 , C 1-5 , C 1-4 , C 1-3 , C 1-2 , C 2-6 , C 2-5 , C 2-4 , C 2-3 , C 3-6 , C 3-5 , C 3-4 , C 4-6 , C 4-5 , C 5-6 Contains an alkyl group.

[0019] "C 1-6 An "alkyl group" refers to a linear or branched saturated hydrocarbon group having 1 to 6 carbon atoms. 1-4 Alkyl groups are preferred. 1-6Examples of alkyl groups include methyl (C1), ethyl (C2), n-propyl (C3), isopropyl (C3), n-butyl (C4), tert-butyl (C4), sec-butyl (C4), iso-butyl (C4), n-pentyl (C5), 3-pentanyl (C5), amyl (C5), neopentyl (C5), 3-methyl-2-butanyl (C5), tertiary amyl (C5), and n-hexyl (C6). 1-6 The term "alkyl group" includes heteroalkyl groups in which one or more (e.g., 1, 2, 3, or 4) carbon atoms are replaced with a heteroatom (e.g., oxygen, sulfur, nitrogen, boron, silicon, phosphorus). An alkyl group can be substituted with one or more substituents, e.g., 1 to 5 substituents, 1 to 3 substituents, or 1 substituent. Common abbreviations for alkyl include Me(-CH), Et(-CHCH), iPr(-CH(CH)), nPr(-CHCHCH), n-Bu(-CHCHCHCHCH), or i-Bu(-CHCH(CH)).

[0020] "C 2-6 An "alkenyl group" refers to a straight or branched chain hydrocarbon group having 2 to 6 carbon atoms and at least one carbon-carbon double bond. In some embodiments, C 2-4 Alkenyl groups are preferred. 2-6 Examples of alkenyl groups include ethenyl (C2), 1-propenyl (C3), 2-propenyl (C3), 1-butenyl (C4), 2-butenyl (C4), butadienyl (C4), pentenyl (C5), pentadienyl (C5), hexenyl (C6), and the like. 2-6 The term "alkenyl group" includes heteroalkenyl in which one or more (e.g., 1, 2, 3, or 4) carbon atoms are replaced by a heteroatom (e.g., oxygen, sulfur, nitrogen, boron, silicon, phosphorus). Alkenyl groups may be substituted with one or more substituents, for example, 1 to 5 substituents, 1 to 3 substituents, or 1 substituent.

[0021] "C 2-6An "alkynyl group" refers to a straight or branched chain hydrocarbon group having 2 to 6 carbon atoms, at least one carbon-carbon triple bond, and optionally one or more carbon-carbon double bonds. In some embodiments, C 2-4 Alkynyl groups are preferred. 2-6 Examples of alkynyl groups include, but are not limited to, ethynyl (C2), 1-propynyl (C3), 2-propynyl (C3), 1-butynyl (C4), 2-butynyl (C4), pentynyl (C5), hexynyl (C6), and the like. 2-6 The term "alkynyl group" includes heteroalkynyl in which one or more (e.g., 1, 2, 3, or 4) carbon atoms are replaced with a heteroatom (e.g., oxygen, sulfur, nitrogen, boron, silicon, phosphorus). The alkynyl may be substituted with one or more substituents, for example, 1 to 5 substituents, 1 to 3 substituents, or 1 substituent.

[0022] "C 1-6 Alkylene, C 2-6 Alkenylene or C 2-6 Alkynylene refers to a group having a C 1-6 Alkyl, C 2-6 Alkenyl or C 2-6 It refers to the divalent group "alkynyl."

[0023] "C 1-6 "Alkylene" is C 1-6 It refers to a divalent group formed by removing another hydrogen from an alkyl group, and may be substituted or unsubstituted. 1-4Alkylene is particularly preferred. Unsubstituted alkylene includes, but is not limited to, methylene (-CH-), ethylene (-CHCH-), propylene (-CHCHCH-), butylene (-CHCHCHCHCH-), pentylene (-CHCHCHCHCHCH-), hexylene (-CHCHCHCHCHCHCH-), and the like. Typical substituted alkylenes include, for example, substituted methylene (-CH(CH)-, -C(CH)-), substituted ethylene (-CH(CH)CH-, -CHCH(CH)-, -C(CH)CH-, -CHC(CH)-). 2- ), alkylene substituted with one or more alkyl (methyl) groups such as substituted propylene (-CH(CH3)CH2CH2-, -CH2CH(CH3)CH2-, -CH2CH2CH(CH3)-, -C(CH3)2CH2CH2-, -CH2C(CH3)2CH2-, -CH2CH2C(CH3)2-).

[0024] "C 2-6 Alkenylene" is C 2-6 It refers to a divalent group formed by removing another hydrogen from alkenyl, and may be substituted or unsubstituted. 2-4 Alkenylene is particularly preferred. Exemplary unsubstituted alkenylene groups include, but are not limited to, ethenylene (-CH=CH-) and propenylene (e.g., -CH=CHCH-, -CH-CH=CH-). Exemplary substituted alkenylene groups include, for example, alkenylene substituted with one or more alkyl groups, including, but not limited to, substituted ethenylene (-C(CH)=CH-, -CH=C(CH)-), substituted propenylene (-C(CH)=CHCH-, -CH=C(CH)CH-, -CH=CHCH(CH)-, -CH=CHC(CH)-, -CH(CH)-CH=CH-, -C(CH)-CH=CH-, -CH-C(CH)=CH-, -CH-CH=C(CH)-).

[0025] "C 2-6 "Alkynylene" is C 2-6It refers to a divalent group formed by removing one hydrogen from an alkynyl, and may be substituted or unsubstituted. 2-4 Alkynylene is particularly preferred. Exemplary alkynylene groups include, but are not limited to, ethynylene (-C≡C-), substituted or unsubstituted propynylene (-C≡CCH2-), and the like.

[0026] "C 1-6 "Heteroalkyl" refers to a C 1-6 C refers to an alkyl group that further comprises one or more (e.g., 1, 2, 3, or 4) heteroatoms (e.g., oxygen, sulfur, nitrogen, boron, silicon, phosphorus) in the parent carbon chain, where one or more heteroatoms are located between adjacent carbon atoms in the parent carbon chain and / or one or more heteroatoms are located between a carbon atom and the parent molecule, i.e., between the attachment points. 1-6 The point of attachment between the heteroalkyl and the parent molecule can be at a carbon atom or a heteroatom.

[0027] "C 2-6 "Heteroalkylene" means C 1-6 A heteroalkyl group is a divalent group formed by removing another hydrogen from a heteroalkyl group, and may be substituted or unsubstituted. 1-6 The attachment points of the heteroalkylene may be two carbon atoms, two heteroatoms, or one carbon atom and one heteroatom.

[0028] "Halo" or "halogen" refers to fluorine (F), chlorine (Cl), bromine (Br) and iodine (I).

[0029] Therefore, "C 1-6 Haloalkyl refers to any of the above "C" groups substituted with one or more halogen groups. 1-6 In some embodiments, C 1-4 Haloalkyl is particularly preferred, C 1-2Haloalkyl is more preferred. Exemplary haloalkyl groups include, but are not limited to, -CF, -CHF, -CHFCHF, -CHCHF, -CFCF, -CCl, -CHCl, -CHCl, 2,2,2-trifluoro-1,1-dimethyl-ethyl, and the like. Haloalkyl may be substituted at any available bonding position with, for example, 1 to 5 substituents, 1 to 3 substituents, or 1 substituent.

[0030] "C 3-10 A "cycloalkyl group" refers to a non-aromatic cyclic hydrocarbon group having 3 to 10 ring carbon atoms and 0 heteroatoms. In some embodiments, C 3-7 Cycloalkyl groups and C 3-6 Cycloalkyl groups are particularly preferred, C 5-6 Cycloalkyl groups are more preferred. Cycloalkyl groups further include ring systems in which the cycloalkyl ring is fused to one or more aryl or heteroaryl groups, where the point of attachment is on the cycloalkyl ring, and in such cases, the number of carbon atoms still refers to the number of carbon atoms in the cycloalkyl system. Exemplary cycloalkyl groups include, but are not limited to, cyclopropyl (C3), cyclopropenyl (C3), cyclobutyl (C4), cyclobutenyl (C4), cyclopentyl (C5), cyclopentenyl (C5), cyclohexyl (C6), cyclohexenyl (C6), cyclohexadienyl (C6), cycloheptyl (C7), cycloheptenyl (C7), cycloheptadienyl (C7), cycloheptatrienyl (C7), and the like. The cycloalkyl group may be substituted with one or more substituents, e.g., 1 to 5 substituents, 1 to 3 substituents, or 1 substituent.

[0031] "C 3-10 "Halocycloalkyl" refers to the above "C" substituted with one or more halogens. 3-10 It refers to "cycloalkyl."

[0032] "3- to 12-membered heterocyclyl" refers to a group of 3- to 12-membered non-aromatic ring systems having ring carbon atoms and 1 to 5 ring heteroatoms, where each heteroatom is independently selected from nitrogen, oxygen, sulfur, boron, phosphorus, and silicon. In heterocyclyls containing one or more nitrogen atoms, the point of attachment can be a carbon or nitrogen atom, as long as valence allows. In some embodiments, 4- to 12-membered heterocyclyls that are 4- to 12-membered non-aromatic ring systems having ring carbon atoms and 1 to 5 ring heteroatoms are preferred. In some embodiments, 3- to 10-membered heterocyclyls that are 3- to 10-membered non-aromatic ring systems having ring carbon atoms and 1 to 5 ring heteroatoms are preferred. In some embodiments, 3- to 8-membered heterocyclyl is a 3- to 8-membered non-aromatic ring system having ring carbon atoms and 1 to 4 ring heteroatoms, preferably 3- to 6-membered non-aromatic ring system having ring carbon atoms and 1 to 3 ring heteroatoms, preferably 4- to 8-membered non-aromatic ring system having ring carbon atoms and 1 to 3 ring heteroatoms, preferably 4- to 8-membered heterocyclyl is a 4- to 8-membered non-aromatic ring system having ring carbon atoms and 1 to 3 ring heteroatoms, and more preferably 5- to 6-membered heterocyclyl is a 5- to 6-membered non-aromatic ring system having ring carbon atoms and 1 to 3 ring heteroatoms. Furthermore, heterocyclyl groups include ring systems in which the heterocyclyl ring is fused to one or more cycloalkyl groups, with the point of attachment located on the cycloalkyl ring, or the heterocyclyl ring is fused to one or more aryl or heteroaryl groups, with the point of attachment located on the heterocyclyl ring, and in such circumstances, the number of ring members still refers to the number of ring members in the heterocyclyl group. Exemplary 3-membered heterocyclyls containing one heteroatom include, but are not limited to, aziridinyl, oxiranyl, and thiorenyl. Exemplary 4-membered heterocyclyls containing one heteroatom include, but are not limited to, azetidinyl, oxetanyl, and thietanyl. Exemplary 5-membered heterocyclyls containing one heteroatom include, but are not limited to, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothiophenyl, dihydrothiophenyl, pyrrolidinyl, dihydropyrrolyl, and pyrrolyl-2,5-dione.Exemplary 5-membered heterocyclyls containing two heteroatoms include, but are not limited to, dioxolanyl, oxasulfuranyl, disulfuranyl, and oxazolidin-2-one. Exemplary 5-membered heterocyclyls containing three heteroatoms include, but are not limited to, triazolinyl, oxadiazolinyl, and thiadiazolinyl. Exemplary 6-membered heterocyclyls containing one heteroatom include, but are not limited to, piperidinyl, tetrahydropyranyl, dihydropyridinyl, and thianyl. Exemplary 6-membered heterocyclyls containing two heteroatoms include, but are not limited to, piperazinyl, morpholinyl, dithianyl, and dioxanyl. Exemplary 6-membered heterocyclyls containing three heteroatoms include, but are not limited to, triazinanyl. Exemplary 7-membered heterocyclyls containing one heteroatom include, but are not limited to, azepanyl, oxepanyl, and thiepanyl. Exemplary 5-membered heterocyclyls (also referred to herein as 5,6-bicyclic heterocyclyls) fused to a C6 aryl ring include, but are not limited to, indolinyl, isoindolinyl, dihydrobenzofuranyl, dihydrobenzothienyl, and benzoxazolinonyl. Exemplary 6-membered heterocyclyls (also referred to herein as 6,6-bicyclic heterocyclyls) fused to a C6 aryl ring include, but are not limited to, tetrahydroquinolinyl and tetrahydroisoquinolinyl. The heterocyclyl may be substituted with one or more substituents, for example, 1 to 5 substituents, 1 to 3 substituents, or 1 substituent.

[0033] The terms "4- to 12-membered heterocyclylene" and "5- to 6-membered heterocyclylene" refer to divalent groups obtained by removing another hydrogen atom from the aforementioned "4- to 12-membered heterocyclyl" and "5- to 6-membered heterocyclyl", respectively, and may be substituted or unsubstituted.

[0034] "C6-10 An "aryl group" refers to a group of monocyclic or polycyclic (e.g., bicyclic) 4n+2 aromatic ring systems (e.g., having 6 or 10 π electrons shared in a cyclic arrangement) having 6 to 10 ring carbon atoms and 0 heteroatoms. In some embodiments, an aryl group has 6 ring carbon atoms (a "C6 aryl group"; e.g., phenyl). In some embodiments, an aryl group has 10 ring carbon atoms (a "C 10 "Aryl group"; for example, naphthyl, such as 1-naphthyl and 2-naphthyl. Aryl groups also include ring systems in which the above-mentioned aryl ring is fused with one or more cycloalkyl or heterocyclyl groups, and the point of attachment is on the above-mentioned aryl ring; in such cases, the number of carbon atoms still refers to the number of carbon atoms in the above-mentioned aryl ring system. The aryl group may be substituted with one or more substituents, for example, 1 to 5 substituents, 1 to 3 substituents, or 1 substituent.

[0035] "C 6-12 "Aralkyl" refers to the group -R-R' where R is alkyl and R' is aryl, and the alkyl and aryl have a total of 6 to 12 carbon atoms.

[0036] A "5- to 14-membered heteroaryl group" refers to a 5- to 14-membered monocyclic or bicyclic 4n+2 aromatic ring system (e.g., having 6, 10, or 14 π-electrons shared in a cyclic arrangement) having ring carbon atoms and 1 to 4 ring heteroatoms, where each heteroatom is independently selected from nitrogen, oxygen, and sulfur. In heteroaryl groups containing one or more nitrogen atoms, the point of attachment can be a carbon or nitrogen atom, where valence allows. Heteroaryl bicyclic ring systems can contain one or more heteroatoms in one or both rings. Heteroaryl groups include ring systems in which the heteroaryl ring described above is fused with one or more cycloalkyl or heterocyclyl groups, where the point of attachment is on the heteroaryl ring described above; in such cases, the number of ring members continues to refer to the number of ring members in the heteroaryl ring system. In some embodiments, 5- to 10-membered monocyclic or bicyclic 4n+2 aromatic ring systems having ring carbon atoms and 1 to 4 ring heteroatoms are preferred. In some other embodiments, 5- to 6-membered heteroaryl groups that are 5- to 6-membered monocyclic or bicyclic 4n+2 aromatic ring systems having ring carbon atoms and 1 to 4 ring heteroatoms are particularly preferred. Exemplary 5-membered heteroaryl groups containing one heteroatom include, but are not limited to, pyrrolyl, furanyl, and thiophenyl. Exemplary 5-membered heteroaryl groups containing two heteroatoms include, but are not limited to, imidazolyl, pyrazolyl, oxazolyl, isoxazolyl, thiazolyl, and isothiazolyl. Exemplary 5-membered heteroaryl groups containing three heteroatoms include, but are not limited to, triazolyl, oxadiazolyl (e.g., 1,2,4-oxadiazolyl), and thiadiazolyl. Exemplary 5-membered heteroaryl groups containing four heteroatoms include, but are not limited to, tetrazolyl. Exemplary 6-membered heteroaryl groups containing one heteroatom include, but are not limited to, pyridinyl. Exemplary 6-membered heteroaryl groups containing two heteroatoms include, but are not limited to, pyridazinyl, pyrimidinyl, and pyrazinyl.Exemplary 6-membered heteroaryl groups containing three or four heteroatoms include, but are not limited to, triazinyl and tetrazinyl, respectively. Exemplary 7-membered heteroaryl groups containing one heteroatom include, but are not limited to, azepinyl, oxepinyl, and thiepinyl. Exemplary 5,6-bicyclic heteroaryl groups include, but are not limited to, indolyl, isoindolyl, indazolyl, benzotriazolyl, benzothiophenyl, isobenzothiophenyl, benzofuranyl, benzisofuranyl, benzimidazolyl, benzoxazolyl, benzisoxazolyl, benzoxadiazolyl, benzthiazolyl, benzisothiazolyl, benzthiadiazolyl, indolizinyl, and purinyl. Exemplary 6,6-bicyclic heteroaryl groups include, but are not limited to, naphthyridinyl, pteridinyl, quinolinyl, isoquinolinyl, cinnolinyl, quinoxalinyl, phthalazinyl, and quinazolinyl. The heteroaryl group may be substituted with one or more substituents, for example, 1 to 5 substituents, 1 to 3 substituents, or 1 substituent.

[0037] "Oxo" stands for =O.

[0038] The alkyl, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, and heteroaryl groups defined herein may be optionally substituted.

[0039] Exemplary carbon atom substituents include halogen, -CN, -NO2, -N3, -SO2H, -SO3H, -OH, -OR aa , -ON(R bb )2, -N(R bb )2, -N(R bb )3 + X - , -N(OR cc )R bb , -SH, -SR aa , -SSR cc , -C(=O)R aa , -CO2H, -CHO, -C(OR cc)2、-CO2R aa 、-OC(=O)R aa 、-OCO2R aa 、-C(=O)N(R bb )2、-OC(=O)N(R bb )2、-NR bb C(=O)R aa 、-NR bb CO2R aa 、-NR bb C(=O)N(R bb )2、-C(=NR bb )R aa 、-C(=NR bb )OR aa 、-OC(=NR bb )R aa 、-OC(=NR bb )OR aa 、-C(=NR bb )N(R bb )2、-OC(=NR bb )N(R bb )2、-NR bb C(=NR bb )N(R bb )2、-C(=O)NR bb SO2R aa 、-NR bb SO2R aa 、-SO2N(R bb )2、-SO2R aa 、-SO2OR aa 、-OSO2R aa 、-S(=O)R aa 、-OS(=O)R aa 、-Si(R aa )3、-OSi(R aa )3、-C(=S)N(R bb )2、-C(=O)SR aa 、-C(=S)SR aa 、-SC(=S)SR aa 、-SC(=O)SR aa 、-OC(=O)SR aa 、-SC(=O)OR aa 、-SC(=O)R aa 、-P(=O)2R aa 、-OP(=O)2R aa 、-P(=O)(R aa)2, -OP(=O)(R aa )2, -OP(=O)(OR cc )2, -P(=O)2N(R bb )2, -OP(=O)2N(R bb )2, -P(=O)(NR bb )2, -OP(=O)(NR bb )2, -NR bb P(=O)(OR cc )2, -NR bb P(=O)(NR bb )2, -P(R cc )2, -P(R cc )3, -OP(R cc )2, -OP(R cc )3, -B(R aa )2, -B(OR cc )2, -BR aa (OR cc ), alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl group, heterocyclyl group, aryl, and heteroaryl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl group, heterocyclyl group, aryl, and heteroaryl each independently have 0, 1, 2, 3, 4, or 5 R dd substituted with a group;

[0040] Or, the two geminal hydrogens on the carbon atom can be =O, =S, or =NN(R bb )2, =NNR bb C(=O)R aa , =NNR bb C(=O)OR aa , =NNR bb S(=O)2R aa , =NR bb or =NOR cc substituted with a group;

[0041] Each R aa are independently selected from alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl groups, heterocyclyl groups, aryl, and heteroaryl, or two R aagroups linked to form a heterocyclyl group or a heteroaryl ring, wherein the alkyl, alkenyl, alkynyl, cycloalkyl group, heterocyclyl group, aryl, and heteroaryl each independently contain 0, 1, 2, 3, 4, or 5 R dd substituted with a group;

[0042] Each R bb are independently hydrogen, -OH, or -OR aa , -N(R cc )2, -CN, -C(=O)R aa , -C(=O)N(R cc )2, -CO2R aa , -SO2R aa , -C(=NR cc ) OR aa , -C(=NR cc )N(R cc )2, -SO2N(R cc )2, -SO2R cc , -SO2OR cc , -SOR aa , -C(=S)N(R cc )2, -C(=O)SR cc , -C(=S)SR cc , -P(=O)2R aa , -P(=O)(R aa )2, -P(=O)2N(R cc )2, -P(=O)(NR cc )2, alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl group, heterocyclyl group, aryl, and heteroaryl, or two R bb groups linked to form a heterocyclyl group or a heteroaryl ring, wherein the alkyl, alkenyl, alkynyl, cycloalkyl group, heterocyclyl group, aryl, and heteroaryl each independently contain 0, 1, 2, 3, 4, or 5 R dd substituted with a group;

[0043] Each R ccare independently selected from hydrogen, alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl group, heterocyclyl group, aryl, and heteroaryl, or two R cc groups linked to form a heterocyclyl group or a heteroaryl ring, wherein the alkyl, alkenyl, alkynyl, cycloalkyl group, heterocyclyl group, aryl, and heteroaryl each independently contain 0, 1, 2, 3, 4, or 5 R dd substituted with a group;

[0044] Each R dd are independently halogen, -CN, -NO2, -N3, -SO2H, -SO3H, -OH, -OR ee , -ON(R ff )2, -N(R ff )2, -N(R ff )3 + X - , -N(OR ee )R ff , -SH, -SR ee , -SSR ee , -C(=O)R ee , -CO2H, -CO2R ee , -OC(=O)R ee , -OCO2R ee , -C(=O)N(R ff )2, -OC(=O)N(R ff )2, -NR ff C(=O)R ee , -NR ff CO2R ee , -NR ff C(=O)N(R ff )2, -C(=NR ff ) OR ee , -OC(=NR ff )R ee , -OC(=NR ff ) OR ee , -C(=NR ff )N(R ff )2, -OC(=NR ff )N(R ff )2, -NR ff C(=NR ff )N(R ff )2, -NRff SO2R ee , -SO2N(R ff )2, -SO2R ee , -SO2OR ee , -OSO2R ee , -S(=O)R ee , -Si(R ee )3, -OSi(R ee )3, -C(=S)N(R ff )2, -C(=O)SR ee , -C(=S)SR ee , -SC(=S)SR ee , -P(=O)2R ee , -P(=O)(R ee )2, -OP(=O)(R ee )2, -OP(=O)(OR ee )2, alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl group, heterocyclyl group, aryl, heteroaryl, wherein the alkyl, alkenyl, alkynyl, cycloalkyl group, heterocyclyl group, aryl, and heteroaryl are each independently selected from 0, 1, 2, 3, 4, or 5 R gg or two geminal R dd the substituents may be linked to form =O or =S;

[0045] Each R ee are independently selected from alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl group, aryl, heterocyclyl group, and heteroaryl, wherein alkyl, alkenyl, alkynyl, cycloalkyl group, heterocyclyl group, aryl, and heteroaryl are each independently selected from 0, 1, 2, 3, 4, or 5 R gg substituted with a group;

[0046] Each R ff are independently selected from hydrogen, alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl group, heterocyclyl group, aryl, and heteroaryl, or two R ffgroups linked to form a heterocyclyl group or a heteroaryl ring, wherein the alkyl, alkenyl, alkynyl, cycloalkyl group, heterocyclyl group, aryl, and heteroaryl each independently contain 0, 1, 2, 3, 4, or 5 R gg substituted with a group;

[0047] Each R gg are independently halogen, -CN, -NO2, -N3, -SO2H, -SO3H, -OH, -OC 1-6 Alkyl group, -ON(C 1-6 alkyl group)2, -N(C 1-6 alkyl group)2, -N(C 1-6 alkyl group)3 + X - , -NH(C 1-6 alkyl group)2 + X - , -NH2(C 1-6 alkyl group) + X - , -NH3 + X - , -N(OC 1-6 alkyl group)(C 1-6 alkyl group), -N(OH)(C 1-6 alkyl group), -NH(OH), -SH, -SC 1-6 Alkyl group, -SS(C 1-6 alkyl group), -C(=O)(C 1-6 alkyl group), -CO2H, -CO2(C 1-6 alkyl group), -OC(=O)(C 1-6 alkyl group), -OCO2(C 1-6 alkyl group), -C(=O)NH2, -C(=O)N(C 1-6 alkyl group)2, -OC(=O)NH(C 1-6 alkyl group), -NHC(=O)(C 1-6 alkyl group), -N(C 1-6 alkyl group)C(=O)(C 1-6 alkyl group), -NHCO2(C 1-6 alkyl group), -NHC(=O)N(C 1-6 alkyl group)2, -NHC(=O)NH(C 1-6alkyl group), -NHC(=O)NH2, -C(=NH)O(C 1-6 alkyl group), -OC(=NH)(C 1-6 alkyl group), -OC(=NH)OC 1-6 Alkyl group, -C(=NH)N(C 1-6 alkyl group)2, -C(=NH)NH(C 1-6 alkyl group), -C(=NH)NH2, -OC(=NH)N(C 1-6 alkyl group)2, -OC(NH)NH(C 1-6 alkyl group), -OC(NH)NH2, -NHC(NH)N(C 1-6 alkyl group), -NHC(=NH)NH, -NHSO(C 1-6 alkyl group), -SO2N(C 1-6 alkyl group)2, -SO2NH(C 1-6 alkyl group), -SO2NH2, -SO2C 1-6 Alkyl group, -SO2OC 1-6 Alkyl group, -OSO2C 1-6 Alkyl group, -SOC 1-6 Alkyl group, -Si(C 1-6 alkyl group)3, -OSi(C 1-6 alkyl group)3, -C(=S)N(C 1-6 alkyl group), C(=S)NH(C 1-6 alkyl group), C(=S)NH2, -C(=O)S(C 1-6 alkyl group), -C(=S)SC 1-6 Alkyl group, -SC(=S)SC 1-6 Alkyl group, -P(=O)2(C 1-6 alkyl group), -P(=O)(C 1-6 alkyl group)2, -OP(=O)(C 1-6 alkyl group)2, -OP(=O)(OC 1-6 Alkyl group)2, C 1-6 Alkyl group, C 1-6 Haloalkyl groups, C2-C6 alkenyl groups, C2-C6 alkynyl groups, C3-C7 cycloalkyl groups, C6-C 10 Aryl groups, C3-C7 heterocyclyl groups, C5-C 10 a heteroaryl group; or two geminal R ggThe substituents may be linked to form =O or =S; where X - is the counter ion.

[0048] Exemplary nitrogen atom substituents include hydrogen, —OH, —OR aa , -N(R cc )2, -CN, -C(=O)R aa , -C(=O)N(R cc )2, -CO2R aa , -SO2R aa , -C(=NR bb )R aa , -C(=NR cc ) OR aa , -C(=NR cc )N(R cc )2, -SO2N(R cc )2, -SO2R cc , -SO2OR cc , -SOR aa , -C(=S)N(R cc )2, -C(=O)SR cc , -C(=S)SR cc , -P(=O)2R aa , -P(=O)(R aa )2, -P(=O)2N(R cc )2, -P(=O)(NR cc ) 2, alkyl, haloalkyl, alkenyl, alkynyl, cycloalkyl group, heterocyclyl group, aryl, and heteroaryl, or two R bonded to a nitrogen atom cc The groups are linked to form a heterocyclyl group or a heteroaryl ring, where the alkyl, alkenyl, alkynyl, cycloalkyl group, heterocyclyl group, aryl, and heteroaryl each independently contain 0, 1, 2, 3, 4, or 5 R dd group, where R aa , R bb , R cc and R dd is as described above.

[0049] Other definitions The term "cancer" includes, but is not limited to, cancers of the breast, ovary, cervix, prostate, testicle, esophagus, stomach, skin, lung, bone, colon, pancreas, thyroid, biliary tract, buccal cavity and pharynx (mouth), lip, tongue, mouth, pharynx, small intestine, colorectal, large intestine, rectum, brain and central nervous system, glioblastoma, neuroblastoma, keratoacanthoma, epidermoid carcinoma, large cell carcinoma, adenocarcinoma, adenoma, follicular carcinoma, undifferentiated carcinoma, papillary carcinoma, seminoma, melanoma, sarcoma, bladder cancer, liver cancer, kidney cancer, bone marrow disorders, lymphatic disorders, Hodgkin's disease, hairy cell carcinoma, and leukemia.

[0050] The term "treatment" as used herein relates to the reversal, alleviation, suppression of the disorder or condition to which the term applies, or the progression or prevention of one or more symptoms of such disorder or condition. The noun "treatment" as used herein relates to the act of treating, which is a verb, as defined above.

[0051] As used herein, the term "pharmaceutically acceptable salts" means carboxylate and amino acid addition salts of the compounds of the present invention that, within the scope of sound medical judgment, are suitable for use in contact with the tissues of patients without undue toxicity, irritation, allergic response, or the like, and are effective for their desired application, commensurate with a reasonable benefit / risk ratio, and include, where possible, zwitterionic forms of the compounds of the present invention.

[0052] Pharmaceutically acceptable base addition salts are formed with metals or amines, such as, for example, alkali metal and alkaline earth metal hydroxides or organic amines. Examples of metals used as cations include sodium, potassium, magnesium, calcium, etc. Examples of preferred amines include N,N'-dibenzylethylenediamine, chloroprocaine, choline, diethanolamine, ethylenediamine, N-methylglucamine, and procaine.

[0053] Base addition salts of acidic compounds can be prepared by contacting the free acid form with a sufficient amount of the necessary base to form the salt in the conventional manner. The free acid is regenerated by contacting the salt form with an acid in the conventional manner and isolating the free acid. The free acid forms may differ somewhat from their respective salt forms in physical properties, such as solubility in polar solvents. However, for purposes of this invention, the salts are equivalent to the respective free acids.

[0054] Salts may be prepared from inorganic acids, such as sulfate, pyrosulfate, bisulfite, sulfite, nitrate, phosphate, monohydrogenphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate, chloride, bromide, and iodide. Examples of acids include hydrochloric acid, nitric acid, sulfuric acid, hydrobromic acid, hydroiodic acid, and phosphoric acid. Representative salts include hydrobromide, hydrochloride, sulfate, bisulfate, nitrate, acetate, oxalate, valerate, oleate, palmitate, stearate, laurate, borate, benzoate, lactate, phosphate, tosylate, citrate, maleate, fumarate, succinate, tartrate, naphthalate, methanesulfonate, glucoheptanoate, lactobionate, laurylsulfonate, and isethionate. Salts may be prepared from organic acids, such as aliphatic mono- and dicarboxylic acids, phenyl-substituted alkanoic acids, hydroxyalkanoic acids, alkanedioic acids, aromatic acids, aliphatic and aromatic sulfonic acids, etc. Representative salts include acetate, propionate, octanoate, isobutyrate, oxalate, malonate, succinate, suberate, sebacate, fumarate, maleate, mandelate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, naphthoate, besylate, tosylate, phenylacetate, citrate, lactate, maleate, tartrate, methanesulfonate, and the like. Pharmaceutically acceptable salts include, for example, alkali and alkaline earth metal cations such as sodium, lithium, potassium, calcium, magnesium, and the like, as well as non-toxic ammonium, quaternary ammonium, and amine cations, including, but not limited to, ammonium, tetramethylammonium, tetraethylammonium, methylamine, dimethylamine, trimethylamine, triethylamine, ethylamine, etc. Also included are salts of amino acids such as arginine, gluconate, galacturonate, and the like (see, e.g., Berge SM et al., "Pharmaceutical Salts," J. Pharm. Sci., 1977;66:1-19).

[0055] The "subject" to be administered includes, but is not limited to, humans (i.e., male or female of any age group, e.g., pediatric subjects (e.g., infants, children, adolescents) or adult subjects (e.g., young adults, middle-aged adults, or elderly adults)) and / or non-human animals, e.g., mammals (e.g., primates (e.g., cynomolgus monkeys, rhesus monkeys), cows, pigs, horses, sheep, goats, rodents, cats, and / or dogs). In some embodiments, the subject is a human. In some embodiments, the subject is a non-human animal. "Human," "patient," and "subject" are used interchangeably herein.

[0056] "Disease," "disorder," and "condition" are used interchangeably herein.

[0057] Unless otherwise specified, the term "treatment" as used herein contemplates actions taken while a subject is suffering from a particular disease, disorder, or condition to reduce the severity of the disease, disorder, or condition or to delay or slow the progression of the disease, disorder, or condition ("therapeutic treatment"), and also actions taken before a subject begins to suffer from a particular disease, disorder, or condition ("prophylactic treatment").

[0058] Generally, the "effective amount" of a compound refers to an amount sufficient to induce a desired biological response. As will be understood by those skilled in the art, the effective amount of the compound of the present invention may vary depending on factors such as the desired biological goal, the pharmacokinetics of the compound, the disease to be treated, the mode of administration, and the age, health and condition of the subject. The effective amount includes a therapeutically effective amount and a prophylactically effective amount.

[0059] Unless otherwise specified, a "therapeutically effective amount" of a compound, as used herein, is an amount sufficient to provide a therapeutic benefit in the treatment of a disease, disorder, or condition, or to delay or minimize one or more symptoms associated with that disease, disorder, or condition. A therapeutically effective amount of a compound means an amount of a therapeutic agent, alone or in combination with other therapies, that provides a therapeutic benefit in the treatment of that disease, disorder, or condition. The term "therapeutically effective amount" includes an amount that improves overall treatment, reduces or avoids the symptoms or causes of a disease or condition, or enhances the therapeutic effect of another therapeutic agent.

[0060] Unless otherwise specified, a "prophylactically effective amount" of a compound, as used herein, is an amount sufficient to prevent a disease, disorder, or condition, or one or more symptoms associated with that disease, disorder, or condition, or to prevent its recurrence. A prophylactically effective amount of a compound means an amount of a therapeutic agent, alone or in combination with other agents, that provides a prophylactic benefit in the prevention of that disease, disorder, or condition. The term "prophylactically effective amount" includes an amount that improves overall prophylaxis or enhances the prophylactic effect of another prophylactic agent.

[0061] "Combination" and related terms refer to simultaneous or sequential administration of a compound of the invention and another therapeutic agent. For example, the compound of the invention can be administered simultaneously or sequentially with the other therapeutic agent in separate unit dosage forms or simultaneously with the other therapeutic agent in a single unit dosage form. [Brief explanation of the drawings]

[0062] [Figure 1] FIG. 1 shows the effect of compound C176 on EGFRL858R / T790M / C797S protein levels. [Figure 2] FIG. 2 shows the effect of compound C213 on EGFR Del19 / T790M / C797S protein levels. DETAILED DESCRIPTION OF THE INVENTION

[0063] As used herein, the term "compound of the present invention" refers to a compound represented by the following formula (X) (including subgeneric formulae such as formulas (I), (I-1), (I-5-1), etc.), its pharmaceutically acceptable salt, enantiomer, diastereomer, racemate, solvate, hydrate, polymorph, prodrug or isotopic variant, and mixtures thereof.

[0064] In this specification, compounds are generally described using standard nomenclature. For compounds with asymmetric centers, it should be understood that all optical isomers and mixtures thereof are included unless otherwise specified. Furthermore, all isomeric compounds and carbon-carbon double bonds included in the present invention may appear in Z and E forms unless otherwise specified. For compounds that exist in different tautomeric forms, the compounds are not limited to a specific tautomer, but are intended to include all tautomeric forms.

[0065] In one embodiment, the present invention relates to a compound represented by general formula (X), its pharmaceutically acceptable salts, enantiomers, diastereomers, racemates, solvates, hydrates, polymorphs, prodrugs or isotopic variants, and mixtures thereof: [ka] however, Ring A may be selected from the group consisting of the following, optionally substituted groups: 3-7 Cycloalkyl, 4-8 membered heterocyclyl, C 6-10 aryl, or 5-10 membered heteroaryl, wherein the substituents are selected from the group consisting of halogen, —CN, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 3-7 Cycloalkyl, 4-8 membered heterocyclyl, -P(O)(C 1-6 alkyl)2, -P(O)(C 2-6 alkenyl)2, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -OC 2-6Alkenyl, -OC 3-7 Cycloalkyl, -O-4 to 8-membered heterocyclyl, -NH-C 1-6 Alkyl, -NH-C 2-6 Alkenyl, -NH-C 3-7 Cycloalkyl, -NH-4-8 membered heterocyclyl, -C(O)-C 1-6 Alkyl, -C(O)-C 2-6 Alkenyl, -C(O)-C 3-7 Cycloalkyl, -C(O)-4 to 8-membered heterocyclyl, -S(O)2-C 1-6 Alkyl, -S(O)2-C 2-6 Alkenyl, -S(O)2-C 3-7 Cycloalkyl, -S(O)2-4 to 8-membered heterocyclyl, -NHC(O)-C 1-6 Alkyl, -NHC(O)-C 2-6 Alkenyl, -NHC(O)-C 3-7 Cycloalkyl, -NHC(O)-4 to 8-membered heterocyclyl, -NHS(O)2-C 1-6 Alkyl, -NHS(O)2-C 2-6 Alkenyl, -NHS(O)2-C 3-7 cycloalkyl, or -NHS(O)2- 4- to 8-membered heterocyclyl; Ring B is [ka] selected from the group consisting of: [ka] represents a single or double bond; [ka] indicates that the attachment site to the remainder of the molecule may be located at any available site on the ring; Z1 is one or two R Z1 or Z1 is absent, Z4 is connected to a C atom of the aromatic ring to which Z1 is bonded, Z2 or Z3, and Z2 and the C atom of the aromatic ring bonded to Z1 are each R Wor Z1, Z2 and Z3 are all absent, so that Z4 is connected to one of the C atoms of the aromatic ring to which Z1 or Z3 is bonded, and another C atom of the aromatic ring is bonded to R W Connected to; Z2 is one or two R Z2 is an O, S, N or C atom optionally substituted with; Z3 is one or two R Z3 is an O, S, N or C atom optionally substituted with [ka] represents a double bond, Z2 is an N or C atom and Z3 is an N or C atom; Z4 is N or CR Z4 and; Z5 is N or CR Z5 and; R a , R b and R c are independently H, halogen, -(CH2) 0-5 -OR'', -(CH2) 0-5 -NR''R''', C 1-6 Alkyl, or C 1-6 haloalkyl; or R a , R b and the C atoms to which they are attached, C=O, C 3-7 forms a cycloalkyl or a 4- to 8-membered heterocyclyl; or R a , R c and the C atoms to which they are attached, C 3-7 forms a cycloalkyl or a 4- to 8-membered heterocyclyl; or R a and R c forms chemical bonds; R N1 is H, C 1-6 Alkyl, or C 1-6 haloalkyl, preferably H; R Z1 is absent or contains H, CN, halogen, -(CH2) 0-5 -OR'', -(CH2)0-5 -NR''R''', C 1-6 Alkyl, C 1-6 Haloalkyl, -(CH2) 0-5 -C 3-7 Cycloalkyl, or -(CH2) 0-5 -4 to 8-membered heterocyclyl; or two R Z1 Together with Z1, C=O, C 3-7 forming a cycloalkyl or a 4- to 8-membered heterocyclyl; R Z2 is absent or contains H, CN, halogen, -(CH2) 0-5 -OR'', -(CH2) 0-5 -NR''R''', C 1-6 Alkyl, C 1-6 Haloalkyl, -(CH2) 0-5 -C 3-7 Cycloalkyl, or -(CH2) 0-5 -4 to 8-membered heterocyclyl; or two R Z2 Together with Z2, C=O, C 3-7 forming a cycloalkyl or a 4- to 8-membered heterocyclyl; R Z3 is absent or contains H, CN, halogen, -(CH2) 0-5 -OR'', -(CH2) 0-5 -NR''R''', C 1-6 Alkyl, C 1-6 Haloalkyl, -(CH2) 0-5 -C 3-7 Cycloalkyl, or -(CH2) 0-5 -4 to 8-membered heterocyclyl; or two R Z3 Together with Z3, C=O, C 3-7 forming a cycloalkyl or a 4- to 8-membered heterocyclyl; R Z4 is H, CN, halogen, -(CH2) 0-5 -OR'', -(CH2) 0-5 -NR''R''', C 1-6 Alkyl, or C 1-6 is haloalkyl; R Z5 is H, CN, halogen, -(CH2) 0-5-OR'', -(CH2) 0-5 -NR''R''', C 1-6 Alkyl, C 1-6 Haloalkyl, -(CH2) 0-5 -C 3-7 Cycloalkyl, or -(CH2) 0-5 -4 to 8-membered heterocyclyl; Alternatively, the ring in which Z4 is located is absent; where R w is H, CN, halogen, -(CH2) 0-5 -OR'', -(CH2) 0-5 -NR''R'''', -C 1-6 Alkyl, C 1-6 Haloalkyl, -(CH2) 0-5 -C 3-7 Cycloalkyl, -(CH2) 0-5 -4-8 membered heterocyclyl, C 2-6 Alkenyl, C 2-6 Alkynyl, -(CH2) 0-5 -C 3-10 Halocycloalkyl, -(CH2) 0-5 -C 6-10 Aryl, or -(CH2) 0-5 - 5 to 14 membered heteroaryl; R'' is H, C 1-6 Alkyl, C 1-6 Haloalkyl, or -(CH2) 0-5 -C 3-7 is cycloalkyl; R''' is H, C 1-6 Alkyl, or C 1-6 is haloalkyl; L1 is a chemical bond, -O-, -S(O) p -, -S(O)(=NR * )-, -NR # -, -CR # R # '-, -C a R # R # '-C b R # R # '-, -N=S(O)(R * )-, or -S(O)(R *)=N-; L2 is a chemical bond, -O-, -S(O) p -, -S(O)(=NR * )-, -NR # -, -CR # R # '-, -C a R # R # '-C b R # R # '-, -N=S(O)(R * )-, or -S(O)(R * )=N-; where C a R # R # ' or C b R # R # ' is O, S(O) p , S(O)(=NR * ) or NR # can be replaced by C a R # R # ' or C b R # R # ' is O, S or NR # If replaced by C a R # R # ' or C b R # R # ', another one is S(O) q can be replaced by; E is independently a chemical bond, -C c R # R # '-C d R # R # '-C e R # R # ', [ka] [ka] selected from the group consisting of: where C c R # R # ', C d R # R # ' or C e R # R # ' or C c R # R # ' and C e R # R # 'Both O and S(O) p , S(O)(=NR * ) or NR # can be replaced by C c R # R # ', C d R # R # ' or C e R # R # ' is O, S or NR # If replaced by one or two adjacent Cs, c R # R # ', C d R # R # ' or C e R # R # ', S(O) q can be replaced by; Alternatively, two E units may be -CH2CH2OCH2CH2-, -OCH2CH2CH2CH2-, -CH2CH2CH2CH2O-, [ka] can be formed; where: [ka] represents the attachment site to L1 or L2; H1 and H2 are N or C atoms, H3 is O, S, N or C atom, and H1 and H3, H2 and H3 are not heteroatoms at the same time; H4 and H5 are N or C atoms; H6, H7, H8 and H9 are C or N atoms; p is 0, 1 or 2; q is 1 or 2; R * is H, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Cycloalkyl, C 3-10 Halocycloalkyl, 3-10 membered heterocyclyl, C 6-10 aryl, or 5- to 14-membered heteroaryl; R # H, halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Cycloalkyl, C 3-10 Halocycloalkyl, 3-10 membered heterocyclyl, C 6-10 aryl, or 5- to 14-membered heteroaryl; R # ' is H, halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Cycloalkyl, C 3-10 Halocycloalkyl, 3-10 membered heterocyclyl, C 6-10 aryl, or 5- to 14-membered heteroaryl; Alternatively, R on the adjacent atom # and R # can form chemical bonds, R on adjacent atoms # ' and R # ' can form chemical bonds; Alternatively, R on the same or different atoms # and R# ' is both, =O, C 3-7 Cycloalkyl, 4-8 membered heterocyclyl, C 6-10 aryl or 5-6 membered heteroaryl, wherein C 3-7 Cycloalkyl, 4-8 membered heterocyclyl, C 6-10 Aryl or 5-6 membered heteroaryl is R x and may be substituted with the above-mentioned R x H, CN, halogens, C 1-6 Alkyl, or C 1-6 is haloalkyl; m is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; R s1 is H, CN, halogen, -(CH2) 0-5 -OR'', -(CH2) 0-5 -NR''R''', C 1-6 Alkyl, C 1-6 Haloalkyl, -(CH2) 0-5 -4-8 membered heterocyclyl, C 2-6 Alkenyl, C 2-6 Alkynyl, -(CH2) 0-5 -C 3-7 Cycloalkyl, -(CH2) 0-5 -C 3-10 Halocycloalkyl, -(CH2) 0-5 -C 6-10 Aryl, -(CH2) 0-5 -5 to 14-membered heteroaryl, -C(O)R W , -S(O)R W or -S(O)2R W selected from the group consisting of: s1 is 0, 1, 2 or 3; R' is H, -C(O)-C 1-6 Alkyl, -C(O)-C 1-6 Haloalkyl, -C(O)-C 2-6 Alkenyl, or -C(O)-C 6-10 aryl; L is a chemical bond, -O- or -NR-; where R is H or C 1-6 is alkyl; Z is -N= or -C(R4)=; T is a chemical bond, C 2-6 selected from the group consisting of heteroalkylene, 4- to 12-membered heterocyclylene, or 5- to 6-membered heterocyclylene substituted with 5- to 6-membered heterocyclylene; R1 is H, halogen, cyano, C 1-6 Alkyl, C 3-7 Cycloalkyl, 4-8 membered heterocyclyl, C 1-6 Haloalkyl, C 2-6 Alkenyl or C 2-6 alkynyl; Alternatively, when L is -NR-, R and R together with the atoms to which they are attached form an optionally substituted 5- to 6-membered heterocyclyl, wherein the substituents are halogen, oxo, C 1-6 Alkyl, C 1-6 Haloalkyl, mono- or polysubstituted with halogen C 6-10 aryl; R2 is H, halogen, hydroxyl, amino, C 1-6 Alkyl, or C 1-6 is haloalkyl; or R1 and R2 together with the atoms to which they are attached form a 5- to 6-membered heterocyclyl or a 5- to 6-membered heteroaryl; R3 is H, -OC 1-6 Alkyl or -OC 1-6 haloalkyl; R4 is H, halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, -NHC(O)-C 1-6 Alkyl, or -NHC(O)-C 2-6 alkenyl; When each of said groups is H or an H-containing group, one or more of said H atoms may be replaced with a D atom; The alkyl, alkylene, haloalkyl, alkenyl, alkynyl, cycloalkyl, halocycloalkyl, heterocyclyl, aryl, heteroaryl, or groups containing OH, NH, NH, CH, CH, CH in L, E, L, and T may each be one, two, three, or more R s and may be substituted with the above-mentioned R s are independently halogen, hydroxyl, amino, cyano, nitro, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Cycloalkyl, C 3-10 Halocycloalkyl, 3-10 membered heterocyclyl, C 6-10 Aryl, 5-14 membered heteroaryl, C 6-12 Aralkyl, -OR a’ , -OC(O)R a’ , -C(O)R a’ , -C(O)OR a’ , -C(O)NR a’ R b’ , -S(O) n R a’ , -S(O) n OR a’ , -S(O) n NR a’ R b’ , -NR a’ R b’ , -NR a’ C(O)R b’ , -NR a’ -C(O)OR b’ , -NR a’ -S(O) n -R b’ , -NR a’ C(O)NR a’ R b’ , -C 1-6 Alkylene-R a’ , -C 1-6 Alkylene-OR a’ , -C 1-6 Alkylene-OC(O)R a’ , -C 1-6 Alkylene-C(O)OR a’ , -C 1-6Alkylene-S(O) n R a’ , -C 1-6 Alkylene-S(O) n OR a’ , -C 1-6 Alkylene-OC(O)NR a’ R b’ , -C 1-6 Alkylene-C(O)NR a’ R b’ , -C 1-6 Alkylene-NR a’ -C(O)NR a’ R b’ , -C 1-6 Alkylene-OS(O) n R a’ , -C 1-6 Alkylene-S(O) n NR a’ R b’ , -C 1-6 Alkylene-NR a’ -S(O) n NR a’ R b’ , -C 1-6 Alkylene-NR a’ R b’ and -OC 1-6 Alkylene-NR a’ R b’ wherein the substituent R s The hydroxyl, amino, alkyl, alkylene, cycloalkyl, heterocyclyl, aryl, heteroaryl and aralkyl mentioned above are independently selected from halogen, OH, amino, cyano, nitro, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkyl hydroxyl, C 3-6 Cycloalkyl, 3-10 membered heterocyclyl, C 6-10 Aryl, 5-14 membered heteroaryl and C 6-12 may be further substituted with one, two, three or more substituents selected from the group consisting of aralkyl; n is independently 1 or 2; R a’ and R b’are independently H, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkyl-O-, C 1-6 Alkyl-S-, C 3-10 Cycloalkyl, 3-10 membered heterocyclyl, C 6-10 Aryl, 5-14 membered heteroaryl and C 6-12 aralkyl.

[0066] In another embodiment, the present invention relates to a compound represented by general formula (X), its pharmaceutically acceptable salts, enantiomers, diastereomers, racemates, solvates, hydrates, polymorphs, prodrugs or isotopic variants, and mixtures thereof: [ka] however, Ring A may be selected from the group consisting of the following, optionally substituted groups: 3-7 Cycloalkyl, 4-8 membered heterocyclyl, C 6-10 aryl, or 5-10 membered heteroaryl, wherein the substituents are selected from the group consisting of halogen, —CN, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 3-7 Cycloalkyl, 4-8 membered heterocyclyl, -P(O)(C 1-6 alkyl)2, -P(O)(C 2-6 alkenyl)2, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -OC 2-6 Alkenyl, -OC 3-7 Cycloalkyl, -O-4 to 8-membered heterocyclyl, -NH-C 1-6 Alkyl, -NH-C 2-6 Alkenyl, -NH-C 3-7 Cycloalkyl, -NH-4-8 membered heterocyclyl, -C(O)-C 1-6 Alkyl, -C(O)-C 2-6 Alkenyl, -C(O)-C 3-7Cycloalkyl, -C(O)-4 to 8-membered heterocyclyl, -S(O)2-C 1-6 Alkyl, -S(O)2-C 2-6 Alkenyl, -S(O)2-C 3-7 Cycloalkyl, -S(O)2-4 to 8-membered heterocyclyl, -NHC(O)-C 1-6 Alkyl, -NHC(O)-C 2-6 Alkenyl, -NHC(O)-C 3-7 Cycloalkyl, -NHC(O)-4 to 8-membered heterocyclyl, -NHS(O)2-C 1-6 Alkyl, -NHS(O)2-C 2-6 Alkenyl, -NHS(O)2-C 3-7 cycloalkyl, or -NHS(O)2- 4- to 8-membered heterocyclyl; Ring B is [ka] selected from the group consisting of: where Y is -CH2- or -C(O)-; R' is H, -C(O)-C 1-6 Alkyl, -C(O)-C 1-6 Haloalkyl, -C(O)-C 2-6 Alkenyl, or -C(O)-C 6-10 aryl; [ka] represents the site of connection to L1; L is a chemical bond, -O- or -NR-; where R is H or C 1-6 is alkyl; Z is -N= or -C(R4)=; T is a chemical bond, C 2-6 selected from the group consisting of heteroalkylene, 4- to 12-membered heterocyclylene, or 5- to 6-membered heterocyclylene substituted with 5- to 6-membered heterocyclylene; L1 is selected from the group consisting of a chemical bond, -O-, -NH-, -CH2-, -C(O)-, -CH2CH2-, -CH=CH-, -C≡C-, -OCH2-, -C2O-, -NHCH2-, -CH2NH-, -C(O)CH2-, -CH2C(O)-, -OC(O)-, -C(O)O-, -NHC(O)-, or -C(O)NH-; E is independently -CH2CH2CH2-, -CH2CH2C(O)-, -CH2C(O)CH2-, -C(O)CH2CH2-, -C(O)CH=CH-, -C(O)C≡C-, -CH2CH2O-, -CH2OCH2-, -OCH2CH2-, -C(O)CH2O-, -OCH2C(O)-, -CH2C(O) O-, -OC(O)CH2-, -C(O)OCH2-, -CH2OC(O)-, -CH2CH2NH-, -CH2NHCH2-, -NHCH2CH2-, -C(O)CH2NH-, -NHCH2C(O)-, -CH2C(O)NH-, -NHC(O)CH2-, -C(O)NHCH2-, -CH2NHC(O)-, [ka] [ka] selected from the group consisting of: where: [ka] represents the attachment site to L1 or L2; m is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; L2 is selected from the group consisting of a chemical bond, -CH2-, -CH2CH2-, -OCH2-, -NHCH2-, -OC(O)-, -NHC(O)-, -CH2C(O)-, or -C(O)CH2-; R1 is H, halogen, cyano, C 1-6 Alkyl, C 3-7 Cycloalkyl, 4-8 membered heterocyclyl, C 1-6 Haloalkyl, C 2-6 Alkenyl or C 2-6 alkynyl; Alternatively, when L is -NR-, R and R together with the atoms to which they are attached form an optionally substituted 5- to 6-membered heterocyclyl, wherein the substituents are halogen, oxo, C 1-6 Alkyl, C 1-6 Haloalkyl, mono- or polysubstituted with halogen C 6-10 aryl; R2 is H, halogen, hydroxyl, amino, C 1-6 Alkyl, or C 1-6 is haloalkyl; or R1 and R2 together with the atoms to which they are attached form a 5- to 6-membered heterocyclyl or a 5- to 6-membered heteroaryl; R3 is H, -OC 1-6 Alkyl or -OC 1-6 haloalkyl; R4 is H, halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, -NHC(O)-C 1-6 Alkyl, or -NHC(O)-C 2-6 alkenyl; The alkyl, alkylene, alkenyl, alkynyl, cycloalkyl, heterocyclyl, aryl, heteroaryl, or groups containing OH, NH, NH, CH, CH, CH in L, E, L, and T may each be one, two, three, or more R s and may be substituted with the above-mentioned R s are independently halogen, hydroxyl, amino, cyano, nitro, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Cycloalkyl, C 3-10 Halocycloalkyl, 3-10 membered heterocyclyl, C 6-10 Aryl, 5-14 membered heteroaryl, C 6-12 Aralkyl, -OR a , -OC(O)R a , -C(O)R a , -C(O)ORa , -C(O)NR a R b , -S(O) n R a , -S(O) n OR a , -S(O) n NR a R b , -NR a R b , -NR a C(O)R b , -NR a -C(O)OR b , -NR a -S(O) n -R b , -NR a C(O)NR a R b , -C 1-6 Alkylene-R a , -C 1-6 Alkylene-OR a , -C 1-6 Alkylene-OC(O)R a , -C 1-6 Alkylene-C(O)OR a , -C 1-6 Alkylene-S(O) n R a , -C 1-6 Alkylene-S(O) n OR a , -C 1-6 Alkylene-OC(O)NR a R b , -C 1-6 Alkylene-C(O)NR a R b , -C 1-6 Alkylene-NR a -C(O)NR a R b , -C 1-6 Alkylene-OS(O) n R a , -C 1-6 Alkylene-S(O) n NR a R b , -C 1-6 Alkylene-NR a -S(O) n NR a Rb , -C 1-6 Alkylene-NR a R b and -OC 1-6 Alkylene-NR a R b wherein the substituent R s The halogen, hydroxyl, amino, alkyl, alkylene, cycloalkyl, heterocyclyl, aryl, heteroaryl and aralkyl mentioned with respect to each independently represent halogen, OH, amino, cyano, nitro, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkyl hydroxyl, C 3-6 Cycloalkyl, 3-10 membered heterocyclyl, C 6-10 Aryl, 5-14 membered heteroaryl and C 6-12 may be further substituted with one, two, three or more substituents selected from the group consisting of aralkyl; n is independently 1 or 2; R a and R b are independently H, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkyl-O-, C 1-6 Alkyl-S-, C 3-10 Cycloalkyl, 3-10 membered heterocyclyl, C 6-10 Aryl, 5-14 membered heteroaryl and C 6-12 aralkyl.

[0067] In a more specific embodiment, the present invention relates to compounds of formula (I) or (IG), or pharmaceutically acceptable salts, enantiomers, diastereomers, racemates, solvates, hydrates, polymorphs, prodrugs, or isotopic variants thereof, and mixtures thereof. [ka] wherein each group is as defined above.

[0068] In a more specific embodiment, the present invention relates to compounds of general formula (I) or (IG), or pharmaceutically acceptable salts, enantiomers, diastereomers, racemates, solvates, hydrates, polymorphs, prodrugs or isotopic variants thereof, and mixtures thereof. however, Ring A is [ka] and; where: R7 is C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 3-7 Cycloalkyl, -P(O)(C 1-6 alkyl)2, or -P(O)(C 2-6 alkenyl)2; R8 is H, -NH-C 1-6 Alkyl, -NH-C 2-6 Alkenyl, -NH-C 3-7 Cycloalkyl, -NH-4-8 membered heterocyclyl, -NHC(O)-C 1-6 Alkyl, -NHC(O)-C 2-6 Alkenyl, -NHC(O)-C 3-7 Cycloalkyl, -NHC(O)-4 to 8-membered heterocyclyl, -NHS(O)2-C 1-6 Alkyl, or -NHS(O)2-C 3-7 cycloalkyl; R9 is H, halogen, -CN, C 1-6 Haloalkyl, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, C 3-7 Cycloalkyl, -OC 3-7 Cycloalkyl, C 1-6 Alkyl, -NH-C 1-6 Alkyl, -NH-C 2-6 Alkenyl, -NH-C 3-7 Cycloalkyl, -NH-4-8 membered heterocyclyl, -NHC(O)-C1-6 Alkyl, -NHC(O)-C 2-6 Alkenyl, -NHC(O)-C 3-7 Cycloalkyl, -NHC(O)-4 to 8-membered heterocyclyl, -NHS(O)2-C 1-6 Alkyl, or -NHS(O)2-C 3-7 cycloalkyl; X is -C(R x )= or -N=; where R x is H, or R x and R8 together with the C atom to which they are attached form a 5- to 6-membered heterocyclyl or a 5- to 6-membered heteroaryl; preferably R x and R8 together with the C atom to which they are attached form a 5-6 membered heteroaryl, preferably pyrazinyl; X1 is -CH(R X1 )-, or -N(R X1 )-and; X2 is -CH(R X2 )-, or -N(R X2 )-and; where R X1 is H, C 1-6 Alkyl, C 3-7 Cycloalkyl, -OC 1-6 Alkyl, -OC 3-7 Cycloalkyl, -NH-C 1-6 Alkyl, -NH-C 3-7 Cycloalkyl, -S(O)2-C 1-6 Alkyl, -S(O)2-C 3-7 Cycloalkyl, -NHS(O)2-C 1-6 Alkyl, -NHS(O)2-C 3-7 Cycloalkyl, -C(O)-C 1-6 Alkyl, -C(O)-C 2-6 Alkenyl, -C(O)-C 3-7 Cycloalkyl, -NHC(O)-C 1-6 Alkyl, -NHC(O)-C 3-7 cycloalkyl, or —C(O)-4- to 8-membered heterocyclyl; R X2 is H, C1-6 Alkyl, C 3-7 Cycloalkyl, -OC 1-6 Alkyl, -OC 3-7 Cycloalkyl, -NH-C 1-6 Alkyl, -NH-C 3-7 Cycloalkyl, -C(O)-C 1-6 Alkyl, -C(O)-C 3-7 Cycloalkyl, -C(O)-4 to 8-membered heterocyclyl, -S(O)2-C 1-6 Alkyl, -S(O)2-C 3-7 Cycloalkyl, -NHS(O)2-C 1-6 Alkyl, -NHS(O)2-C 3-7 Cycloalkyl, -NHC(O)-C 1-6 Alkyl, -NHC(O)-C 2-6 Alkenyl, -NHC(O)-C 3-7 cycloalkyl, or -NHC(O)-4- to 8-membered heterocyclyl; [ka] represents the attachment site to L; Each of the other groups is as defined above.

[0069] In a more specific embodiment, the present invention relates to compounds of general formula (I) or (IG), or pharmaceutically acceptable salts, enantiomers, diastereomers, racemates, solvates, hydrates, polymorphs, prodrugs or isotopic variants thereof, and mixtures thereof. however, T is a chemical bond, [ka] and; where: R5 is H or C 1-6 is alkyl; R6 is H or C 1-6 is alkyl; Alternatively, R5 and R6 may be joined to form C 1-6 Forming alkylene; [ka] represents the attachment site to the mother nucleus or L2; Each of the other groups is as defined above.

[0070] In a more specific embodiment, the present invention relates to compounds of general formula (I) or (IG), or pharmaceutically acceptable salts, enantiomers, diastereomers, racemates, solvates, hydrates, polymorphs, prodrugs or isotopic variants thereof, and mixtures thereof. however, When L is -NR-, R and R together are -C(O)N(R N )C(O)-, or -C(C 1-6 alkyl)=C(R N ) forming C(O)-; where: R N is C 1-6 alkyl, or [ka] selected from the group consisting of: R 11 is H or a halogen; R 12 is H or a halogen; R 13 is H or a halogen; [ka] represents the connection site; Each of the other groups is as defined above.

[0071] In a more specific embodiment, the present invention relates to compounds of general formula (I) or (IG), or pharmaceutically acceptable salts, enantiomers, diastereomers, racemates, solvates, hydrates, polymorphs, prodrugs or isotopic variants thereof, and mixtures thereof. wherein R1 and R2 together with the atoms to which they are attached form a 5- to 6-membered heteroaryl; preferably pyrrolyl; and each other group is as defined above.

[0072] Ring A In certain embodiments, ring A is an optionally substituted C 3-7 In another particular embodiment, ring A is an optionally substituted 4-8 membered heterocyclyl; in another particular embodiment, ring A is an optionally substituted C 6-10 aryl; in another particular embodiment, ring A is an optionally substituted 5-10 membered heteroaryl; in another particular embodiment, ring A is [ka] In another particular embodiment, ring A is [ka] In another particular embodiment, ring A is [ka] is.

[0073] In certain embodiments above, the substituent on ring A is halogen; in another particular embodiment above, the substituent on ring A is —CN; in another particular embodiment above, the substituent on ring A is C 1-6 alkyl; in another particular embodiment of the above, the substituent on ring A is C 1-6 haloalkyl; in another particular embodiment of the above, the substituent on ring A is C 2-6 alkenyl; in another particular embodiment of the above, the substituent on ring A is C 3-7 In another particular embodiment of the above, the substituent on ring A is 4-8 membered heterocyclyl; in another particular embodiment of the above, the substituent on ring A is —P(O)(C 1-6In another particular embodiment of the above, the substituent on ring A is —P(O)(C 2-6 alkenyl); in another particular embodiment of the above, the substituent on ring A is -OC 1-6 In another particular embodiment of the above, the substituent on ring A is -OC 1-6 haloalkyl; in another particular embodiment of the above, the substituent on Ring A is -OC 2-6 alkenyl; in another particular embodiment of the above, the substituent on ring A is -OC 3-7 In another particular embodiment of the above, the substituent on ring A is —O-4- to 8-membered heterocyclyl; in another particular embodiment of the above, the substituent on ring A is —NH—C 1-6 In another particular embodiment of the above, the substituent on ring A is -NH-C 2-6 alkenyl; in another particular embodiment of the above, the substituent on Ring A is -NH-C 3-7 In another particular embodiment of the above, the substituent on ring A is —NH-4- to 8-membered heterocyclyl; in another particular embodiment of the above, the substituent on ring A is —C(O)—C 1-6 alkyl; in another particular embodiment of the above, the substituent on ring A is —C(O)—C 2-6 alkenyl; in another particular embodiment of the above, the substituent on ring A is —C(O)—C 3-7 In another particular embodiment of the above, the substituent on ring A is —C(O)-4- to 8-membered heterocyclyl; in another particular embodiment of the above, the substituent on ring A is —S(O)2-C 1-6 In another particular embodiment of the above, the substituent on ring A is -S(O)2-C 2-6 alkenyl; in another particular embodiment of the above, the substituent on ring A is -S(O)2-C 3-7 In another particular embodiment of the above, the substituent on ring A is -S(O)2-4 to 8-membered heterocyclyl; in another particular embodiment of the above, the substituent on ring A is -NHC(O)-C 1-6alkyl; in another particular embodiment of the above, the substituent on Ring A is —NHC(O)—C 2-6 alkenyl; in another particular embodiment of the above, the substituent on Ring A is —NHC(O)—C 3-7 In another particular embodiment of the above, the substituent on ring A is —NHC(O)-4- to 8-membered heterocyclyl; in another particular embodiment of the above, the substituent on ring A is —NHS(O)2-C 1-6 In another particular embodiment of the above, the substituent on ring A is -NHS(O)2-C 2-6 alkenyl; in another particular embodiment of the above, the substituent on ring A is -NHS(O)2-C 3-7 cycloalkyl; in another particular embodiment of the above, the substituent on Ring A is -NHS(O)2-4 to 8-membered heterocyclyl.

[0074] L In certain embodiments, L is a chemical bond; in other particular embodiments, L is -O-; in other particular embodiments, L is -NR-.

[0075] Y In certain embodiments, Y is -CH2-; in another particular embodiment, Y is -C(O)-.

[0076] Z In certain embodiments, Z is -N=; in other particular embodiments, Z is -C(R4)=.

[0077] T In certain embodiments, T is C 2-6 In another particular embodiment, T is a 4- to 12-membered heterocyclylene; in another particular embodiment, T is a 5- to 6-membered heterocyclylene substituted with a 5- to 6-membered heterocyclylene; in another particular embodiment, T is [ka] In another particular embodiment, T is [ka] In another particular embodiment, T is [ka] In another particular embodiment, T is [ka] In another particular embodiment, T is a chemical bond. [ka] In certain embodiments, [ka] represents a single bond; in another particular embodiment, [ka] represents a double bond.

[0078] Z1 In certain embodiments, Z1 is an O atom; in another particular embodiment, Z1 is an S atom; in another particular embodiment, Z1 is an N atom; in another particular embodiment, Z1 is a C atom; in another particular embodiment, Z1 is one R Z1 In another particular embodiment, is substituted with two R Z1 In another particular embodiment, Z1 is absent.

[0079] Z2 In certain embodiments, Z2 is an O atom; in another particular embodiment, Z2 is an S atom; in another particular embodiment, Z2 is an N atom; in another particular embodiment, Z2 is a C atom; in another particular embodiment, Z2 is one R Z2 In another particular embodiment, Z2 is substituted with two R Z2 is replaced by

[0080] Z3 In certain embodiments, Z3 is an O atom; in another particular embodiment, Z3 is an S atom; in another particular embodiment, Z3 is an N atom; in another particular embodiment, Z3 is a C atom; in another particular embodiment, Z3 is one R Z3 In another particular embodiment, Z is substituted with two R Z3 is replaced by

[0081] In certain embodiments, Z1, Z2 and Z3 are all absent.

[0082] Z4 In certain embodiments, Z4 is N; in other certain embodiments, Z4 is CR Z4 is.

[0083] Z5 In certain embodiments, Z5 is N; in other certain embodiments, Z5 is CR Z5 is.

[0084] R a , R b and R c In certain embodiments, R a is H; in another particular embodiment, R a is halogen; in another particular embodiment, R a is OR'; in another particular embodiment, R a is NR'R''; in another particular embodiment, R a is C 1-6 alkyl; in another particular embodiment, R a is C 1-6 It is haloalkyl.

[0085] In certain embodiments, R b is H; in another particular embodiment, R b is halogen; in another particular embodiment, R bis OR'; in another particular embodiment, R b is NR'R''; in another particular embodiment, R b is C 1-6 alkyl; in another particular embodiment, R b is C 1-6 It is haloalkyl.

[0086] In certain embodiments, R c is H; in another particular embodiment, R c is halogen; in another particular embodiment, R c is OR'; in another particular embodiment, R c is NR'R''; in another particular embodiment, R c is C 1-6 alkyl; in another particular embodiment, R c is C 1-6 It is haloalkyl.

[0087] In certain embodiments, R a , R b and together with the C atom to which they are attached form C=O; in another particular embodiment, R a , R b and the C atoms to which they are attached, C 3-7 In another particular embodiment, R a , R b and together with the C atom to which they are attached form a 4-8 membered heterocyclyl; in another particular embodiment, R a and R c forms a chemical bond; in another particular embodiment, R a and R c and the C atoms to which they are attached, C 3-7 It forms a cycloalkyl or a 4- to 8-membered heterocyclyl.

[0088] R Z1 In certain embodiments, R Z1 is absent; in another particular embodiment, RZ1 is H; in another particular embodiment, R Z1 is CN; in another particular embodiment, R Z1 is halogen; in another particular embodiment, R Z1 Ha-(CH2) 0-5 -OR'; in another particular embodiment, R Z1 Ha-(CH2) 0-5 -NR'R''; in another particular embodiment, R Z1 is C 1-6 alkyl; in another particular embodiment, R Z1 is C 1-6 haloalkyl; in another particular embodiment, R Z1 Ha-(CH2) 0-5 -C 3-7 cycloalkyl; in another particular embodiment, R Z1 Ha-(CH2) 0-5 -4- to 8-membered heterocyclyl; in another particular embodiment, two R Z1 together with Z1 form C=O; in another particular embodiment, two R Z1 But Z1 and C 3-7 In another particular embodiment, two R Z1 forms a 4- to 8-membered heterocyclyl together with Z1.

[0089] R Z2 In certain embodiments, R Z2 is absent; in another particular embodiment, R Z2 is H; in another particular embodiment, R Z2 is CN; in another particular embodiment, R Z2 is halogen; in another particular embodiment, R Z2 Ha-(CH2) 0-5 -OR'; in another particular embodiment, R Z2 Ha-(CH2) 0-5 -NR'R''; in another particular embodiment, R Z2 is C 1-6 alkyl; in another particular embodiment, RZ2 is C 1-6 haloalkyl; in another particular embodiment, R Z2 Ha-(CH2) 0-5 -C 3-7 cycloalkyl; in another particular embodiment, R Z2 Ha-(CH2) 0-5 -4- to 8-membered heterocyclyl; in another particular embodiment, two R Z2 together with Z2 form C=O; in another particular embodiment, two R Z2 C with Z2 3-7 In another particular embodiment, two R Z2 forms a 4- to 8-membered heterocyclyl together with Z2.

[0090] R Z3 In certain embodiments, R Z3 is absent; in another particular embodiment, R Z3 is H; in another particular embodiment, R Z3 is CN; in another particular embodiment, R Z3 is halogen; in another particular embodiment, R Z3 Ha-(CH2) 0-5 -OR'; in another particular embodiment, R Z3 Ha-(CH2) 0-5 -NR'R''; in another particular embodiment, R Z3 is C 1-6 alkyl; in another particular embodiment, R Z3 is C 1-6 haloalkyl; in another particular embodiment, R Z3 Ha-(CH2) 0-5 -C 3-7 cycloalkyl; in another particular embodiment, R Z3 Ha-(CH2) 0-5 -4- to 8-membered heterocyclyl; in another particular embodiment, two R Z3 together with Z3 form C=O; in another particular embodiment, two R Z3 But Z3 and C 3-7In another particular embodiment, two R Z3 forms a 4- to 8-membered heterocyclyl together with Z3.

[0091] R Z4 In certain embodiments, R Z4 is H; in another particular embodiment, R Z4 is CN; in another particular embodiment, R Z4 is halogen; in another particular embodiment, R Z4 Ha-(CH2) 0-5 -OR'; in another particular embodiment, R Z4 Ha-(CH2) 0-5 -NR'R''; in another particular embodiment, R Z4 is C 1-6 alkyl; in another particular embodiment, R Z4 is C 1-6 It is haloalkyl.

[0092] R Z5 In certain embodiments, R Z5 is H; in another particular embodiment, R Z5 is CN; in another particular embodiment, R Z5 is halogen; in another particular embodiment, R Z5 Ha-(CH2) 0-5 -OR'; in another particular embodiment, R Z5 Ha-(CH2) 0-5 -NR'R''; in another particular embodiment, R Z5 is C 1-6 alkyl; in another particular embodiment, R Z5 is C 1-6 haloalkyl; in another particular embodiment, R Z5 Ha-(CH2) 0-5 -C 3-7 cycloalkyl; in another particular embodiment, R Z5 Ha-(CH2) 0-5 -4 to 8-membered heterocyclyl.

[0093] In certain embodiments, the ring in which Z4 is located is absent.

[0094] L1 In certain embodiments, L1 is a chemical bond; in other particular embodiments, L1 is -O-; in other particular embodiments, L1 is -S(O) p -; in another particular embodiment, L is -S(O)(=NR * )-; in another particular embodiment, L1 is -NR # In another particular embodiment, L is -CR # R # In another particular embodiment, L is -C a R # R # '-C b R # R # In another particular embodiment, L is -N=S(O)(R * )-; in another particular embodiment, L is -S(O)(R * )=N-.

[0095] L2 In certain embodiments, L2 is a chemical bond; in other particular embodiments, L2 is -O-; in other particular embodiments, L2 is -S(O) p -; in another particular embodiment, L2 is -S(O)(=NR * )-; in another particular embodiment, L2 is -NR # In another particular embodiment, L2 is -CR # R # In another particular embodiment, L2 is -C a R # R # '-C b R # R # In another particular embodiment, L2 is -N=S(O)(R * )—; in another particular embodiment, L2 is —S(O)(R *)=N-.

[0096] In another particular embodiment, C in L1 or L2 a R # R # ' or C b R # R # ' is O, S(O) p , S(O)(=NR * ) or NR # can be replaced by C a R # R # ' or C b R # R # ' is O, S or NR # If replaced by C a R # R # ' or C b R # R # ', another one is S(O) q can be replaced by

[0097] E In certain embodiments, E is a chemical bond; in other certain embodiments, E is -C c R # R # '-C d R # R # '-C e R # R # In another particular embodiment, E is [ka] In another particular embodiment, E is [ka] In another particular embodiment, E is [ka] In another particular embodiment, E is [ka] In another particular embodiment, E is [ka] is.

[0098] In another particular embodiment, C c R # R # ', C d R # R # ' or C e R # R # ' or C c R # R # ' and C e R # R # 'Both O and S(O) p , S(O)(=NR * ) or NR # can be replaced by C c R # R # ', C d R # R # ' or C e R # R # ' is O, S or NR # If replaced by one or two adjacent Cs, c R # R # ', C d R # R # ' or C e R # R # ', S(O) q can be replaced by

[0099] In another particular embodiment, two E units can form -CH2CH2OCH2CH2-; in another particular embodiment, two E units can form -OCH2CH2CH2CH2-; in another particular embodiment, two E units can form -CH2CH2CH2CH2O-; in another particular embodiment, two E units can form [ka] In another particular embodiment, two E units can form [ka] In another particular embodiment, two E units can form [ka] In another particular embodiment, two E units can form [ka] In another particular embodiment, two E units can form [ka] In another particular embodiment, two E units can form [ka] can be formed.

[0100] In another particular embodiment, in the embodiment of L, L or E, R on adjacent atoms # and R # can form chemical bonds, R on adjacent atoms # ' and R # ' is capable of forming chemical bonds.

[0101] In another particular embodiment, in the embodiments of L, L or E, R on the same atom # and R # ' are both =O or R x C optionally substituted with 3-7 Cycloalkyl, 4-8 membered heterocyclyl, C 6-10 In another particular embodiment, in the embodiment of L, L or E, R on different atoms form an aryl or a 5- to 6-membered heteroaryl. # and R # ' is both R x C optionally substituted with 3-7 Cycloalkyl, 4-8 membered heterocyclyl, C 6-10 Forms an aryl or a 5- to 6-membered heteroaryl.

[0102] m In certain embodiments, m is 0; in other particular embodiments, m is 1; in other particular embodiments, m is 2; in other particular embodiments, m is 3; in other particular embodiments, m is 4; in other particular embodiments, m is 5; in other particular embodiments, m is 6; in other particular embodiments, m is 7; in other particular embodiments, m is 8; in other particular embodiments, m is 9; in other particular embodiments, m is 10.

[0103] R1 In certain embodiments, R1 is H; in other particular embodiments, R1 is halogen; in other particular embodiments, R1 is cyano; in other particular embodiments, R1 is C 1-6 alkyl; in another particular embodiment, R is C 3-7 In another particular embodiment, R1 is 4-8 membered heterocyclyl; in another particular embodiment, R1 is C 1-6 haloalkyl; in another particular embodiment, R is C 2-6 alkenyl; in another particular embodiment, R is C 2-6In another specific embodiment, when L is -NR-, R and R together with the atom to which they are attached form an optionally substituted 5- to 6-membered heterocyclyl, wherein said substituents are halogen, oxo, C 1-6 Alkyl, C 1-6 Haloalkyl, mono- or polysubstituted with halogen C 6-10 aryl; in another particular embodiment, R and R are both selected from the group consisting of —C(O)N(R N )C(O)—; in another particular embodiment, R and R together form —C(C 1-6 alkyl)=C(R N )C(O)- is formed.

[0104] R2 In certain embodiments, R2 is H; in other particular embodiments, R2 is halogen; in other particular embodiments, R2 is hydroxyl; in other particular embodiments, R2 is amino; in other particular embodiments, R2 is C 1-6 alkyl; in another particular embodiment, R2 is C 1-6 haloalkyl; in another particular embodiment, R1 and R2 together with the atom to which they are attached form a 5- to 6-membered heterocyclyl; in another particular embodiment, R1 and R2 together with the atom to which they are attached form a 5- to 6-membered heteroaryl; in another particular embodiment, R1 and R2 together with the atom to which they are attached form a pyrrolyl.

[0105] R3 In certain embodiments, R3 is H; in other certain embodiments, R3 is HOC 1-6 alkyl; in another particular embodiment, R3 is -OC 1-6 It is haloalkyl.

[0106] R4 In certain embodiments, R4 is H; in other particular embodiments, R4 is halogen; in other particular embodiments, R4 is C 1-6alkyl; in another particular embodiment, R4 is C 1-6 haloalkyl; in another particular embodiment, R4 is -NHC(O)-C 1-6 In another particular embodiment, R4 is -NHC(O)-C 2-6 It is alkenyl.

[0107] Any one or any combination of the technical features in the above specific embodiments can be combined with any one or any combination of the technical features in other specific embodiments. For example, any one or any combination of the technical features related to ring A can be combined with any one or any combination of the technical features related to L, Y, Z1-Z5, R', T, L1, E, m, L2, R1-R4, etc. The present invention includes all combinations of these technical features, but the enumeration thereof is omitted.

[0108] In a more specific embodiment, the present invention provides a compound represented by general formula (I) or (IG), or a pharmaceutically acceptable salt, enantiomer, diastereomer, racemate, solvate, hydrate, polymorph, prodrug, or isotopic variant thereof, and mixtures thereof, wherein: Ring A may be selected from the group consisting of the following, optionally substituted groups: 3-7 Cycloalkyl, 4-8 membered heterocyclyl, C 6-10 aryl, or 5-10 membered heteroaryl, wherein said substituents are selected from the group consisting of -F, -Cl, -Br, -Me, -OMe, -CF3, -OCF3, -CN, -NHMe, cyclopropyl, -P(O)Me2, -NHC(O)CH2CH3, -C(O)CH=CH2, -NHS(O)2CH2CH3, -NH-cyclopropyl, -NHC(O)CH=CH2, or -C(O)CH2CH3; preferably, Ring A is [ka] selected from the group consisting of: where: R7 is selected from the group consisting of -Me, cyclopropyl, or -P(O)Me2; R8 is selected from the group consisting of H, -NHMe, -NHC(O)CH2CH3 or -NH-cyclopropyl; R9 is selected from the group consisting of H, -F, -Cl, -Br, -Me, -CF3, -OMe, -OCF3, -CN, -NHC(O)CH2CH3, -NHS(O)2CH2CH3, -NHC(O)CH=CH2 or -NH-cyclopropyl; X is -C(R x )= or -N=; where R x is H, or R x and R8 together with the C atom to which they are attached form a 5-6 membered heterocyclyl or a 5-6 membered heteroaryl; preferably a 5-6 membered heteroaryl (preferably pyrazinyl); X1 is -CH2- or -N(R X1 )-and; X2 is -CH(R X2 )-, or -N(R X2 )-and; where R X1 is -C(O)CH2CH3 or -C(O)CH=CH2; R X2 is H, -Me, -OMe, -NHMe, -C(O)CH2CH3, -NHS(O)2CH2CH3 or -NHC(O)CH2CH3; [ka] represents the attachment site to L; T is a chemical bond, C 2-6 is selected from the group consisting of heteroalkylene, 4- to 12-membered heterocyclylene, or 5- to 6-membered heterocyclylene substituted with 5- to 6-membered heterocyclylene; preferably, [ka] where: R5 is -Me; R6 is -Me; Alternatively, R5 and R6 combine to form -CH2CH2-; [ka] represents the attachment site to the mother nucleus or L2; R1 is selected from the group consisting of H, -Cl, -Br, -CH3, -CF3, cyclopropyl, or -CH=CH2; Alternatively, when L is -NR-, R1 and R together with the atoms to which they are attached form an optionally substituted 5- to 6-membered heterocyclyl, wherein said substituents are selected from the group consisting of halogen, oxo, -iPr, -Et, and phenyl mono- or polysubstituted with halogen; preferably, R1 and R are -C(O)N(R N )C(O)-, or -C(CH3)=C(R N ) forming C(O)-; where: R N -iPr, -Et or [ka] selected from the group consisting of: R 11 are -Cl, -Br; R 12 is H or -F; R 13 is H or -F; [ka] represents the connection site; R2 is H; Alternatively, R1 and R2 together with the atoms to which they are attached form a 5- to 6-membered heterocyclyl or a 5- to 6-membered heteroaryl; preferably pyrrolyl; R3 is selected from the group consisting of H or -OMe; R4 is selected from the group consisting of H, -F, -Me, -CF3, or -NHC(O)CH=CH2; Each of the other groups is as defined above.

[0109] In one form of the compound represented by general formula (I) or (IG) above, L1 is selected from the group consisting of a chemical bond, -O-, -NH-, -CH2-, -C(O)-, -CH2CH2-, -CH=CH-, -C≡C-, -OCH2-, -C2O-, -NHCH2-, -CH2NH-, -C(O)CH2-, -CH2C(O)-, -OC(O)-, -C(O)O-, -NHC(O)-, or -C(O)NH-; E is independently -CH2CH2CH2-, -CH2CH2C(O)-, -CH2C(O)CH2-, -C(O)CH2CH2-, -C(O)CH=CH-, -C(O)C≡C-, -CH2CH2O-, -CH2OCH2-, -OCH2CH2-, -C(O)CH2O-, -OCH2C(O)-, -CH2C(O) O-, -OC(O)CH2-, -C(O)OCH2-, -CH2OC(O)-, -CH2CH2NH-, -CH2NHCH2-, -NHCH2CH2-, -C(O)CH2NH-, -NHCH2C(O)-, -CH2C(O)NH-, -NHC(O)CH2-, -C(O)NHCH2-, -CH2NHC(O)-, [ka] [ka] [ka] selected from the group consisting of: m is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9, or 10; L2 is selected from the group consisting of a chemical bond, -CH2-, -CH2CH2-, -OCH2-, -NHCH2-, -OC(O)-, -NHC(O)-, -CH2C(O)-, or -C(O)CH2-; where: [ka] represents the attachment site to L1 or L2.

[0110] In a more specific embodiment, the present invention provides a compound represented by general formula (I), or a pharmaceutically acceptable salt, enantiomer, diastereomer, racemate, solvate, hydrate, polymorph, prodrug, or isotopic variant thereof, and mixtures thereof, wherein said compound represented by general formula (I) has a structure represented by the general formula: [ka] [ka] [ka] [ka] [ka] [ka] [ka] wherein each group is as defined above.

[0111] In a more specific embodiment, the present invention provides a compound represented by general formula (I-1), (I-1-A), (I-1-B), (I-1-C), (I-1-D), (I-1-E), (I-1-F), (I-1-G), (I-1-H) or (I-1-I), or a pharmaceutically acceptable salt, enantiomer, diastereomer, racemate, solvate, hydrate, polymorph, prodrug or isotopic variant thereof, and mixtures thereof, with the proviso that: R1 is selected from the group consisting of -Cl, -Br, -CF3 or -CH=CH2; preferably, R1 is selected from the group consisting of -Cl or -Br; R4 is H or -Me; R8 is H, -NHMe, -NHC(O)CH2CH3 or -NH-cyclopropyl; R9 is H, -F, -Cl, -Br, -Me, -CF3, -OMe, -OCF3, -CN, -NHC(O)CH2CH3, -NHS(O)2CH2CH3 or -NHC(O)CH=CH2; X is -C(R x )= or -N=; R x is H, or R x and R8 together with the C atom to which they are attached form a pyrazinyl; The other groups are as defined above.

[0112] In a more specific embodiment, the present invention provides a compound represented by general formula (IG), its pharmaceutically acceptable salts, enantiomers, diastereomers, racemates, solvates, hydrates, polymorphs, prodrugs or isotopic variants, and mixtures thereof: [ka] however, Ring A is [ka] and; where: R7 is -P(O)(C 1-6 alkyl)2; R8 is H; R9 is H, halogen, C 1-6 Alkyl, -CN or C 1-6 haloalkyl; X is -C(R x )=and; where R x is H, or R x and R8 together with the C atom to which they are attached form a 5-6 membered heteroaryl; preferably pyrazinyl; Y is a C atom and one or two R Z1 where R Z1 is H, CN, or halogen; or two R Z1together with Y form C=O; preferably, Y is CH2 or C=O; preferably, Y is CH2; L1 is -C a R # R # '-C b R # R # '-and; L2 is a chemical bond, -CR # R # '-or-C a R # R # '-C b R # R # '- selected from the group consisting of; where C a R # R # ' or C b R # R # ' is O, S(O) p or NR # can be replaced by; E is independently a chemical bond or -C c R # R # '-C d R # R # '-C e R # R # ' selected from the group consisting of; where C c R # R # ', C d R # R # ' or C e R # R # ' or C c R # R # ' and C e R # R # 'Both O and S(O) p or NR # can be replaced by; p is 0, 1 or 2; R # H, halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl or C 2-6 is alkynyl; R # ' is H, halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl or C 2-6 is alkynyl; Alternatively, R on the adjacent atom # and R # can form chemical bonds, R on adjacent atoms # ' and R # ' can form chemical bonds; Alternatively, R on the same or different atoms # and R # ' together form =O; m is 0, 1, 2, 3, 4 or 5; R s1 are H, CN, halogens, OH, NH2, C 2-6 Alkenyl, C 2-6 Alkynyl, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -NH-C 1-6 Alkyl, C 1-6 Alkyl, or C 1-6 haloalkyl; s1 is 0, 1, 2 or 3; L is -NR-; where R is H or C 1-6 is alkyl; Z is -C(R4)=; T is [ka] and; R1 is H, halogen, cyano, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl or C 2-6 alkynyl; R2 is H, halogen, hydroxyl, amino, C 1-6 Alkyl, or C 1-6 is haloalkyl; R3 is H, -OC 1-6 Alkyl or -OC 1-6 haloalkyl; R4 is H, halogen, C 1-6 Alkyl, or C 1-6 haloalkyl; When each of the above groups is H or an H-containing group, one or more of the H atoms can be replaced with a D atom.

[0113] In a more specific embodiment, the present invention provides compounds represented by general formula (I-1-G), (I-1-H), (I-1-H'), (I-1-H''), pharmaceutically acceptable salts, enantiomers, diastereomers, racemates, solvates, hydrates, polymorphs, prodrugs or isotopic variants thereof, and mixtures thereof. [ka] however, X is -CH=; Y is a C atom and one or two R Z1 where R Z1 is H, CN, or halogen; or two R Z1 together with Y form C=O; preferably, Y is CH2 or C=O; R1 is H, halogen, cyano, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl or C 2-6 alkynyl; preferably, R1 is H or halogen; R4 is H, halogen, C 1-6 Alkyl, or C 1-6 haloalkyl; preferably, R4 is H; R8 is H; R9 is H, halogen, C 1-6 Alkyl, -CN or C 1-6 haloalkyl; preferably, R9 is H; L1 is selected from the group consisting of -CH2CH2-, -CH=CH-, -C≡C-, -OCH2-, -SCH2-, -S(O)CH2-, -S(O)2CH2-, -NHCH2-, -N(Me)CH2-, -C(O)CH2-, -CH2C(O)-, -OC(O)-, -SC(O)-, -NHC(O)-, or -N(Me)C(O)-, and one or more H atoms in said groups may be replaced by D atoms; preferably, L1 is selected from the group consisting of -CH2CH2-, -CH=CH-, -C≡C-, -OCH2-, or -NHCH2-; preferably, L1 is selected from the group consisting of -CH2CH2-, -C≡C-, or -OCH2-; L2 is selected from the group consisting of a chemical bond, -CH2- or -CH2CH2-, and one or more H atoms in said group may be replaced with D atoms; E is -CH2CH2CH2-, -CH2CH2O-, -CH2OCH2-, -OCH2CH2-, -CH2CH2S-, -CH2SCH2- or -SCH2CH2-, and one or more H atoms in said groups may be replaced by D atoms; preferably, E is -CH2CH2CH2-; m is 0, 1, 2 or 3; preferably -L1-(E) m the chain length of -L2- is 4-14 bond lengths, more preferably 5, 6, 7, 8, 9 or 10 bond lengths; R s1 are H, CN, halogens, OH, NH2, C 2-6 Alkenyl, C 2-6 Alkynyl, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -NH-C 1-6 Alkyl, C 1-6 Alkyl, or C 1-6 haloalkyl; preferably, R s1 is H, CN, or a halogen; s1 is 0, 1 or 2.

[0114] In a more specific embodiment, the present invention provides compounds represented by general formula (I-1-G), (I-1-H), (I-1-H'), (I-1-H''), pharmaceutically acceptable salts, enantiomers, diastereomers, racemates, solvates, hydrates, polymorphs, prodrugs or isotopic variants thereof, and mixtures thereof. however, X is CH or N; Ring A is [ka] where: X is -CH=; Y is a C atom and one or two R Z1 where R Z1 is H, CN, or halogen; or two R Z1 together with Y form C=O; preferably, Y is CH2; R1 is H, halogen, cyano, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl or C 2-6 alkynyl; preferably, R1 is halogen; R4 is H, halogen, C 1-6 Alkyl, or C 1-6 haloalkyl; preferably, R4 is H; R8 is H; R9 is H, halogen, C 1-6 Alkyl, -CN or C 1-6 haloalkyl; preferably, R9 is H; L1 is selected from the group consisting of -CH2CH2-, -CH=CH-, -C≡C-, -OCH2-, -SCH2-, -S(O)CH2-, -S(O)2CH2-, -NHCH2-, -N(Me)CH2-, -C(O)CH2-, -CH2C(O)-, -OC(O)-, -SC(O)-, -NHC(O)-, or -N(Me)C(O)-, and one or more H atoms in said groups may be replaced by D atoms; preferably, L1 is selected from the group consisting of -CH2CH2-, -CH=CH-, -C≡C-, -OCH2-, or -NHCH2-; preferably, L1 is selected from the group consisting of -CH2CH2-, -C≡C-, -OCH2-, or -NHCH2-; L2 is selected from the group consisting of a chemical bond, -CH2- or -CH2CH2-, and one or more H atoms in said group may be replaced with D atoms; E is -CH2CH2CH2-, -CH2CH2O-, -CH2OCH2-, -OCH2CH2-, -CH2CH2S-, -CH2SCH2- or -SCH2CH2-, and one or more H atoms in said groups may be replaced by D atoms; preferably, E is -CH2CH2CH2-; m is 0, 1, 2 or 3; preferably -L1-(E) m The chain length of -L2- is 4-14 bond lengths, more preferably 5, 6, 7, 8, 9 or 10 bond lengths; R s1 are H, CN, halogens, OH, NH2, C 2-6 Alkenyl, C 2-6 Alkynyl, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -NH-C 1-6 Alkyl, C 1-6 Alkyl, or C 1-6 haloalkyl; preferably, R s1 is H or a halogen; s1 is 0, 1 or 2.

[0115] In a more specific embodiment, the present invention provides compounds represented by general formula (I-1-G), (I-1-H), (I-1-H'), (I-1-H''), pharmaceutically acceptable salts, enantiomers, diastereomers, racemates, solvates, hydrates, polymorphs, prodrugs or isotopic variants thereof, and mixtures thereof. [ka] however, X is -CH=; Y is a C atom and one or two R Z1 where R Z1 is H, CN, or halogen; or two R Z1 together with Y form C=O; preferably, Y is CH2 or C=O; R1 is H, halogen, cyano, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl or C 2-6 alkynyl; preferably, R1 is halogen; R4 is H, halogen, C 1-6 Alkyl, or C 1-6 haloalkyl; preferably, R4 is H; R8 is H; R9 is H, halogen, C 1-6 Alkyl, -CN or C 1-6 haloalkyl; preferably, R9 is H; L1 is selected from the group consisting of -CH2CH2-, -CH=CH-, -C≡C-, -OCH2-, -SCH2-, -S(O)CH2-, -S(O)2CH2-, -NHCH2-, -N(Me)CH2-, -C(O)CH2-, -CH2C(O)-, -OC(O)-, -SC(O)-, -NHC(O)-, or -N(Me)C(O)-, and one or more H atoms in said groups may be replaced by D atoms; preferably, L1 is selected from the group consisting of -CH2CH2-, -CH=CH-, -C≡C-, -OCH2-, or -NHCH2-; preferably, L1 is selected from the group consisting of -C≡C-, -OCH2-, or -NHCH2-; L2 is selected from the group consisting of a chemical bond, -CH2- or -CH2CH2-, and one or more H atoms in said group may be replaced with D atoms; E is -CH2CH2CH2-, -CH2CH2O-, -CH2OCH2-, -OCH2CH2-, -CH2CH2S-, -CH2SCH2- or -SCH2CH2-, and one or more H atoms in said groups may be replaced by D atoms; preferably, E is -CH2CH2CH2-; m is 1, 2 or 3; preferably -L1-(E) m The chain length of -L2- is less than 14 bond lengths; preferably, the chain length is 5-10 bond lengths, preferably 5, 6, 7, 8, 9 or 10 bond lengths; R s1 are H, CN, halogens, OH, NH2, C 2-6 Alkenyl, C 2-6 Alkynyl, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -NH-C 1-6 Alkyl, C 1-6 Alkyl, or C 1-6 haloalkyl; preferably, R s1 is H or a halogen; s1 is 0, 1 or 2.

[0116] In a more specific embodiment, the present invention provides compounds represented by the general formula (I-1-I), (I-1-I'), (I-1-I''), (I-1-I'''), pharmaceutically acceptable salts, enantiomers, diastereomers, racemates, solvates, hydrates, polymorphs, prodrugs or isotopic variants thereof, and mixtures thereof. [ka] however, Y is a C atom and one or two R Z1 where R Z1 is H, CN, or halogen; or two R Z1 together with Y form C=O; preferably, Y is CH2 or C=O; R1 is H, halogen, cyano, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl or C 2-6 alkynyl; preferably, R1 is halogen; R4 is H, halogen, C 1-6 Alkyl, or C 1-6 haloalkyl; preferably, R4 is selected from the group consisting of C 1-6 Alkyl or C 1-6 haloalkyl; R9 is H, halogen, C 1-6 Alkyl, -CN or C 1-6 haloalkyl; preferably, R9 is H; L1 is selected from the group consisting of -CH2CH2-, -CH=CH-, -C≡C-, -OCH2-, -SCH2-, -S(O)CH2-, -S(O)2CH2-, -NHCH2-, -N(Me)CH2-, -C(O)CH2-, -CH2C(O)-, -OC(O)-, -SC(O)-, -NHC(O)-, or -N(Me)C(O)-; preferably, L1 is selected from the group consisting of -CH2CH2-, -CH=CH-, -C≡C-, or -OCH2-; preferably, L1 is selected from the group consisting of -CH2CH2-, -C≡C-, or -OCH2-; L2 is selected from the group consisting of a chemical bond, -CH2-, or -CH2CH2-; E is -CH2CH2CH2-, -CH2CH2O-, -CH2OCH2-, -OCH2CH2-, -CH2CH2S-, -CH2SCH2- or -SCH2CH2-; preferably, E is -CH2CH2CH2-; m is 1 or 2; preferably -L1-(E) m The chain length of -L2- is 4-14 bond lengths, more preferably 5, 6, 7, 8, 9 or 10 bond lengths; R s1 are H, CN, halogens, OH, NH2, C 2-6 Alkenyl, C 2-6 Alkynyl, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -NH-C 1-6 Alkyl, C 1-6 Alkyl, or C 1-6 haloalkyl; preferably, R s1 is H, halogen or CN; s1 is 0, 1 or 2.

[0117] In a more specific embodiment, the present invention provides compounds represented by the general formula (I-1-I), (I-1-I'), (I-1-I''), (I-1-I'''), pharmaceutically acceptable salts, enantiomers, diastereomers, racemates, solvates, hydrates, polymorphs, prodrugs or isotopic variants thereof, and mixtures thereof. [ka] however, Y is a C atom and one or two R Z1 where R Z1 is H, CN, or halogen; or two R Z1 together with Y form C=O; preferably, Y is CH2; R1 is H, halogen, cyano, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl or C 2-6 alkynyl; preferably, R1 is halogen; R4 is H, halogen, C 1-6 Alkyl, or C 1-6 haloalkyl; preferably, R4 is selected from the group consisting of C 1-6 Alkyl, or C 1-6 haloalkyl; R9 is H, halogen, C 1-6 Alkyl, -CN or C 1-6 haloalkyl; preferably, R9 is H; L1 is selected from the group consisting of -CH2CH2-, -CH=CH-, -C≡C-, -OCH2-, -SCH2-, -S(O)CH2-, -S(O)2CH2-, -NHCH2-, -N(Me)CH2-, -C(O)CH2-, -CH2C(O)-, -OC(O)-, -SC(O)-, -NHC(O)-, or -N(Me)C(O)-; preferably, L1 is selected from the group consisting of -CH2CH2-, -CH=CH-, -C≡C-, or -OCH2-; preferably, L1 is selected from the group consisting of -C≡C- or -OCH2-; L2 is selected from the group consisting of a chemical bond, -CH2-, or -CH2CH2-; E is -CH2CH2CH2-; m is 1 or 2; preferably -L1-(E) mThe chain length of -L2- is less than 14 bond lengths; preferably, more preferably, 5, 6, 7, 8, 9 or 10 bond lengths; R s1 are H, CN, halogens, OH, NH2, C 2-6 Alkenyl, C 2-6 Alkynyl, -OC 1-6 Alkyl, -OC 1-6 Haloalkyl, -NH-C 1-6 Alkyl, C 1-6 Alkyl, or C 1-6 haloalkyl; preferably, R s1 is H or a halogen; s1 is 0, 1 or 2.

[0118] In a more specific embodiment, the present invention provides compounds represented by the general formula (I-2-I), (I-2-I'), (I-2-I''), (I-2-I'''), pharmaceutically acceptable salts, enantiomers, diastereomers, racemates, solvates, hydrates, polymorphs, prodrugs or isotopic variants thereof, and mixtures thereof. [ka] however, Y is a C atom and one or two R Z1 where R Z1 is H, CN, or halogen; or two R Z1 together with Y form C=O; preferably, Y is CH2; R1 is H, halogen, cyano, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl or C 2-6 alkynyl; preferably, R1 is halogen; R4 is H, halogen, C 1-6 Alkyl, or C 1-6 haloalkyl; preferably, R4 is selected from the group consisting of C 1-6 Alkyl, or C 1-6haloalkyl; R9 is H, halogen, C 1-6 Alkyl, -CN or C 1-6 haloalkyl; preferably, R9 is H; L1 is selected from the group consisting of -CH2CH2-, -CH=CH-, -C≡C-, -OCH2-, -SCH2-, -S(O)CH2-, -S(O)2CH2-, -NHCH2-, -N(Me)CH2-, -C(O)CH2-, -CH2C(O)-, -OC(O)-, -SC(O)-, -NHC(O)-, or -N(Me)C(O)-; preferably, L1 is selected from the group consisting of -CH2CH2-, -CH=CH-, -C≡C-, or -OCH2-; preferably, L1 is selected from the group consisting of -C≡C- or -OCH2-; L2 is selected from the group consisting of a chemical bond, -CH2-, or -CH2CH2-; E is -CH2CH2CH2-, -CH2CH2O-, -CH2OCH2-, -OCH2CH2-, -CH2CH2S-, -CH2SCH2- or -SCH2CH2-; preferably, E is -CH2CH2CH2-; m is 1 or 2; preferably -L1-(E) m The chain length of -L2- is less than 14 bond lengths; preferably 5, 6, 7, 8, 9 or 10 bond lengths; R s1 H, CN, halogens, C 1-6 Alkyl, or C 1-6 haloalkyl; preferably, R s1 is H or a halogen; s1 is 0, 1 or 2.

[0119] In more specific embodiments, the present invention provides compounds represented by general formula (I-2), (I-2-A), (I-2-B), (I-2-C), (I-2-D), (I-2-E), (I-2-F), (I-2-G), (I-2-H), or (I-2-I), pharmaceutically acceptable salts, enantiomers, diastereomers, racemates, solvates, hydrates, polymorphs, prodrugs, or isotopic variants thereof, and mixtures thereof. however, R1 is -Cl, -Br or -CH=CH2; R4 is H or -Me; R8 is H, -NHMe, -NHC(O)CH2CH3 or -NH-cyclopropyl; R9 is H, -F, -Cl, -Br, -Me, -CF3, -OMe, -OCF3, -CN, -NHC(O)CH2CH3, -NHS(O)2CH2CH3 or -NHC(O)CH=CH2; X is -C(R x )=and; R x is H, or R x and R8 together with the C atom to which they are attached form a pyrazinyl; The other groups are as defined above.

[0120] In more specific embodiments, the present invention provides compounds represented by general formula (I-3), (I-3-A), (I-3-B), (I-3-C), (I-3-D), (I-3-E), (I-3-F), (I-3-G) or (I-3-H), pharmaceutically acceptable salts, enantiomers, diastereomers, racemates, solvates, hydrates, polymorphs, prodrugs or isotopic variants thereof, and mixtures thereof. however, R1 is H, -Cl or -CH=CH2; R4 is -NHC(O)CH=CH2; R5 is -Me; R6 is -Me; Alternatively, R5 and R6 combine to form -CH2CH2-; R7 is -Me or cyclopropyl; The other groups are as defined above.

[0121] In a more specific embodiment, the present invention provides a compound represented by general formula (I-4), (I-4-A), (I-4-B), (I-4-C), (I-4-D), (I-4-E), (I-4-F), (I-4-G) or (I-4-H), a pharmaceutically acceptable salt, enantiomer, diastereomer, racemate, solvate, hydrate, polymorph, prodrug or isotopic variant thereof, and mixtures thereof. however, R1 is -CF3; R9 is H, -F, -Cl, -Br, -Me, -CF3, -OMe, -OCF3, -CN, -NHC(O)CH=CH2 or -NH-cyclopropyl; The other groups are as defined above.

[0122] In more specific embodiments, the present invention provides compounds represented by general formula (I-5), (I-5-A), (I-5-B), (I-5-C), (I-5-D), (I-5-E), (I-5-F), (I-5-G) or (I-5-H), pharmaceutically acceptable salts, enantiomers, diastereomers, racemates, solvates, hydrates, polymorphs, prodrugs or isotopic variants thereof, and mixtures thereof. however, Ring A is an optionally substituted C 3-7 Cycloalkyl or C 6-10 aryl, wherein said substituents are selected from the group consisting of -F, -Cl, -Br, -Me, -OMe, -CF3, -OCF3, -CN, -NHMe, -P(O)Me2, -NHC(O)CH2CH3, -C(O)CH=CH2, -NHS(O)2CH2CH3, -NH-cyclopropyl, -NHC(O)CH=CH2 or -C(O)CH2CH3; preferably, Ring A is [ka] and; where: R9 is H, -F, -Cl, -Br, -Me, -CF3, -OMe, -OCF3, -CN, -NHC(O)CH2CH3, -NHS(O)2CH2CH3 or -NHC(O)CH=CH2; X1 is -CH2- or -N(R X1 )-and; X2 is -CH(R X2 )- or -N(R X2 )-and; where: R X1 is -C(O)CH2CH3 or -C(O)CH=CH2; R X2 is H, -Me, -OMe, -NHMe, -NHS(O)2CH2CH3, -C(O)CH2CH3 or -NHC(O)CH2CH3; [ka] represents the connection site; R1 and R together with the atoms to which they are attached form an optionally substituted 5- to 6-membered heterocyclyl, wherein said substituents are selected from the group consisting of halogen, oxo, -iPr, -Et, and phenyl mono- or polysubstituted with halogen; preferably, R1 and R are -C(O)N(R N )C(O)-, or -C(CH3)=C(R N ) forming C(O)-; where: R N -iPr, -Et or [ka] selected from the group consisting of: R 11 are -Cl, -Br; R 12 is H or -F; R 13 is H or -F; [ka] represents the connection site; R3 is H or -OMe; R4 is H or -Me; The other groups are as defined above.

[0123] In a more specific embodiment, the present invention provides compounds represented by general formula (I-5-1) or (I'-5-1), pharmaceutically acceptable salts, enantiomers, diastereomers, racemates, solvates, hydrates, polymorphs, prodrugs, or isotopic variants thereof, and mixtures thereof. [ka] where: R9 is -NHC(O)CH2CH3 or -NHC(O)CH=CH2; R N is -iPr or -Et; The other groups are as defined above.

[0124] In a more specific embodiment, the present invention provides a compound represented by general formula (I-5-2) or (I'-5-2), a pharmaceutically acceptable salt, enantiomer, diastereomer, racemate, solvate, hydrate, polymorph, prodrug, or isotopic variant thereof, and mixtures thereof. [ka] however, R3 is H or -OMe; R4 is H or -Me; The other groups are as defined above.

[0125] In a more specific embodiment, the present invention provides compounds represented by general formula (I-5-3) or (I'-5-3), pharmaceutically acceptable salts, enantiomers, diastereomers, racemates, solvates, hydrates, polymorphs, prodrugs, or isotopic variants thereof, and mixtures thereof. [ka] however, X1 is -CH2- or -N(R X1 )-and; X2 is -CH(R X2 )-, or -N(R X2 )-and; where: R X1 is -C(O)CH2CH3; R X2 is H, -Me, -OMe, -NHMe, -C(O)CH2CH3, -NHS(O)2CH2CH3 or -NHC(O)CH2CH3; R 11 is -Cl or -Br; R 12 is H or -F; R 13 is H or -F; The other groups are as defined above.

[0126] In more specific embodiments, the present invention provides compounds represented by general formula (I-6), (I-6-A), (I-6-B), (I-6-C), (I-6-D), (I-6-E), (I-6-F), (I-6-G) or (I-6-H), pharmaceutically acceptable salts, enantiomers, diastereomers, racemates, solvates, hydrates, polymorphs, prodrugs or isotopic variants thereof, and mixtures thereof. however, L is -O- or -NH-; R3 is H or -OMe; R4 is H or -F; R9 is -CF3, -OMe, -OCF3, -CN, -NHC(O)CH2CH3 or -NHC(O)CH=CH2; The other groups are as defined above.

[0127] In more specific embodiments, the present invention relates to compounds represented by any of the above general formulas, their pharmaceutically acceptable salts, enantiomers, diastereomers, racemates, solvates, hydrates, polymorphs, prodrugs or isotopic variants, and mixtures thereof. however, [ka] teeth, [ka] [ka] is selected from the group consisting of In addition, one or more H atoms in the above groups may be replaced by D atoms.

[0128] In more specific embodiments, the present invention relates to compounds represented by any of the above general formulas, their pharmaceutically acceptable salts, enantiomers, diastereomers, racemates, solvates, hydrates, polymorphs, prodrugs or isotopic variants, and mixtures thereof. however, L1 and L2 are independently a chemical bond, -O-, -S-, -S(O)-, -S(O)2-, -S(O)(=NH)-, -S(O)(=NMe)-, [ka] [ka] -NH-, -N(Me)-, [ka] -N(CF3)-, -CH2-, -CH(OMe)-, -CH(Cl)-, -CH(F)-, -CF2-, -CH(CF3)-, -C(O)-, -CH2CH2-, -CH=CH-, -C≡C-, -OCH2-, -CH2O-, -SCH2-, -CH2S-, -S(O)CH2-, -CH2S(O)-, -S(O)2CH2-, -CH2S(O)2-, -NHCH2-, -N(Me)CH2-, -CH2NH-, -CH2N(Me)-, -C(O)CH2-, -CH2C(O)-, -C(O)CMe2-, -CMe2C(O)-, -OC(O)-, -C(O)O-, -SC(O)-, -C( O)S-, -NHC(O)-, -N(Me)C(O)-, -C(O)NH-, -C(O)N(Me)-, -S(O)=NH-, -NH=S(O)-, -N=S(O)Me-, -S(O)Me=N-, [ka] selected from the group consisting of: In addition, one or more H atoms in the above groups may be replaced by D atoms.

[0129] In more specific embodiments, the present invention relates to compounds represented by any of the above general formulas, their pharmaceutically acceptable salts, enantiomers, diastereomers, racemates, solvates, hydrates, polymorphs, prodrugs or isotopic variants, and mixtures thereof. however, E is a chemical bond, -CH2CH2CH2-, -CH2CH=CH-, -CH=CHCH2-, -CH2C≡C-, -C≡CCH2-, -CH2CH2C(O)-, -CH2C(O)CH2-, -C(O)CH2CH2-, -CH2CH2S(O)2-, -CH2S(O)2CH 2-, -S(O)2CH2CH2-, -C(O)CH=CH-, -C(O)C≡C-, -CH2CH2O-, -CH2OCH2-, -OCH2CH2-, -CH2CH2S-, -CH2SCH2-, -SCH2CH2-, -C(O)CH2O-, -OCH2C(O)-, -CH 2C(O)O-, -C(O)CH2S-, -SCH2C(O)-, -CH2C(O)S-, -OC(O)CH2-, -C(O)OCH2-, -CH2OC(O)-, -SC(O)CH2-, -C(O)SCH2-, -CH2SC(O)-, -CH2CH2NH-, -CH2NH CH2-, -NHCH2CH2-, -CH2CH2NMe-, -CH2NMeCH2-, -NMeCH2CH2-, -C(O)CH2NH-, -NHCH2C(O)-, -CH2C(O)NH-, -NHC(O)CH2-, -C(O)NHCH2-, -CH2NHC(O)-, [ka] [ka] selected from the group consisting of: Alternatively, two E units or two E' units may be -CH2CH2OCH2CH2-, -OCH2CH2CH2CH2-, -CH2CH2CH2CH2O-, [ka] [ka] can be formed; In addition, one or more H atoms in the above groups may be replaced by D atoms.

[0130] In more specific embodiments, the present invention relates to compounds represented by any of the general formulae above, or pharmaceutically acceptable salts, enantiomers, diastereomers, racemates, solvates, hydrates, polymorphs, prodrugs or isotopic variants thereof, and mixtures thereof, wherein m is 0, 1, 4, 5, 6, 7, 8, 9 or 10; preferably, m is 0, 1, 4, 5, 6, 7 or 8; preferably, m is 0, 1, 4, 5 or 6; preferably, m is 0, 1, 4 or 5.

[0131] In more specific embodiments, the present invention relates to compounds represented by any of the general formulae above, or pharmaceutically acceptable salts, enantiomers, diastereomers, racemates, solvates, hydrates, polymorphs, prodrugs or isotopic variants thereof, and mixtures thereof, wherein -L1-(E) m The chain length of -L2- is 4-14 bond lengths; preferably, the chain length is less than 12 bond lengths; preferably, the chain length is 5-10 bond lengths; preferably, the chain length is 5, 6, 7, 8, 9 or 10 bond lengths.

[0132] In a more specific embodiment, the present invention relates to a compound, or a pharmaceutically acceptable salt, enantiomer, diastereomer, racemate, solvate, hydrate, polymorph, prodrug, or isotopic variant thereof, and mixtures thereof, wherein said compound is [ka] [ka] [ka] [ka] [ka] is selected from the group consisting of:

[0133] The compounds of the present invention may contain one or more asymmetric centers, and therefore may exist as various stereoisomers, such as enantiomers and / or diastereomers.For example, the compounds of the present invention may be in the form of individual enantiomers, diastereomers, or geometric isomers (e.g., cis and trans isomers), or may be in the form of a mixture of stereoisomers (including racemic mixtures and mixtures enriched in one or more stereoisomers).Isomers are isolated from mixtures by methods known to those skilled in the art, including chiral high-performance liquid chromatography (HPLC) and the formation and crystallization of chiral salts; or preferred isomers are prepared by asymmetric synthesis.

[0134] Those skilled in the art will recognize that organic compounds may form complexes with solvents when reacted in or precipitated or crystallized from such solvents. These complexes are called "solvates." When the solvent is water, the complex is called a "hydrate." The present invention includes all solvates of the compounds of the present invention.

[0135] The term "solvate" generally refers to a form of a compound or its salt combined with a solvent, formed by solvolysis. This physical association involves hydrogen bonding. Common solvents include water, methanol, ethanol, acetic acid, DMSO, THF, diethyl ether, etc. The compounds of the present invention can be prepared, for example, as crystals, and solvated. Suitable solvates include pharmaceutically acceptable solvates, and further include stoichiometric and non-stoichiometric solvates. In certain embodiments, the solvates are isolated, for example, when one or more solvent molecules are incorporated into the crystal lattice of a crystalline solid. "Solvate" includes solvates in solution and separable solvates. Representative solvates include hydrates, ethanolates, and methanolates.

[0136] The term "hydrate" refers to a compound in combination with water. Typically, the ratio of the number of water molecules contained in a hydrate of a compound to the number of molecules of that compound in the hydrate is constant. Thus, a hydrate of a compound may be, for example, a compound of the general formula R x HO, where R is the compound and x is a number greater than 0. A given compound may form multiple types of hydrates, such as monohydrates (x is 1), lower hydrates (x is a number greater than 0 but less than 1, e.g., hemihydrates (R 0.5 HO), and polyhydrates (where x is greater than 1, e.g., dihydrate (RHO) and hexahydrate (RHO)).

[0137] The compounds of the present invention may be amorphous or crystalline (polymorphic). They may also exist as one or more crystal forms. Therefore, the present invention encompasses all amorphous and crystalline forms of the compounds of the present invention. The term "polymorph" refers to a crystalline form of a compound (or its salts, hydrates, or solvates) in which a particular crystal is stacked and arranged. All polymorphs have the same elemental composition. Different crystalline forms typically have different X-ray diffraction patterns, infrared spectra, melting points, densities, hardnesses, crystal shapes, photoelectric properties, stability, and solubility. The recrystallization solvent, crystallization rate, storage temperature, and other factors may result in a predominant crystalline form. Various polymorphs of a compound can be prepared by crystallization under different conditions.

[0138] The present invention also includes isotopically labeled compounds (isotopic variants) equivalent to those described in formula (I), but in which one or more atoms have been replaced by atoms whose atomic mass or mass number differs from the atomic mass or mass number typically found in nature. Examples of isotopes that can be introduced into the compounds of the present invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, and chlorine, such as isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorus, sulfur, fluorine, and chlorine, respectively. 2 H, 3 H, 13 C. 11 C. 14 C. 15 N, 18 O. 17 O. 31P, 32 P, 35 S, 18 F and 36 Examples of such isotopes include Cl. Compounds of the present invention, prodrugs thereof, and pharmaceutically acceptable salts of said compounds or said prodrugs that contain the above isotopes and / or other isotopes of other atoms are included within the scope of the present invention. 3 H and 14 Some isotopically labeled compounds of the present invention, such as those incorporating tritium (i.e., C), are useful in determining the tissue distribution of drugs and / or substrates. 3 H) and carbon-14 (i.e. 14 C) isotopes are particularly preferred due to their ease of preparation and detectability. 2 Substitution with heavier isotopes such as H can be advantageous in therapy due to superior metabolic stability. For example, it may be possible to increase in vivo half-life or reduce dosage, which may be considered preferred depending on the circumstances. In general, isotopically labeled compounds of formula (I) of the present invention and prodrugs thereof can be prepared by using readily available isotopically labeled reagents in place of non-isotopically labeled reagents when the processes disclosed in the following schemes and / or examples and preparations are carried out.

[0139] Furthermore, prodrugs are also included in the present specification. As used herein, the term "prodrug" refers to a compound that is converted into an active form having medical effects in vivo, for example, by hydrolysis in blood. Pharmaceutically acceptable prodrugs are described in T. Higuchi and V. Stella, Prodrugs as Novel Delivery Systems, ACS Symposium Series, Vol. 14, Edward B. Roche, ed., Bioreversible Carriers in Drug Design, American Pharmaceutical Association and Pergamon Press, 1987, and D. Fleisher, S. Ramon, and H. Barbra, "Improved oral drug delivery: solubility limitations overcome by the use of prodrugs," Advanced Drug Delivery Reviews (1996) 19(2) 115-130, each of which is incorporated herein by reference.

[0140] A prodrug is any covalently bonded compound of the present invention that releases the parent compound in vivo upon administration to a patient. Prodrugs are typically prepared by modifying functional groups so that they can be cleaved, either by routine manipulation or in vivo, to yield the parent compound. Prodrugs include, for example, compounds of the present invention in which a hydroxyl, amino, or mercapto group is bonded to any group that, upon administration to a patient, can be cleaved to form a hydroxyl, amino, or mercapto group. Thus, representative examples of prodrugs include, but are not limited to, acetate / acetamide, formate / formamide, and benzoate / benzamide derivatives of the hydroxyl, amino, or mercapto group of a compound of Formula (I). Additionally, in the case of carboxylic acids (—COOH), esters such as methyl esters and ethyl esters can be used. The esters themselves may be active and / or may be hydrolyzed under conditions in the human body. Suitable pharmaceutically acceptable in vivo hydrolyzable ester groups include those that readily decompose in the human body to release the parent acid or its salt.

[0141] The present invention also provides a pharmaceutical formulation comprising a therapeutically effective amount of a compound of formula (I) or a therapeutically acceptable salt thereof and a pharmaceutically acceptable carrier, diluent or excipient thereof, all of which are encompassed by the present invention.

[0142] Pharmaceutical Compositions and Kits In another aspect, the present invention provides pharmaceutical compositions comprising a compound of the present invention (also referred to as an "active ingredient") and a pharmaceutically acceptable excipient. In some embodiments, the pharmaceutical composition comprises an effective amount of a compound of the present invention. In some embodiments, the pharmaceutical composition comprises a therapeutically effective amount of a compound of the present invention. In some embodiments, the pharmaceutical composition comprises a prophylactically effective amount of a compound of the present invention.

[0143] The pharmaceutically acceptable excipient of the present invention refers to a non-toxic carrier, adjuvant or vehicle that does not destroy the pharmacological activity of the compound that is incorporated.The pharmaceutically acceptable carrier, adjuvant or vehicle that can be used in the composition of the present invention includes, but is not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum albumin (e.g., human serum albumin), buffer substances (e.g., phosphates), glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes (e.g., protamine sulfate), disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate, polyvinylpyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylate, wax, polyethylene-polyoxypropylene-block polymers, polyethylene glycol and wool fat.

[0144] The present invention also includes kits (e.g., pharmaceutical packs). The provided kits include a compound of the invention, another therapeutic agent, and first and second containers (e.g., vials, ampoules, bottles, syringes, and / or dispersion packages, or other suitable containers) containing the compound of the invention and the other therapeutic agent. In some embodiments, the provided kits may also include a third container containing a pharmaceutically acceptable excipient for diluting or suspending the compound of the invention and / or the other therapeutic agent. In some embodiments, the compound of the invention in the first container and the second container is provided in combination with the other therapeutic agent to form a unit dosage form.

[0145] Administration The pharmaceutical compositions provided by the present invention can be administered by a variety of routes, including, but not limited to, oral, parenteral, inhalation, topical, rectal, nasal, buccal, vaginal, implant, or other administration methods. For example, parenteral administration used in the present invention includes subcutaneous, intradermal, intravenous, intramuscular, intraarticular, intraarterial, intrasynovial, intrasternal, intrathecal, intralesional, and intracranial injection and infusion techniques.

[0146] The compounds provided by the present invention are typically administered in an effective amount, and the amount of compound actually administered will be determined by a physician depending on the circumstances, including the condition being treated, the selected administration method, the compound actually administered, the age, weight, and response of the patient, the severity of the patient's symptoms, etc.

[0147] When used to prevent the conditions described herein, the compounds provided by the present invention are administered to subjects at risk of developing the condition, typically at dosage levels as described above, based on a physician's recommendation. Subjects at risk of developing a particular condition typically include subjects with a family history of the condition or subjects predisposed to developing the condition by genetic testing or screening.

[0148] The pharmaceutical compositions provided by the present invention ("long-term administration") can also be administered chronically. Long-term administration refers to administration of a compound or pharmaceutical composition thereof for an extended period of time, such as 3 months, 6 months, 1 year, 2 years, 3 years, 5 years, etc., or can be administered continuously indefinitely, for example, for the rest of the subject's life. For example, in some embodiments, long-term administration is intended to provide a constant level of the compound in the blood over an extended period of time, e.g., within a therapeutic window.

[0149] The pharmaceutical composition of the present invention can also be delivered using various administration methods.For example, in some embodiments, pharmaceutical compositions can be administered by bolus injection, for example, to increase the concentration of compound in blood to an effective level.The placement of bolus dose depends on the target systemic level of active ingredient, for example, intramuscular or subcutaneous bolus dose allows for slow release of active ingredient, while bolus delivered directly into vein (for example, by IV drip) allows for faster delivery, which quickly increases the concentration of active ingredient in blood to an effective level.In other embodiments, the pharmaceutical composition can be administered as continuous infusion, for example, by IV drip, to provide the maintenance of steady-state concentration of active ingredient in the subject's body.

[0150] Compositions for oral administration can take the form of bulk liquid solutions or suspensions or bulk powders. However, compositions are typically provided in unit dosage forms to allow for precise dosage administration. The term "unit dosage form" refers to physically discrete units suitable as unit dosages for human subjects and other mammals, each unit containing a predetermined amount of active ingredient calculated to produce a desired therapeutic effect, along with suitable pharmaceutical excipients. Typical unit dosage forms include pre-measured, pre-filled ampoules or syringes for liquid compositions, or pills, tablets, capsules, etc. for solid compositions. In such compositions, the compound is usually a minor component (about 0.1 to about 50% by weight, or preferably about 1 to about 40% by weight), with the remainder being various carriers or excipients and processing aids that serve to form the desired dosage form.

[0151] For oral administration, a typical regimen is 1 to 5, particularly 2 to 4, and typically 3 oral doses per day. Using these dosing patterns, each dose provides about 0.01 to about 20 mg / kg of the compound of the invention, with preferred doses providing about 0.1 to about 10 mg / kg, particularly about 1 to about 5 mg / kg, respectively.

[0152] Transdermal doses are generally selected to provide blood levels similar to or lower than those achieved using injection doses, and generally range from about 0.01% to about 20% by weight, preferably from about 0.1% to about 20% by weight, preferably from about 0.1% to about 10% by weight, and more preferably from about 0.5% to about 15% by weight.

[0153] Injectable dose levels range from about 0.1 mg / kg / hour to at least 10 mg / kg / hour, all over a period of about 1 to about 120 hours, particularly 24 to 96 hours. A preloading bolus of about 0.1 mg / kg to about 10 mg / kg or more may also be administered to achieve adequate steady-state levels. The maximum total dose will not exceed about 2 g / day for a 40-80 kg human patient.

[0154] Liquid forms suitable for oral administration may include a suitable aqueous or nonaqueous vehicle with buffers, suspending and dispensing agents, colorants, flavors, etc. Solid forms may include, for example, any of the following ingredients, or compounds of a similar nature: binders (e.g., microcrystalline cellulose, gum tragacanth, or gelatin); excipients (e.g., starch or lactose); disintegrating agents (e.g., alginic acid, Primogel, or corn starch); lubricants (e.g., magnesium stearate); glidants (e.g., colloidal silicon dioxide); sweetening agents (e.g., sucrose or saccharin); or flavoring agents (e.g., peppermint, methyl salicylate, or orange flavor).

[0155] Injectable compositions are typically based on injectable sterile saline or phosphate-buffered saline or other injectable excipients known in the art. Conventionally, the active compound in such compositions is typically a minor component, often about 0.05-10% by weight, with the remainder being the injectable excipient, etc.

[0156] Transdermal compositions are typically formulated as topical ointments or creams containing active ingredient(s).When formulated as an ointment, the active ingredient is typically mixed with a paraffin ointment base or a water-miscible ointment base.Alternatively, the active ingredient can be formulated as a cream, for example, containing an oil-in-water cream base.Such transdermal formulations are well known in the art and generally contain additional ingredients that enhance the skin penetration or stability of the active ingredient or formulation.All such known transdermal formulations and ingredients are included within the scope provided by the present invention.

[0157] The compounds of this invention can also be administered by a transdermal device. Accordingly, transdermal administration can be accomplished using a patch either of the reservoir or porous membrane type or of a solid matrix variety.

[0158] The components described above for orally administrable, injectable, or topically administrable compositions are merely representative. Other materials and processing techniques are set forth in Part 8 of Remington's Pharmaceutical Sciences, 17th Edition, 1985, Mack Publishing Company, Easton, Pennsylvania (incorporated herein by reference).

[0159] The compounds of this invention can also be administered in sustained release forms or from sustained release drug delivery systems. A description of representative sustained release materials can be found in Remington's Pharmaceutical Sciences.

[0160] The present invention also relates to pharmaceutically acceptable formulations of the compounds of the present invention. In one embodiment, the formulation contains water. In another embodiment, the formulation contains a cyclodextrin derivative. The most common cyclodextrins are α-, β-, and γ-cyclodextrins, which consist of 6, 7, and 8 α-1,4-linked glucose units, respectively, optionally containing one or more substituents on the linked sugar moiety, including, but not limited to, methylation, hydroxyalkylation, acylation, and sulfoalkyl ether substitution. In a specific embodiment, the cyclodextrin is a sulfoalkyl ether β-cyclodextrin, e.g., sulfobutyl ether β-cyclodextrin, also known as Captisol. See, e.g., U.S. Patent No. 5,376,645. In some embodiments, the formulation contains hexapropyl-β-cyclodextrin (e.g., 10-50% in water).

[0161] treatment As mentioned above, EGFR kinase is known to play a role in tumorigenesis as well as many other diseases. The compounds of the present invention exhibit potent antitumor activity, which is believed to be achieved by inhibiting EGFR kinase.

[0162] The compounds of the present invention are valuable as antitumor agents. In particular, the compounds of the present invention are valuable as antiproliferative, apoptotic, and / or anti-invasive agents in the prevention and / or treatment of solid and / or liquid tumor diseases. In particular, the compounds of the present invention are expected to be useful in the prevention or treatment of tumors sensitive to ATR inhibition. Furthermore, the compounds of the present invention are expected to be useful in the prevention or treatment of tumors mediated solely or in part by EGFR. Thus, the compounds are useful for producing EGFR enzyme inhibitory effects in warm-blooded animals in need of such treatment.

[0163] As noted above, inhibitors of EGFR kinase are useful in the treatment of cancers such as, for example, ovarian cancer, cervical cancer, colorectal cancer, breast cancer, pancreatic cancer, glioma, glioblastoma, melanoma, prostate cancer, leukemia, lymphoma, non-Hodgkin's lymphoma, gastric cancer, lung cancer, hepatocellular carcinoma, gastrointestinal stromal tumor (GIST), thyroid cancer, cholangiocarcinoma, endometrial cancer, renal cancer, anaplastic large cell lymphoma, acute myeloid leukemia (AML), multiple myeloma, melanoma, and mesothelioma.

[0164] Therefore, anti-cancer effects useful in treating cancer in patients include, but are not limited to, anti-tumor effects, response rates, time to disease progression, and survival rates. Anti-tumor effects of the therapeutic methods of the present invention include, but are not limited to, inhibition of tumor growth, delay of tumor growth, tumor regression, tumor reduction, increasing the time until tumor regrowth after treatment is stopped, and delay of disease progression. Anti-cancer effects include not only preventative treatment, but also treatment of existing disease.

[0165] Furthermore, EGFR kinase inhibitors, or pharmaceutically acceptable salts thereof, are useful for treating cancer patients, including hematological malignancies such as leukemia and multiple myeloma; lymphomas such as Hodgkin's disease, non-Hodgkin's lymphoma (including mantle cell lymphoma), and myelodysplastic syndrome; and solid tumors and their metastases, such as breast cancer, lung cancer (non-small cell lung cancer (NSCL), small cell lung cancer (SCLC), non-small cell lung cancer (NSCL)), endometrial cancer, central nervous system tumors (e.g., glioma, dysembryoplastic neuroepithelial tumor, glioblastoma multiforme, mixed glioma, medulloblastoma, retinoblastoma, neuroblastoma, germinoma, and teratoma), gastrointestinal cancer. Cancers that may be affected include, but are not limited to, cancers of the esophagus (e.g., stomach cancer), esophageal cancer, hepatocellular (liver) cancer, bile duct cancer, colorectal cancer, small intestine cancer, pancreatic cancer, skin cancer such as melanoma (especially metastatic melanoma), thyroid cancer, head and neck and salivary gland cancer, prostate cancer, testicular cancer, ovarian cancer, cervical cancer, uterine cancer, vulvar cancer, bladder cancer, kidney cancer (including renal cell carcinoma, clear cell carcinoma, and renal oncocytoma), squamous cell carcinoma, sarcomas such as osteosarcoma, chondrosarcoma, leiomyosarcoma, soft tissue sarcoma, Ewing's sarcoma, gastrointestinal stromal tumor (GIST), Kaposi's sarcoma, and childhood cancers such as rhabdomyosarcoma and neuroblastoma.

[0166] An effective amount of the compound of the present invention is typically 0.01 mg to 50 mg of compound / kg of patient body weight per day, preferably 0.1 mg to 25 mg of compound / kg of patient body weight, administered in one or more doses. Typically, the compound of the present invention can be administered to a patient in need of this treatment at a daily dose ranging from about 1 mg to about 3500 mg per patient, preferably 10 mg to 1000 mg per patient. For example, the daily dose per patient can be 10, 20, 30, 40, 50, 60, 70, 80, 90, 100, 150, 200, 250, 300, 350, 400, 500, 600, 700, 800, 900, or 1000 mg. The compound can be administered in one or more doses daily, weekly (or every few days), or on an intermittent schedule. For example, the compound can be administered weekly (e.g., every Monday), once or multiple times daily, irregularly, or continuously for several weeks, e.g., 4 to 10 weeks. Alternatively, the compound can be administered daily for several days (e.g., 2 to 10 days), followed by no administration for several days (e.g., 1 to 30 days), and this cycle can be repeated at random or a predetermined number of times, e.g., 4 to 10 times. For example, the compound of the present invention can be administered continuously daily for 5 days, followed by a 9-day break, followed by another 5 days of continuous daily administration, followed by a 9-day break, and this cycle can be repeated irregularly or a total of 4 to 10 times.

[0167] Combination therapy The treatments defined herein may be applied as the sole treatment or may include, in addition to the compounds of the present invention, conventional surgery or radiotherapy or chemotherapy. Thus, the compounds of the present invention may also be used in combination with existing therapeutic agents for treating cancer.

[0168] Combination therapy also refers to conventional surgery, radiation therapy, chemotherapy, or immunotherapy in addition to the compounds of the present invention. Such chemotherapy may be administered simultaneously, sequentially, or separately from the compounds of the present invention and may include one or more of the following types of anti-tumor agents:

[0169] (i) Antiproliferative and antitumor agents and their combinations used in medical oncology, such as alkylating agents (e.g., cisplatin, oxaliplatin, carboplatin, cyclophosphamide, nitrogen mustard, melphalan, chlorambucil, busulfan, temozolomide, nitrosoureas); antimetabolites (e.g., gemcitabine and folate antagonists, such as fluoropyrimidines (5-fluorouracil and tegafur), raltitrexate, methotrexate, cytosine arabinoside, hydroxyurea); antitumor antibiotics (e.g., adriamycin, anthracyclines such as vincristine, bleomycin, doxorubicin, daunomycin, epirubicin, idarubicin, mitomycin-C, dactinomycin, and mithramycin; mitotic inhibitors (e.g., vinca alkaloids such as vincristine, vinblastine, vindesine, and vinorelbine; taxoids such as paclitaxel, taxotere, and polo-kinase inhibitors); and topoisomerase inhibitors (e.g., epipodophyllotoxins such as etoposide, teniposide, amsacrine, topotecan, and camptothecin);

[0170] (ii) cell proliferation inhibitors, such as antiestrogens (e.g., tamoxifen, fulvestrant, toremifene, raloxifene, droloxifene, and iodoxifene), antiandrogens (e.g., bicalutamide, flutamide, nilutamide, and cyproterone acetate), LHRH antagonists or agonists (e.g., goserelin, leuprorelin, and buserelin), progestogens (e.g., megestrol acetate), aromatase inhibitors (e.g., anastrozole, letrozole, vorazole, and exemestane), and 5α-reductase inhibitors (e.g., finasteride);

[0171] (iii) anti-invasion agents: for example, c-Src kinase family inhibitors (e.g., 4-(6-chloro-2,3-methylenedioxyanilino)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5-tetrahydropyran-4-yloxyquinazoline [AZD0530 (saracatinib)], N-(2-chloro-6-methylphenyl)-2-{6-[4-(2-hydroxyethyl)piperazin-1-yl]-2-methylpyrimidin-4-ylamino}thiazole-5-carboxamide (dasatinib, BMS-354825) and bosutinib (SKI-606), as well as metalloproteinase inhibitors (e.g., marimastat), inhibitors of urokinase plasminogen activator receptor function or antibodies against heparanase);

[0172] (iv) Growth factor function inhibitors: for example, growth factor antibodies and growth factor receptor antibodies (e.g., the anti-erbB2 antibody trastuzumab [Herceptin], the anti-EGFR antibody panitumumab, the anti-erbB1 antibody cetuximab [Erbitux, C225]); further, tyrosine kinase inhibitors, for example, inhibitors of the epidermal growth factor family (e.g., EGFR family tyrosine kinase inhibitors, such as N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinylpropoxy)-quinazolin-4-amine (gefitinib, ZD1839), N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)quinazolin-4-amine (erlotinib, OSI-774), 6-acrylamido-N-(3-chloro-4-fluorophenyl)-7-(3-morpholinylpropoxy)-quinazolin-4-amine (CI 1033), erbB2 tyrosine kinase inhibitors (e.g., lapatinib); inhibitors of the hepatocyte growth factor family; inhibitors of the insulin growth factor family; inhibitors of the platelet-derived growth factor family, such as imatinib and / or nilotinib (AMN107); inhibitors of serine / threonine kinases (e.g., Ras / Raf signaling inhibitors such as farnesyltransferase inhibitors, e.g., sorafenib (BAY43-9006), tipifarnib (R115777), lonafarnib (SCH66336)), inhibitors of mEK and / or AKT kinase-mediated cell signaling, c-kit inhibitors, abl kinase inhibitors, PI3 kinase inhibitors, Plt3 kinase inhibitors, CSF-1R kinase inhibitors, IGF receptor (insulin-like growth factor) kinase inhibitors; aurora kinase (aurora kinase) inhibitors (e.g., AZD1152, PH739358, VX-680, MLN8054, R763, MP235, MP529, VX-528, AX39459), including cyclin-dependent kinase inhibitors such as CDK2 and / or CDK4 inhibitors; (v) Antiangiogenic agents: for example, those that inhibit the effects of vascular endothelial growth factor (e.g., the anti-vascular endothelial growth factor antibody bevacizumab (Avastin)); and VEGF receptor tyrosine kinase inhibitors, such as vandetanib (ZD6474), vatalanib (PTK787), sunitinib (SU11248), axitinib (AG-013736), pazopanib (GW786034), 4-(4-fluoro-2-methylindol-5-yloxy)-6-methoxy-7-(3-pyrrolidin-1-ylpropoxy)quinazoline (AZD2171), and compounds that act by other mechanisms (e.g., linomide, integrin ανβ3 function inhibitors, and angiostatin); (vi) vascular damaging agents: e.g., combretastatin A4; (vii) endothelin receptor antagonists: for example, zibotentan (ZD4054) or atrasentan; (viii) Antisense therapy: for example, directed against the above targets, such as ISIS2503 (antisense therapeutic agent); (ix) Gene therapy approaches, including approaches that replace abnormal genes (e.g., abnormal p53 or abnormal BRCA1 or BRCA2); GDEPT (gene-directed enzyme prodrug therapy) approaches, such as approaches that use cytosine deaminase, thymidine kinase, or bacterial nitroreductase; and approaches that increase a patient's resistance to chemotherapy or radiation therapy (e.g., multidrug resistance gene therapy); (x) Immunotherapy approaches: ex-vivo and in-vivo approaches to increase the immunogenicity of a patient's tumor cells, such as transfection with cytokines (e.g., interleukin-2, interleukin-4, or granulocyte-macrophage colony-stimulating factor); approaches to reduce T cell anergy; approaches using transfected immune cells (e.g., cytokine-transfected dendritic cells); approaches using cytokine-transfected tumor cell lines; approaches using anti-idiotypic antibodies; approaches to reduce the function of immunosuppressive cells (e.g., regulatory T cells, myeloid-derived immunosuppressive cells, or IDO (indoleamine 2,3-deoxygenase)-expressing dendritic cells); and approaches using cancer vaccines consisting of proteins or peptides derived from tumor-associated antigens (e.g., NY-ESO-1, mAGE-3, WT1, or Her2 / neu).

[0173] Example The materials or reagents used in the present invention are either commercially available or prepared by synthetic methods generally known in the art.

[0174] Preparation of intermediates Preparation of 2-(2,6-dioxopiperidin-3-yl)-4-hydroxyisoindoline-1,3-dione (A2-1) [ka] 4-Hydroxyisobenzofuran-1,3-dione (5.0 g, 30.5 mmol), 3-aminopiperidine-2,6-dione (6.85 g, 41.8 mmol), and sodium acetate (4.1 g, 50.0 mmol) were dispersed in 100 mL of CH3COOH and refluxed at 140 °C for 8 h under nitrogen gas protection. After cooling to room temperature, the reaction mixture was concentrated under reduced pressure to remove CH3COOH. 200 mL of water was added to the residue, which was then slurried and stirred for 2 h. The mixture was filtered under suction, and the solid product was rinsed twice with water and dried to give 7.4 g of an off-white solid product. Yield: 89.15%. LCMS: [M+H] + =275. 1 H-NMR:(400MHz,DMSO-d6)δ 11.164(s,1H),11.080(s,1H),7.675(dd,J=7.2Hz,8.4Hz,1H),7.329(dd,J=7.2Hz,26.4Hz,2H), 5.094(dd,J=5.2Hz,12.8Hz,1H),2.919-2.840(m,1H),2.619-2.530(m,2H),2.048-1.989(m,1H).

[0175] Preparation of 2-(2,6-dioxopiperidin-3-yl)-4-fluoroisoindoline-1,3-dione (A6-1) [ka] The preparation method was the same as that of 2-(2,6-dioxopiperidin-3-yl)-4-hydroxyisoindoline-1,3-dione, and 4-fluoroisobenzofuran-1,3-dione was used as the raw material to obtain a white solid. LCMS: [M+H] + =277.

[0176] Preparation of 4-bromo-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (A1-1) [ka] The preparation method was the same as that of 2-(2,6-dioxopiperidin-3-yl)-4-hydroxyisoindoline-1,3-dione, and 4-bromoisobenzofuran-1,3-dione was used as the raw material to obtain a white solid. LCMS: [M+H] + =337,339.

[0177] Preparation of 2-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)acetic acid (A6-5) [ka] In a 100 mL three-necked flask equipped with a condenser, (2-((5-chloro-2-((2-methoxy-4-(4-(piperazin-1-yl)piperidin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)phenyl)dimethylphospholeoxide (300 mg, 0.527 mmol), potassium carbonate (145 mg, 1.054 mmol), and tert-butyl bromoacetate (113.04 mg, 0.527 mmol) were added in that order, dissolved in DMF (5 mL), heated to 60 °C, and reacted with stirring for 3 hours. The reaction mixture was cooled to room temperature, diluted with 20 mL of water, and extracted three times with ethyl acetate (20 mL each time). The organic phases were combined, washed three times with saturated brine, and dried over anhydrous sodium sulfate. The mixture was concentrated under reduced pressure to obtain the crude product. Silica gel column chromatography yielded 120 mg of a yellow solid. The solid obtained above was dissolved in 1,4-dioxane (5 mL), 2 mL of hydrogen chloride / 1,4-dioxane solution (4 mol / L) was added, and the mixture was stirred at room temperature for 2 hours. LCMS showed that the reaction mixture was mostly the desired product, and the mixture was concentrated under reduced pressure to give 112 mg of a yellow solid. Yield: 34%. LCMS: [M+H] + =628.

[0178] Preparation of 3-(4-bromo-1-oxoisoindolin-2-yl)piperidine-2,6-dione (C1-1) [ka] Methyl 3-bromo-2-methylbenzoate (1.14 g, 5.0 mmol) was dissolved in 20.0 mL of CCl4. Under nitrogen gas protection, NBS (1.34 g, 7.5 mmol) and AIBN (164 mg, 1.0 mmol) were added, and the mixture was heated to 85 °C and refluxed for 20 h. TLC showed no remaining starting material. The reaction mixture was cooled to room temperature, filtered under suction, and the filtrate was concentrated under reduced pressure to obtain the crude product. Purification by flash chromatography afforded 1.35 g of a pale yellow oil. This oil (1.35 g, 4.41 mmol) and 3-aminopiperidine-2,6-dione hydrochloride (941 mg, 5.74 mmol) were dispersed in 25.0 mL of anhydrous MeCN. TEA (580 mg, 5.74 mmol) was added, and the mixture was heated to 80 °C and refluxed for 16 h. LCMS showed that the reaction was complete. After cooling to room temperature, the reaction mixture was filtered under suction, the filter cake was washed three times with MeCN, and the solid was dried to give compound C1-1 (1.31 g, 92.3% yield). LCMS: [M+H] + =323,325.

[0179] Preparation of 2-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-N-(piperidin-4-yl)acetamide (C88-4) [ka] Compound A6-5 (75 mg, 0.12 mmol), HATU (45 mg, 0.118 mmol), and DIEA (77 mg, 0.60 mmol) were dissolved in 2.5 mL of DMF and stirred at room temperature for 1 hour under nitrogen gas protection. tert-Butyl 4-aminopiperidine-1-carboxylate (26 mg, 0.13 mmol) was then added and stirred for an additional 2.5 hours. After removing the solvent under reduced pressure, the mixture was dissolved in dichloromethane (4.0 mL), added dropwise to TFA (1.0 mL), and stirred at room temperature for 2 hours. The solvent was removed under reduced pressure, and the residue was separated by thin layer chromatography to obtain compound C88-4. LCMS: [M+H] + =710.

[0180] Preparation of 3-(5-bromo-1-oxoisoindolin-2-yl)piperidine-2,6-dione (C192-1) [ka] Methyl 4-bromo-2-(bromomethyl)benzoate (300 mg, 0.974 mmol), 3-aminopiperidine-2,6-dione hydrochloride (208 mg, 1.266 mmol), and triethylamine (128 mg, 1.266 mmol) were dissolved in 5 mL of acetonitrile and stirred overnight at 80 °C under nitrogen gas protection. After cooling to room temperature, the solvent was removed under reduced pressure, and the crude product was purified by flash filtration to give compound C192-1 (180 mg, 57.0% yield) as a white solid. LCMS: [M+H] + =323,325.

[0181] Preparation of 4-(7-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-7-oxoheptyl)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (A1) [ka]

[0182] Step 1: A1-1 (600 mg, 1.79 mmol), 6-alkynylheptanoic acid (450 mg, 3.58 mmol), CuI (69 mg, 0.36 mmol), Pd(PPh3)2Cl2 (501 mg, 0.71 mmol), and triethylamine (903 mg, 8.94 mmol) were added to DMF (15 mL) and stirred at 70 °C for 5 h under nitrogen gas protection. TLC confirmed that the starting material was consumed. LCMS confirmed that the desired product was produced. The mixture was concentrated under reduced pressure, and the crude product was separated by column chromatography to give solid A1-2 (680 mg, 99.7% yield). LCMS: [M+H] + =383.

[0183] Step 2: A1-2 (340 mg, 0.89 mmol) and Pd / C (10%, 74 mg) were added to methanol (8 mL) and hydrogenated at 3 MPa and room temperature for 7 hours. The solid was filtered off, and the solvent was removed under reduced pressure to give solid A1-3 (300 mg, 87.5% yield). LCMS: [M+H] + =387.

[0184] Step 3: A1-3 (85 mg, 0.22 mmol), DIEA (85 mg, 0.66 mmol), and HATU (84 mg, 0.22 mmol) were dissolved in DMF and stirred at room temperature under nitrogen gas protection for 0.5 h. Then, A1-4 (175 mg, 0.31 mmol) was added to the reaction mixture, and the mixture was stirred for an additional 3 h. TLC showed that the starting material was consumed. LCMS showed that the desired product was produced. The reaction mixture was directly purified by flash chromatography to give a white solid A1 (50 mg, 24.3% yield). LCMS: [M+H] + =938.

[0185] Preparation of 4-((7-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-7-oxoheptyl)oxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (A2) [ka]

[0186] Step 1: A mixture of A2-1 (200 mg, 0.73 mmol), tert-butyl 7-bromoheptanoate (232 mg, 0.87 mmol), KI (12 mg, 0.072 mmol), and potassium bicarbonate (110 mg) in DMF (5 mL) was stirred overnight at 60° C. under nitrogen gas protection. After filtration and removal of the solvent under reduced pressure, 160 mg of a white solid, A2-2, was obtained by flash chromatography.

[0187] Step 2: A2-2 (160 mg) was dissolved in 2 mL of TFA and stirred at room temperature for 1 hour. The solvent was removed under reduced pressure to give crude product A2-3, which was used directly in the next step.

[0188] Step 3: A2-3 (140 mg, 0.348 mmol), DIEA (225 mg, 1.744 mmol), and HATU (133 mg, 0.35 mmol) were dissolved in DMF (7 mL) and stirred at room temperature under nitrogen gas protection for 0.5 h. A1-4 (237 mg, 0.417 mmol) was then added to the reaction mixture, and the mixture was stirred for an additional 2 h. The reaction mixture was purified directly by flash chromatography to give A2 (25 mg, 7.5%). LCMS: [M+H] + =954.

[0189] Preparation of N-(2-(2-(2-(2-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)ethoxy)ethoxy)ethoxy)ethyl)-2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetamide (A3) [ka]

[0190] Step 1: A mixture of A2-1 (300 mg, 1.15 mmol), tert-butyl bromoacetate (467 mg, 1.79 mmol), KI (18 mg, 0.109 mmol), and potassium bicarbonate (164 mg, 1.64 mmol) in DMF was stirred overnight at 60°C under nitrogen gas protection. After filtration and removal of the solvent under reduced pressure, the product A3-1 (116 mg) was purified by preparative flash chromatography (26.9% yield).

[0191] Step 2: A3-1 (116 mg) was dissolved in TFA (1 mL) and stirred at room temperature for 1 hour. The solvent was evaporated to give crude product A3-2, which was used directly in the next step.

[0192] Step 3: Under nitrogen gas protection, A1-4 (150 mg, 0.21 mmol), A3-3 (94 mg, 0.26 mmol), and K2CO3 (73 mg, 0.53 mg) were added to acetonitrile and stirred overnight at 90 °C. The solid was filtered off, and the solvent was evaporated under reduced pressure. The solid was purified by flash chromatography to give compound A3-4 (110 mg, yield 49.5%).

[0193] Step 4: A3-4 (110 mg, 0.13 mmol) and TFA (1 mL) were dissolved in dichloromethane and stirred at room temperature for 1 hour. The solvent was evaporated under reduced pressure to give crude product A3-5, which was used directly in the next step.

[0194] Step 5: A3-2 (99 mg, 0.31 mmol), DIEA (192 mg, 1.49 mmol), and HATU (118 mg, 0.31 mmol) were dissolved in DMF and stirred at room temperature for 0.5 hours under nitrogen gas protection. A3-5 (222 mg, 0.30 mmol) was then added to the reaction mixture, which was then stirred for an additional 3 hours. The reaction mixture was purified directly by flash chromatography to give a white solid, A3 (25 mg, yield: 18.1%). LCMS: [M+H] + =1059.

[0195] Preparation of 2-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-N-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethyl)acetamide (A6) [ka]

[0196] Step 1: Compound A6-1 (276.2 mg, 1.0 mmol), compound A6-2 (160.2 mg, 1.0 mmol), DIPEA (387 mg, 3.0 mmol), and N,N-dimethylacetamide (5 mL) were added to a three-neck flask equipped with a condenser in that order. The mixture was heated to 90 °C under nitrogen gas protection and stirred overnight. LCMS analysis revealed that the starting materials had been consumed and the desired product had been produced. After cooling, the reaction mixture was diluted with 50 mL of water and extracted three times with ethyl acetate (25 mL each time). The combined organic phases were washed three times with saturated brine (20 mL each time). The organic phases were dried over anhydrous sodium sulfate for 2 h, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product. The crude product was purified by silica gel column chromatography to obtain a yellow solid, A6-3 (200 mg, 48% yield).

[0197] Step 2: Compound A6-3 (100 mg, 0.24 mmol) and 1,4-dioxane (5 mL) were added to a 50 mL single-neck flask and dissolved by stirring. Hydrogen chloride / 1,4-dioxane solution (2 mL, 4 M) was added and the mixture was stirred at room temperature for 2 hours. TLC showed that the starting material was consumed. LCMS showed that the desired product was produced. Concentration under reduced pressure gave compound A6-4 hydrochloride (80 mg, 95% yield) as a yellow solid. LCMS: [M+H] + =317.

[0198] Step 3: Compound A6-5 (31.4 mg, 0.05 mmol), HATU (23 mg, 0.06 mmol), and dichloromethane (3 mL) were added to a 50 mL three-neck flask and stirred at room temperature under nitrogen gas protection to dissolve the compound. Then, DIPEA (64 mg, 0.5 mmol) was added and the mixture was stirred at room temperature for 30 minutes. Next, a solution of compound A6-4 (22 mg, 0.05 mmol) in DMF (2.0 mL) was added and the mixture was stirred overnight at room temperature. LCMS analysis confirmed the formation of the desired product. The reaction mixture was concentrated under reduced pressure to remove the dichloromethane, and the mixture was separated by preparative flash column chromatography to obtain compound A6 (14 mg, 30.4% yield) as a pale yellow powder. LCMS: [M+H] + =926.

[0199] Preparation of 2-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-N-(2-(2-(2-(2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)amino)ethoxy)ethoxy)ethoxy)ethyl)acetamide (A8) [ka]

[0200] Step 1: Compound A3-3 (260.7 mg, 0.732 mmol), commercially available compound A8-1 (200 mg, 0.732 mmol), sodium bicarbonate (232 mg, 2.196 mmol), and N,N-dimethylformamide (5 mL) were added to a 20 mL microwave reactor in that order. The reaction was heated to 90 °C under nitrogen gas protection using a microwave reactor (reactor: CEM, output: 100 W) for 2 hours. Thin-layer chromatography showed that compound A8-1 had almost completely disappeared. LCMS showed that the desired product had been produced. The reaction mixture was cooled and filtered to remove inorganic salts. The mixture was diluted with 20 mL of water and extracted three times with ethyl acetate (25 ml each time). The organic phases were combined, washed twice with saturated brine (10 mL each time), then dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product. The crude product was separated by silica gel column chromatography to obtain compound A8-2 (100 mg, yield: 24.9%).

[0201] Step 2: Compound A8-2 (100 mg, 0.182 mmol) and 1,4-dioxane (4 mL) were added to a 50 mL single-neck flask and stirred to dissolve. Trifluoroacetic acid (2 mL) was further added and the mixture was stirred at room temperature for 2 hours. TLC showed the reaction was complete. Concentration under reduced pressure gave a brown oil. The product was dissolved in 20 mL of dichloromethane, washed twice with saturated sodium bicarbonate solution (5 mL each time), washed once with 10 mL of water, dried over anhydrous magnesium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give 55 mg of a yellow-green solid, A8-3. Yield: 68%. LCMS: [M+H] + =449.

[0202] Step 3: Compound A6-5 (70 mg, 0.1 mmol), HATU (45.6 mg, 0.12 mmol), and dichloromethane (3 mL) were added to a 50 mL three-neck flask and stirred at room temperature under nitrogen gas protection to dissolve the compound. DIPEA (64.5 mg, 0.5 mmol) was then added and the mixture was stirred at room temperature for 30 minutes. Compound A8-3 (45 mg, 0.1 mmol) was then added and the mixture was stirred overnight at room temperature. LCMS analysis confirmed the formation of the desired product. The reaction mixture was diluted with 20 mL of dichloromethane, washed twice with water (5 mL each time), and concentrated under reduced pressure to obtain the crude product. The crude product was separated using a preparative silica gel plate to obtain a pale yellow powder, A8 (22 mg, 20.8% yield). LCMS: [M+H] + =1058.

[0203] Preparation of 4-((7-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)heptyl)oxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (A10) [ka]

[0204] Step 1: A2-1 (274 mg, 1.0 mmol), NaHCO3 (252 mg, 3.0 mmol), and KI (83 mg, 0.5 mmol) were added to a 20 mL reaction flask. Under nitrogen gas protection, 5.5 mL of anhydrous DMF was added, and 7-bromo-1-heptanol (292.5 mg, 1.5 mmol) was added dropwise with stirring. After the addition was complete, the reaction was allowed to proceed at 70 °C for 20 h. The reaction mixture was diluted with 100 mL of ethyl acetate and washed sequentially with saturated NH4Cl solution (30 mL x 1), HO (30 mL x 3), and saturated brine (30 mL x 2). The organic layer was dried over anhydrous Na2SO4, filtered by suction to remove the drying agent, and the filtrate was concentrated under reduced pressure to obtain the crude product. Purification by prep-TLC afforded 300 mg of the white solid product A10-1. Yield: 77.3%. LCMS: [M+H]+ =389. 1 H-NMR:(400MHz,DMSO-d6)δ 11.092(s,1H),7.827(dd,J=7.6Hz,8.8Hz,1H),7.523(dd,J=8.4Hz,29.6Hz,2H),5.098-5.052(m,1H),4.358(t,J=5.2 Hz,1H),4.218(t,J=6.4Hz,2H),2.926-2.836(m,1H),2.045-1.995(m,1H),1.791-1.722(m,2H),1.492-1.237(m,12H).

[0205] Step 2: A10-1 (80 mg, 0.206 mmol) was dissolved in 15 mL of anhydrous DCM, and Dess-Martin reagent (262 mg, 0.618 mmol) was added under nitrogen gas protection. The mixture was then reacted at 55 °C for 2 h. The reaction mixture was diluted with 30 mL of DCM, and 15 mL of saturated NaHCO3 solution and 15 mL of saturated Na2S2O3 solution were added. After stirring for 5 min, the organic layer was separated, dried over anhydrous Na2SO4, and suction filtered to remove the drying agent. The filtrate was concentrated under reduced pressure to give crude A10-2 (75 mg). LCMS: [M+H] + = 387. This crude product was used directly in the next reaction.

[0206] Step 3: A10-2 (75 mg, 0.194 mmol) and A1-4 (110.3 mg, 0.194 mmol) were dissolved in 12.0 mL of anhydrous DCM and, under nitrogen gas protection, 2 drops of CH3COOH were added. The mixture was stirred at room temperature for 5 min. NaBH4 (73.7 mg, 1.94 mmol) was then added and the mixture was stirred at room temperature for 2 h. The reaction mixture was diluted with 30 mL of DCM, 15 mL of saturated NH4Cl solution was added, and the mixture was stirred for 5 min. The organic layer was separated and washed once with 15 mL of saturated brine, then dried over anhydrous Na2SO4. The drying agent was removed by suction filtration, and the filtrate was concentrated under reduced pressure to give the crude product. The crude product was purified by RP-Flash chromatography to give 65 mg of a white solid with a purity of approximately 60%. This product was further purified by prep-TLC to give 30 mg of a white solid with a purity of 90%. Purification again by RP-Flash chromatography gave 15 mg of pure product as a white solid. Yield 8.2%. LCMS: [M+H] + =940.5. 1 H-NMR:(400MHz,DMSO-d6) δ 11.164(s,1H),11.106(s,1H),8.480(s,1H),8.063-8.046(m,2H),7.827(t,J=8.0Hz,1H),7.555-7.502(m,2H),7.450-7. 432(m,1H),7.391-7.336(m,2H),7.111(t,J=7.2Hz,1H),6.625(d,J=2.4Hz,1H),6.474(d,J=8.0Hz,1H),5.085(dd,J=5.6, 12.8Hz,1H),4.204(t,J=6.4Hz,2H),3.757(s,3H),3.724-3.695(m,2H),2.884-2.851(m,1H),2.688-2.661(m,2H),2.630- 2.566(m,3H),2.333-2.246(m,6H),2.227-1.990(m,2H),1.858-1.830(m,2H),1.779-1.745(m,9H),1.524-1.239(m,12H).

[0207] Preparation of 4-((9-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)nonyl)oxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (A11) [ka]

[0208] Step 1: A2-1 (137 mg, 0.5 mmol), NaHCO3 (126 mg, 1.5 mmol), and KI (41.5 mg, 0.25 mmol) were added to a 20 mL reaction flask. Under nitrogen gas protection, 5.0 mL of anhydrous DMF was added, and 9-bromo-1-nonanol (167.3 mg, 0.75 mmol) was added dropwise with stirring. After the addition was complete, the reaction was allowed to proceed at 70 °C for 20 h. The reaction mixture was diluted with 80 mL of ethyl acetate and washed sequentially with saturated NH4Cl solution (20 mL x 1), HO (20 mL x 3), and saturated brine (20 mL x 2). The organic layer was dried over anhydrous Na2SO4, suction filtered to remove the drying agent, and the filtrate was concentrated under reduced pressure to obtain the crude product. Purification by prep-TLC afforded 70 mg of the A11-1 product as a white solid. Yield: 33.6%. LCMS: [M+H] + =417.

[0209] Step 2: A11-1 (60 mg, 0.144 mmol) was dissolved in 12 mL of anhydrous DCM, and Dess-Martin reagent (305.8 mg, 0.721 mmol) was added under nitrogen gas protection. The mixture was then reacted at 55 °C for 3 h. The reaction mixture was diluted with 30 mL of DCM, and 15 mL of saturated NaHCO3 solution and 15 mL of saturated Na2S2O3 solution were added. After stirring for 5 min, the organic layer was separated, dried over anhydrous Na2SO4, and filtered with suction to remove the drying agent. The filtrate was concentrated under reduced pressure to give crude A11-2 (55 mg). LCMS: [M+H] + = 415. This crude product was used directly in the next reaction.

[0210] Step 3: A11-2 (50 mg, 0.121 mmol) and A1-4 (68.7 mg, 0.121 mmol) were dissolved in 10.0 mL of anhydrous DCM. Under nitrogen gas protection, 2 drops of CH3COOH were added dropwise, followed by stirring at room temperature for 5 min. Next, NaBH4 (46 mg, 1.21 mmol) was added, and the reaction was allowed to proceed with stirring at room temperature for 2 h. The reaction mixture was diluted with 20 mL of DCM, 15 mL of saturated NH4Cl solution was added, and the mixture was stirred for 5 min. The organic layer was separated and washed once with 15 mL of saturated brine, then dried over anhydrous Na2SO4. The drying agent was removed by suction filtration, and the filtrate was concentrated under reduced pressure to give the crude product. The crude product was purified by RP-Flash chromatography to give 20 mg of the product as a white solid. Yield: 17%. LCMS: [M+H] + =968.5. 1 H-NMR:(400MHz,DMSO-d6)δ 11.169(s,1H),11.114(s,1H),8.475(s,1H),8.047(d,J=6.4Hz,2H),7.825-7.860(m,1H),7.555-7.502(m ,3H),7.448-7.317(m,2H),7.092(t,J=7.6Hz,1H),6.624-6.450(m,2H),5.085(dd,J=5.2,12.8Hz,1H),4. 201(t,J=6.4Hz,2H),3.725(t,J=12.8Hz,6H),3.287(s,2H),2.688-2.540(m,6H),2.328-2.195(m,6H),2. 029-1.991(m,2H),1.861-1.830(m,2H),1.779-1.746(m,10H),1.661-1.274(m,4H),1.275-1.237(m,8H).

[0211] Preparation of 3-(4-((7-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)heptyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (A12) [ka]

[0212] Step 1: 7-Bromo-1-heptanol (200 mg, 1.03 mmol) was added to pyridinium chlorochromate (333 mg, 1.54 mmol) in THF (5 mL) and the mixture was stirred at room temperature overnight. The solvent was removed under reduced pressure, and 20 mL of diethyl ether was added to dissolve the mixture. The mixture was filtered and concentrated to give crude product A12-2 (160 mg, 80.8% yield). LCMS: [M+H] + =193,195.

[0213] Step 2: A12-2 (200 mg, 1.04 mmol) and 3-(4-amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione (A12-3) (270 mg, 1.04 mmol) were dissolved in DCM (10 mL) and MeOH (5 mL) and stirred at 50 °C for 1 h under nitrogen gas protection. After cooling to room temperature, sodium cyanoborohydride (98 mg, 1.56 mmol) and 2 drops of glacial acetic acid were added, and the mixture was heated to 50 °C and stirred for an additional 1.5 h. After cooling to room temperature, the mixture was quenched with saturated aqueous ammonium chloride solution, extracted with dichloromethane, and the layers were separated. The organic phases were combined, dried over anhydrous sodium sulfate, allowed to settle, filtered, and concentrated. The crude product was purified by flash filtration to give A12-4 (100 mg, 22.1% yield). LCMS: [M+H] + =436,438.

[0214] Step 3: A12-4 (10 mg, 0.023 mmol), A1-4 (13 mg, 0.023 mmol), and DIEA (16 mg, 0.124 mmol) were dissolved in DMF (0.5 mL) and stirred at 80 °C for 7 h under nitrogen gas protection. The solvent was removed under reduced pressure, and the residue was purified by flash filtration to give A12 (2.97 mg, 14.0% yield). LCMS: [M+H] + =925. 1H NMR(400MHz,DMSO-d6) δ 11.17(s,1H),11.00(s,1H),8.48(s,1H),8.06(d,J=5.3Hz,1H),7.53(dd,J=13.9,7.4Hz,1H),7.43-7.24(m,4H),7.18(s ,1H),7.09(t,J=7.4Hz,1H),6.92(d,J=7.4Hz,1H),6.74(d,J=8.1Hz,1H),6.62(d,J=2.5Hz,1H),6.47(d,J=8.3Hz,1H),5 .55(s,1H),5.11(dd,J=13.1,5.1Hz,1H),4.23(d,J=17.0Hz,1H),4.12(d,J=17.2Hz,1H),3.76(s,3H),3.73(m,2H),3.52 (m,1H),3.10(m,2H),2.93(m,1H),2.63(m,3H),2.33(m,3H),2.29-2.27(m,2H),2.03-1.98(m,4H),1.85(m,2H),1.78(s, 3H), 1.75(s, 3H), 1.57-1.50(m, 6H), 1.42(m, 2H), 1.34(m, 2H), 1.26(m, 2H).

[0215] Preparation of 3-(4-((9-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)nonyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (A13) [ka]

[0216] Step 1: 9-Bromo-1-nonanol (222 mg, 1.03 mmol) was added to pyridinium dichlorochromate (333 mg, 1.54 mmol) in THF (5 mL) and the mixture was stirred at room temperature overnight. The solvent was removed under reduced pressure, and 20 mL of diethyl ether was added to dissolve the mixture. The mixture was filtered and concentrated to give crude product A13-2 (150 mg, 68.2% yield). LCMS: [M+H] + =221,223.

[0217] Step 2: A13-2 (228 mg, 1.04 mmol) and 3-(4-amino-1-oxoisoindolin-2-yl)piperidine-2,6-dione (A12-3) (270 mg, 1.04 mmol) were dissolved in DCM (10 mL) and MeOH (5 mL) and stirred at 50 °C for 1 h under nitrogen gas protection. After cooling to room temperature, sodium cyanoborohydride (98 mg, 1.56 mmol) and 2 drops of glacial acetic acid were added, and the mixture was heated to 50 °C and stirred for an additional 1.5 h. After cooling to room temperature, the mixture was quenched with saturated aqueous ammonium chloride solution, extracted with dichloromethane, and the layers were separated. The organic phases were combined, dried over anhydrous sodium sulfate, allowed to settle, filtered, and concentrated. The crude product was purified by Flash to give A13-3 (100 mg, 20.9% yield). LCMS: [M+H] + =464,466.

[0218] Step 3: A13-3 (11 mg, 0.023 mmol), A1-4 (13 mg, 0.023 mmol), and DIEA (16 mg, 0.124 mmol) were dissolved in DMF (0.5 mL) and stirred at 80 °C for 7 hours under nitrogen gas protection. The solvent was removed under reduced pressure, and the residue was purified by flash filtration to give A13 (2.49 mg, 11.0% yield). LCMS: [M+H] + =953. 1H-NMR (400MHz, DMSO-d6) δ 11.17(s,1H),11.01(s,1H),8.48(s,1H),8.06(s,1H),7.56-7.50(m,1H),7.4 0-7.25(m,4H),7.18(s,1H),7.09(t,J=7.5Hz,1H),6.90(dd,J=15.3,7.3Hz,1H ),6.77-6.67(m,1H),6.62(d,J=2.6Hz,1H),6.47(d,J=9.2Hz,1H),5.54(t,1H ),5.11(dd,J=13.2,5.0Hz,1H),4.23(d,J=17.2Hz,1H),4.12(d,J=17.2Hz,1H) ,3.76(s,3H),3.73(m,1H),3.70(m,1H),3.52(s,1H),3.11(d,J=6.1Hz,2H),2 .99-2.86(m,1H),2.66(t,J=11.7Hz,3H),2.32(m,3H),2.26(m,2H),2.01(m,4H) ),1.85(d,J=12.2Hz,2H),1.78(s,3H),1.75(s,3H),1.59-1.49(m,4H),1.44- 1.38(m,4H),1.34(m,2H),1.30(m,2H),1.27(m,2H),1.26(m,2H),1.25(m,2H).

[0219] Preparation of 2-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-N-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)acetamide (A17) [ka]

[0220] Step 1: A17-1 (or A12-3) (200 mg, 0.772 mmol) and TEA (234 mg, 2.32 mmol) were dissolved in DCM (3 mL). Chloroacetyl chloride (78 mg, 0.697 mmol) was added dropwise under nitrogen gas protection at 0 °C, and the mixture was stirred at 0 °C for an additional 2 h. LCMS monitoring showed the reaction was complete. The reaction was quenched with 1 mL of methanol, and the solvent was evaporated under reduced pressure at 40 °C. The crude product was purified by flash filtration to give a white solid A17-2 (170 mg, 73.0% yield). LCMS: [M+H] + =336.

[0221] Step 2: A17-2 (30 mg, 0.090 mmol), A1-4 (51 mg, 0.090 mmol), and DIEA (59 mg, 0.457 mmol) were added to DMF (2 mL) and reacted under nitrogen gas protection at 60°C with stirring for 2 hours. LCMS monitoring showed the reaction was complete. The reaction mixture was purified by flash filtration to give an off-white solid A17 (15 mg, 19.5% yield). LCMS: [M+H] + =869. 1 H-NMR(400MHz,DMSO-d6) δ 11.17(s,1H),11.03(s,1H),8.49(s,1H),8.06(m,J=4.4Hz,2H),7.87-7.72(m,1H),7.58-7.49(m,3H),7.38(dd,J=15.7, 8.0Hz,1H),7.10(t,J=7.6Hz,1H),6.71-6.60(m,1H),6.56-6.45(m,1H),5.15(dd,J=13.3,5.2Hz,2H),4.45-4.33(m ,3H),3.97-3.89(m,1H),3.80-3.69(m,4H),3.49(d,J=15.9Hz,1H),3.38(s,1H),3.19(s,1H),3.02(s,4H),2.65(q, J=17.0, 15.0Hz,8H),2.42-2.22(m,2H),1.90(d,J=12.9Hz,3H),1.78(s,3H),1.75(s,2H),1.28(d,J=15.9Hz,2H).

[0222] Preparation of 3-(4-((2-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-2-oxoethyl)amino)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (A18) [ka]

[0223] Step 1: A18-1 (or A12-3) (259.1 mg, 1 mmol), tert-butyl 2-bromoacetate (232.8 mg, 1.2 mmol), KI (16.6 mg, 0.1 mmol), and NaHCO (126.0 mg, 1.5 mmol) were added to DMF (7 mL) and stirred overnight at 60 °C under nitrogen gas protection. The solvent was evaporated under reduced pressure, and the crude product was separated by column chromatography to give a white solid A18-2 (150 mg, 40.2% yield).

[0224] Step 2: A18-2 (44 mg, 0.118 mmol) was dissolved in 1 mL of TFA at 0° C. and stirred at room temperature for 1 hour. The solvent was removed under reduced pressure at 40° C. to give crude product A18-3. LCMS: [M+H] + =318.

[0225] Step 3: The crude product A18-3 was dispersed in dichloromethane (2 mL) at room temperature, and DIEA (81 mg, 0.628 mmol) and HATU (44 mg, 0.116 mmol) were added. The mixture was stirred at room temperature for 0.5 hours under nitrogen gas protection. Then, A1-4 (51 mg, 0.090 mmol) was added and the mixture was stirred at room temperature for an additional 3 hours. LCMS monitoring showed the reaction was complete. The solvent was evaporated under reduced pressure at 40 °C, and the crude product was purified by flash filtration to give an off-white solid A18 (25 mg, 32.1% yield). LCMS: [M+H] + =869. 1H-NMR(400MHz,DMSO-d6) δ 11.16(s,1H),8.48(s,1H),8.05(d,J=7.4Hz,2H),7.56-7.48(m,1H),7.40-7.33(m,3H),7.19(t,J=7.6Hz,1H),7.09(t,J=7. 4Hz,1H),6.92(d,J=7.4Hz,1H),6.80(d,J=7.9Hz,1H),6.68-6.60(m,1H),6.52-6.44(m,1H),5.45(s,1H),5.27(dd,J=13.3, 5.2Hz,1H),4.51(d,J=6.1Hz,3H),4.24(d,J=16.9Hz,1H),4.02(d,J=16.8Hz,1H),3 .75(s,4H),3.46(d,J=26.8Hz,3H),3.09(s,1H),2.84(d,J=17.2Hz,1H),2.66(t,J= 12.1Hz,8H),2.30(d,J=13.6Hz,1H),2.15(s,1H),1.84(d,J=11.8Hz,1H),1.76(d,J =13.5Hz,6H),1.55(d,J=11.8Hz,1H),1.28(d,J=15.9Hz,2H),0.85(t,J=6.6Hz,1H).

[0226] Preparation of 3-(4-(7-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)hept-1-yn-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (C1) [ka]

[0227] Step 1: C1-1 (322 mg, 1 mmol), hept-6-yn-1-ol (280 mg, 2.50 mmol), CuI (38 mmol, 0.2 mmol), Pd(PPh3)2Cl2 (280 mg, 0.4 mmol), and TEA (303 mg, 3 mmol) were added to DMF (10 mL) and reacted overnight at 70 °C under nitrogen gas protection with stirring. After cooling to room temperature, 30 mL of water was added, and the mixture was extracted with ethyl acetate (20 mL x 3). The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was purified by flash filtration to give 200 mg of C1-2. Yield: 56.5%. LCMS: [M+H] + =355.

[0228] Step 2: C1-2 (40 mg, 0.11 mmol) and CBr4 (75.5 mg, 0.22 mmol) were dissolved in DCM (15 mL) and stirred at room temperature for 1 h. The mixture was cooled to 0 °C, and a solution of PPh3 (59.2 mg, 0.22 mmol) in DCM (2 mL) was added dropwise under nitrogen gas protection and stirred for 0.5 h. The mixture was heated to 50 °C and stirred for an additional 3 h. The solvent was removed under reduced pressure, and the crude product was purified by flash filtration to give 200 mg of Cl-3. Yield: 63.8%. LCMS: [M+H] + =417,419.

[0229] Step 3: C1-3 (10 mg, 0.024 mmol), A1-4 (15 mg, 0.026 mmol), and DIEA (16 mg, 0.124 mmol) were dissolved in DMF (0.5 mL) and stirred at 80 °C for 7 hours under nitrogen gas protection. The solvent was removed under reduced pressure, and the residue was purified by flash filtration to give 15 mg of compound C1 (69.1% yield). LCMS: [M+H] + =906.

[0230] Preparation of 4-(2-(1-(2-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)acetyl)piperidin-4-yl)ethoxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (C4) [ka]

[0231] Step 1: A6-5 (66.3 mg, 0.1 mmol) and 4-(2-bromoethyl)piperidine trifluoroacetate (30.5 mg, 0.1 mmol) were dissolved in 5.0 mL of anhydrous DCM, and T3P (159 mg, 0.25 mmol) and DIPEA (64.5 mg, 0.5 mmol) were added sequentially. The mixture was then allowed to react at room temperature for 2 h. The reaction mixture was diluted with 20 mL of DCM and washed sequentially with saturated ammonium chloride solution (10 mL x 1) and saturated NaCl (10 mL x 1). The organic layer was dried over anhydrous MgSO4, filtered with suction, and the filtrate was concentrated under reduced pressure to give the crude product. This crude product was purified by prep-TLC to give 35 mg of product C4-1 as a pale yellow solid. Yield: 43.8%. LCMS: [M+H] + =801,803.

[0232] Step 2: A2-1 (11.3 mg, 0.041 mmol), C4-1 (30.0 mg, 0.038 mmol), KI (3.1 mg, 0.019 mmol), and NaHCO3 (9.45 mg, 0.113 mmol) were dispersed in 2.0 mL of anhydrous DMF and reacted at 70 °C for 20 h under nitrogen gas protection. LCMS showed the reaction was complete. The reaction solution was directly purified by prep-HPLC to give 13 mg of pure product C4 as a pale yellow solid. Yield: 35.1%. LCMS: [M+H] + =995.

[0233] Preparation of 2-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)acetic acid 3-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-2,2-dimethyl-3-oxopropyl ester (C6) [ka]

[0234] Step 1: A1-4 (56.9 mg, 0.1 mmol), 3-hydroxy-2,2-dimethylpropionic acid (11.8 mg, 0.1 mmol), and T3P (49.4 mg, 0.13 mmol) were dissolved in 3.0 mL of anhydrous DCM. DIPEA (51.6 mg, 0.4 mmol) was added with stirring, and the mixture was allowed to react at room temperature for 2 h. LCMS showed the reaction was complete. The reaction mixture was diluted with 30 mL of ethyl acetate and washed sequentially with saturated NH4Cl solution (20 mL x 1) and saturated brine (20 mL x 1). The organic layer was dried over anhydrous Na2SO4, filtered with suction, and the filtrate was concentrated under reduced pressure to give the crude product. Purification by prep-TLC afforded 65 mg of product C6-1 as a white solid. Yield: 97.0%. LCMS: [M+H] + =670.

[0235] Step 2: C6-1 (80.0 mg, 0.1144 mmol), A3-2 (57.0 mg, 0.1716 mmol), DCC (28.3 mg, 0.1373 mmol), and DMAP (14.0 mg, 0.1144 mmol) were dispersed in 6.0 mL of anhydrous DMF and stirred at room temperature for 8 h under nitrogen gas protection. DCC (35.3 mg, 0.1716 mmol) and DMAP (14.0 mg, 0.1144 mmol) were added to the reaction mixture and the mixture was allowed to react at room temperature for an additional 12 h. LCMS showed the reaction was complete. The reaction mixture was diluted with 50 mL of ethyl acetate and washed sequentially with saturated NH4Cl solution (20 mL x 1), HO (20 mL x 3), and saturated brine (20 mL x 2). The organic layer was dried over anhydrous Na2SO4, filtered, and concentrated under reduced pressure to give the crude product. The crude product was purified by Prep-HPLC to give 20 mg of pure product as a pale yellow solid. Yield 17.8%. LCMS: [M+H] + =984. 1 H-NMR:(400MHz,DMSO-d6)δ 11.168(s,1H),11.099(s,1H),8.477(s,1H),8.064(d,J=7.6Hz,2H),8.064(t,J=8.0Hz,1H),7.553-7.50 4(m,2H),7.499-7.321(m,3H),7.111(t,J=7.6Hz,1H),6.628(d,J=2.4Hz,1H),6.484(dd,J=2.4,8.8Hz,1 H),5.123(s,2H),4.164(s,2H),3.760-3.710(m,5H),3.504(s,4H),2.938-2.846(m,1H),2.665-2.455(m ,8H),2.373-2.324(m,1H),2.054-1.989(m,1H),1.857-1.746(m,8H),1.565-1.475(m,3H),1.192(s,6H).

[0236] Preparation of 4-((9-(4-(1-(4-((4-((2-(dimethylphosphoryl)phenyl)amino)-5-vinylpyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)nonyl)oxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (C25) [ka]

[0237] Step 1: A11-1 (120 mg, 0.288 mmol), PPh3 (113.4 mg, 0.432 mmol), and NBS (77.0 mg, 0.432 mmol) were dissolved in 8.0 mL of anhydrous DCM and reacted at room temperature for 2 h under N2 gas protection. TLC showed no remaining starting material. The reaction mixture was diluted with 40 mL of ethyl acetate and washed sequentially with H2O (20 mL x 1) and saturated brine (20 mL x 1). The organic layer was dried over anhydrous Na2SO4, filtered with suction, and the filtrate was concentrated under reduced pressure to obtain the crude product. Purification by prep-TLC afforded 100 mg of product C25-1 as a white solid. Yield: 72.6%. LCMS: [M+H] + =479,481.

[0238] Step 2: C25-1 (15 mg, 0.0314 mmol) and C25-2 (17.6 mg, 0.0314 mmol) were dissolved in 2.0 mL of anhydrous DMF. DIPEA (20.3 mg, 0.157 mmol) was added under N2 gas protection, and the mixture was reacted at 80 °C for 8 h. LCMS showed no remaining starting material. The reaction mixture was diluted with 20 mL of ethyl acetate and washed sequentially with saturated NH4Cl (10 mL x 1), H2O (10 mL x 3), and saturated brine (10 mL x 1). The organic layer was dried over anhydrous Na2SO4, filtered with suction, and the filtrate was concentrated under reduced pressure to obtain the crude product. The crude product was purified by prep-HPLC to obtain 3.0 mg of product C25 as a pale yellow solid. Yield: 10.0%. LCMS: [M+1] + =960.

[0239] Preparation of 4-((7-(9-(4-((5-bromo-4-((5-(dimethylphosphoryl)quinoxalin-6-yl)amino)pyrimidin-2-yl)amino)-5-methoxy-2-methylphenyl)-3,9-diazaspiro[5.5]undecan-3-yl)heptyl)oxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (C47) [ka]

[0240] A10-2 (46.3 mg, 0.12 mmol) and C47-1 (66.4 mg, 0.1 mmol) were dissolved in 10.0 mL of anhydrous DCM. Under nitrogen gas protection, CH3COOH (6.0 mg, 0.1 mmol, dissolved in 0.5 mL of DCM) was added and stirred at room temperature for 1 h. Solid NaBH3CN (15.7 mg, 0.25 mmol) was then added to the reaction mixture and the mixture was allowed to react at room temperature for an additional 2 h. LCMS showed the reaction was complete. The reaction mixture was diluted with 20 mL of DCM and washed sequentially with saturated NH4Cl (1 x 15 mL) and saturated brine (1 x 15 mL). The organic layer was dried over anhydrous Na2SO4, filtered under suction, and the filtrate was concentrated under reduced pressure to give the crude product. This crude product was purified by prep-HPLC to give 40 mg of pure product as a yellow solid. Yield: 38.7%. LCMS: [M+H] + =1035,1037. 1H-NMR:(400MHz,DMSO-d6) δ 12.763(s,1H),11.102(s,1H),9.017(br s, 1H),8.886(d,J=1.6Hz,1H),8.856(d,J=2.0Hz,1H),8.401(s,1H),8.292(s,1H),7.951(d,J=9.6Hz,1H),7.841(t,J=8.0Hz, 1H),7.532(d,J=8.4Hz,1H),7.466(d,J=7.2Hz,1H),7.380(s,1H),6.868(s,1H),5.102(dd,J=5.6, 12.8Hz,1H),4.834(s,4H),4.238(t,J=6.0Hz,2H),3.797(s,3H),3.398-3.369(m,2H),3.097-2.857(m,8 H),2.575-2.542(m,1H),2.110(s,3H),2.048-2.012(m,7H),1.804-1.678(m,6H),1.572-1.371(m,10H).

[0241] Preparation of 2-((1-(2-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)acetylpiperidin-4-yl)oxy)-N-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)acetamide (C78) [ka]

[0242] Step 1: C78-1 (560 mg, 2.78 mmol) was dissolved in 5.0 mL of anhydrous THF, and NaH (222.4 mg, 5.56 mmol) was added at 0 °C. The mixture was stirred at room temperature for 2 hours. The reaction mixture was cooled to 0 °C, and bromoacetic acid (386 mg, 2.78 mmol, dissolved in 5.0 mL of anhydrous THF) was added dropwise to the mixture. After the addition was complete, the mixture was warmed to room temperature and allowed to react for 20 hours. The reaction mixture was quenched with water (10 mL) at 0 °C, adjusted to pH 11-12 with 1 M NaOH, extracted twice with diethyl ether, and the remaining aqueous phase was adjusted to pH 3-4 with 2 N HCl and extracted with ethyl acetate (50 mL x 3). The combined ethyl acetate layers were washed with saturated brine (50 mL x 1). The organic layer was dried over anhydrous Na2SO4, filtered with suction to remove the drying agent, and the filtrate was concentrated under reduced pressure to give crude product C78-2 (520 mg, yield 72.2%). This crude product was used directly in the next reaction.

[0243] Step 2: C78-2 (104 mg, 0.4 mmol) and C78-3 (or A12-3) (104 mg, 0.4 mmol) were dispersed in a mixture of 8.0 mL of anhydrous DCM and 1.6 mL of anhydrous DMF. Under nitrogen gas protection, T3P (508.8 mg, 0.8 mmol) and DIPEA (258 mg, 2.0 mmol) were added sequentially and the reaction mixture was allowed to react at room temperature for 2 h. The reaction mixture was diluted with 30 mL of ethyl acetate and washed sequentially with saturated NH4Cl (20 mL x 1), HO (20 mL x 2), and saturated NaCl (20 mL x 2). The organic layer was dried over anhydrous MgSO4, filtered under suction, and the filtrate was concentrated under reduced pressure to give the crude product. The crude product was purified by flash filtration to give C78-4 (120 mg, 60% yield) as a pale yellow oil.

[0244] Step 3: C78-4 (120 mg, 0.24 mmol) was dissolved in 3.0 mL of anhydrous DCM, and 1.0 mL of TFA was added with stirring. The reaction was allowed to proceed at room temperature for 2.0 h. LCMS showed the reaction was complete. The reaction mixture was concentrated under reduced pressure to give the crude product. The crude product was purified by RP-Flash to give the product C78-5 (39 mg, 52.1% yield) as a white solid. LCMS: [M+H] + =401.

[0245] Step 4: C78-5 (50 mg, 0.125 mmol) and A6-5 (78.4 mg, 0.125 mmol) were dispersed in a mixed solvent of 5.0 mL of anhydrous DCM and 1.0 mL of anhydrous DMF. Under nitrogen gas protection, T3P (159 mg, 0.25 mmol) and DIPEA (80.6 mg, 0.625 mmol) were added and stirred at room temperature for 2 h. The reaction mixture was concentrated under reduced pressure to give the crude product. This crude product was purified by RP-Flash to give the pure product C78 (20 mg, 15.9% yield) as a yellow solid. LCMS: [M+H] + =1010.

[0246] Preparation of 2-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-N-(1-(2-((2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)amino)-2-oxoethyl)piperidin-4-yl)acetamide (C88) [ka]

[0247] Step 1: Compound C88-1 (or A12-3) (259.1 mg, 1 mmol), tert-butyl bromoacetate (232.8 mg, 1.2 mmol), potassium iodide (16.6 mg, 0.1 mmol), and sodium bicarbonate (126.0 mg, 1.5 mmol) were added to dry DMF (7 ml) and stirred overnight at 60 °C under nitrogen gas protection. The solvent was evaporated under reduced pressure, and the crude product was separated by column chromatography to give compound C88-2 (150 mg, 40.2% yield) as a white solid.

[0248] Step 2: Compound C88-2 (44 mg, 0.118 mmol) was dissolved in 1 mL of TFA at 0° C. and stirred at room temperature for 1 hour. The solvent was removed under reduced pressure at 40° C., and 3 ml of toluene was added and the solvent was evaporated to give crude product C88-3. The crude product was used directly in the next step. LCMS: [M+H] + =318.

[0249] Step 3: The crude product C88-3 was dispersed in dichloromethane (2 ml) at room temperature, HATU (9.2 mg, 0.024 mmol) was added, and the mixture was stirred at room temperature for 0.5 hours under nitrogen gas protection. DIEA (15 mg, 0.116 mmol) and compound C88-4 (51 mg, 0.072 mmol) were then added, and the mixture was stirred at room temperature for another 4.5 hours. After the reaction was completed, the solvent was evaporated under reduced pressure at 40 °C, and the crude product was purified by flash filtration to give an off-white solid C88 (5 mg, 19.7% yield). LCMS: [M+H] + =1009.

[0250] Preparation of 4-((1-(2-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)acetyl)azetidin-3-yl)oxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (C93) [ka]

[0251] Step 1: Compound C93-1 (or A2-1) (116 mg, 0.42 mmol), compound C93-2 (100 mg, 0.42 mmol), and sodium bicarbonate (106 mg, 1.26 mmol) were added to a 50 mL single-neck flask, and DMF (3 mL) was added. The mixture was heated to 60 °C and reacted for 12 hours. After cooling, water (30 mL) was added and the mixture was extracted with ethyl acetate three times (20 mL each time). The organic phases were combined, washed with brine (15 mL x 3), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product. The crude product was separated by column chromatography to obtain 110 mg of a pale white solid, C93-3. Yield: 61%.

[0252] Step 2: Compound C93-3 (110 mg, 0.256 mmol) and hydrogen chloride / 1,4-dioxane solution (5 mL, 4 mol / L) were added to a 25 mL single-neck flask and reacted for 2 hours with stirring at room temperature. The reaction was monitored by TLC. After completion of the reaction, the solvent was concentrated under reduced pressure, dissolved in dichloromethane (20 mL), adjusted to pH 8-9 with sodium bicarbonate solution, extracted, and separated. The dichloromethane solution was dried over anhydrous magnesium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give 51 mg of a pale yellow solid, C93-4. Yield: 60.7%. LCMS: [M+H] + =330.

[0253] Step 3: Compound C93-4 (20 mg, 0.06 mmol), compound A6-5 (38 mg, 0.06 mmol), HATU (27.3 mg, 0.072 mmol), and DIPEA (38.7 mg, 0.03 mmol) were added to a 25 mL single-neck flask, and dichloromethane (2 mL) was added. The mixture was stirred for 3 hours. After completion of the reaction, dichloromethane (10 mL) was added to the reaction mixture, which was then washed with water (5 mL x 2). The combined organic phase was washed with brine (5 mL x 2), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product. Separation by prep-HPLC afforded 5.6 mg of a pale white solid, C93. Yield: 10%. LCMS: [M+H] + =939.

[0254] Preparation of 4-((1-(2-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)acetyl)azetidin-3-yl)methoxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (C94) [ka]

[0255] Step 1: Compound C94-1 (or A2-1) (100 mg, 0.365 mmol), compound C94-2 (109 mg, 0.438 mmol), potassium iodide (6 mg, 0.036 mmol), and sodium bicarbonate (61 mg, 0.726 mmol) were added to dry DMF (3 ml) and stirred at 60 °C for 24 hours under nitrogen gas protection. The solvent was evaporated under reduced pressure, and the crude product was separated by column chromatography to obtain a white solid, compound C94-3 (50 mg, 31.6% yield).

[0256] Step 2: Compound C94-3 (50 mg, 0.113 mmol) was dissolved in a solution of trifluoroacetic acid in dichloromethane (1 ml) and stirred at room temperature for 2 hours. The solvent was removed under reduced pressure at 40° C. to give crude product C94-4, which was used directly in the next step. LCMS: [M+H] + =344.

[0257] Step 3: The crude product C94-4 was dispersed in DMF (2 ml) at room temperature, and DIEA (53 mg, 0.411 mmol) and HATU (24 mg, 0.063 mmol) were added. The mixture was stirred at room temperature for 1 hour under nitrogen gas protection. Compound A6-5 (40 mg, 0.064 mmol) was then added, and the mixture was stirred at room temperature for an additional 2.5 hours. After the reaction was completed, the solvent was evaporated under reduced pressure at 40 °C, and the crude product was purified by flash filtration to give an off-white solid C94 (20 mg, 36.0% yield). LCMS: [M+H] + =953. 1 H NMR(400MHz,DMSO-d6) δ 11.16(s,1H),11.08(s,1H),8.47(d,1H),8.04(d,2H),7.87-7.81(m,1H),7.57-7.47(m,3H),7.43-7.30(m ,2H),7.09(t,1H),6.62(t,1H),6.47(d,1H),5.08(m,1H),4.37(d,2H),4.32(t,1H),4.14(m,1H),3.98(t, 1H),3.76(s,4H),3.71(d,2H),3.10-3.04(m,1H),2.97(s,2H),2.95-2.83(m,2H),2.70-2.60(m,4H),2.57 (s,1H),2.44(s,3H),2.08-1.94(m,2H),1.83(d,2H),1.78(s,3H),1.74(s,3H),1.51(d,2H),1.25(m,3H).

[0258] Preparation of 4-(2-(4-(2-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-2-oxoethyl)piperazin-1-yl)-2-oxoethoxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (C99) [ka]

[0259] Step 1: A3-2 (223 mg, 0.5 mmol) and C99-1 (93 mg, 0.5 mmol) were dissolved in 10.0 mL of anhydrous DCM. Under nitrogen gas protection, T3P (636 mg, 1.0 mmol) and DIPEA (322.5 mg, 2.5 mmol) were added sequentially and the mixture was allowed to react at room temperature for 2 h. The reaction mixture was diluted with 30 mL of ethyl acetate and washed sequentially with saturated NH4Cl (20 mL x 1) and saturated NaCl (20 mL x 2). The organic layer was dried over anhydrous MgSO4, filtered under suction, and the filtrate was concentrated under reduced pressure to give the crude product. The crude product was purified by flash filtration to give the product C99-2 (230 mg, 92% yield) as a white solid.

[0260] Step 2: C99-2 (230 mg, 0.46 mmol) was dissolved in 6.0 mL of anhydrous DCM, and 2.0 mL of HCl / dioxane (4.0 M) was added with stirring. The reaction was allowed to proceed at room temperature for 2.0 h. LCMS showed the reaction was complete. The reaction solution was concentrated under reduced pressure to give the product C99-3 (250 mg, 100% yield) as a white solid. LCMS: [M+H] + =401.

[0261] Step 3: C99-3 (109 mg, 0.25 mmol), KI (20.8 mg, 0.125 mmol), and NaHCO3 (84 mg, 1.0 mmol) were dispersed in 5.0 mL of anhydrous DMF. Under nitrogen gas protection, tert-butyl bromoacetate (48.8 mg, 0.25 mmol) was added and the reaction was allowed to proceed at 60 °C for 20 h. TLC showed the reaction was complete. The reaction mixture was diluted with 30 mL of ethyl acetate and washed sequentially with saturated NH4Cl (10 mL x 1), HO (10 mL x 2), and saturated NaCl (10 mL x 2). The organic layer was dried over anhydrous Na2SO4, filtered under suction, and the filtrate was concentrated under reduced pressure to give the crude product. This crude product was purified by prep-TLC to give the product C99-4 (95 mg, 74.2% yield) as a pale yellow solid. LCMS: [M+H] + =515.

[0262] Step 4: C99-4 (95 mg, 0.185 mmol) was dissolved in 3.0 mL of anhydrous DCM, and 1.5 mL of HCl / dioxane (4.0 M) was added with stirring. The mixture was allowed to react at room temperature for 2.0 h. The product C99-5 (70 mg, 82.6% yield) was obtained as a pale yellow solid by suction filtration. LCMS: [M+H] + =459.

[0263] Step 5: C99-5 (70 mg, 0.142 mmol) and A1-4 (64.6 mg, 0.114 mmol) were dispersed in 5.0 mL of anhydrous DCM and 1.0 mL of anhydrous DMF. Under nitrogen gas protection, T3P (180.6 mg, 0.284 mmol) and DIPEA (91.6 mg, 0.71 mmol) were added and the mixture was stirred at room temperature for 2 h. The reaction mixture was concentrated under reduced pressure to give the crude product. This crude product was purified by prep-HPLC to give the pure product C99 (25 mg, 17.5% yield) as a yellow solid. LCMS: [M+H] + =1010.

[0264] Preparation of 4-(2-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-2-oxoethoxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (C101) [ka]

[0265] A3-2 (16.6 mg, 0.05 mmol), A1-4 (28.5 mg, 0.05 mmol), and HATU (28.5 mg, 0.075 mmol) were dispersed in a mixed solvent of 2.0 mL of anhydrous DCM and 0.2 mL of anhydrous DMF. Under nitrogen gas protection, DIPEA (32.3 mg, 0.25 mmol) was added dropwise and stirred at room temperature for 2 h. The reaction mixture was concentrated under reduced pressure to give the crude product. This crude product was purified by RP-Flash to give 30 mg of crude product. This crude product was further purified by Prep-HPLC to give the pure product C101 (15 mg, 34.1% yield) as a pale yellow solid. LCMS: [M+H] + =884.

[0266] Preparation of 2-(((1-(2-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-2-oxoethyl)cyclopropyl)methyl)thio)-N-(2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)acetamide (C103) [ka]

[0267] Step 1: Under nitrogen gas protection, compound C103-2 (or A8-1) (226 mg, 2.02 mmol) was slowly added dropwise to compound C103-1 (500 mg, 1.83 mmol) in dry THF (10 ml) at 0 °C, and then heated to reflux for 4 hours. After cooling to room temperature, the solvent was evaporated under reduced pressure, and the crude product was separated by column chromatography to obtain a white solid compound C103-3 (300 mg, 46.9% yield). LCMS: [M+H] + =350.

[0268] Step 2: Compound C103-3 (250 mg, 0.716 mmol), compound C103-4 (105 mg, 0.716 mmol), and sodium acetate (70 mg, 0.854 mmol) were added to absolute ethanol (5 ml) and refluxed with stirring for 3 hours. The solvent was removed under reduced pressure at 40 °C, and the crude product was separated by column chromatography to obtain compound C103-5 (100 mg, 30.4%). LCMS: [M+H] + =460.

[0269] Step 3: Compound C103-5 (40 mg, 0.087 mmol), compound A1-4 (50 mg, 0.088 mmol), DIEA (34 mg, 0.264 mmol), and HATU (33 mg, 0.087 mmol) were dissolved in 2 mL of DMF and stirred at room temperature for 7 hours under nitrogen gas protection. LCMS monitoring showed the reaction was complete. The solvent was evaporated under reduced pressure at 40 °C, and the crude product was purified by flash filtration to give an off-white solid C103 (28 mg, 31.8% yield). LCMS: [M+H] + =1011, 1H NMR(400MHz,DMSO-d6) δ 11.16(s,1H),10.45(s,1H),8.63(d,1H),8.48(s,1H),8.05(d,2H),7.86(t,1H),7.63(d,1H),7 .53(dd,1H),7.42-7.31(m,2H),7.09(t,1H),6.62(d,1H),6.47(d,1H),5.75(s,1H),5.17(dd,1H) ),3.76(s,3H),3.71(d,2H),3.57(s,2H),3.38(s,4H),2.79(d,2H),2.65(s,4H),2.43(s,5H),2 .32(s,1H),2.13-2.05(m,1H),2.00(d,1H),1.82(s,1H),1.76(d,7H),1.48(s,3H),0.43(d,4H).

[0270] Preparation of 1-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazine-1-carbonyl)cyclopropane-1-carboxylic acid 2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl ester (C104) [ka]

[0271] Step 1: Compound C104-1 (or A2-1) (100 mg, 0.365 mmol), compound C104-2 (119 mg, 0.915 mmol), DCC (90 mg, 0.436 mmol), and DMAP (45 mg, 0.368 mmol) were dissolved in DMF (4 mL) and stirred at room temperature under nitrogen gas protection for 5 hours. The solvent was evaporated under reduced pressure, and the crude product was separated by column chromatography to give compound C104-3 (70 mg, 49.6% yield) as a white solid.

[0272] Step 2: Compound C104-3 (40 mg, 0.104 mmol), compound A1-4 (56 mg, 0.098 mmol), HATU (40 mg, 0.105 mmol), and DIEA (40 mg, 0.310 mmol) were added to DMF (2 mL) and stirred at room temperature under nitrogen gas protection for 3 hours. The solvent was removed under reduced pressure at 40 °C, and the crude product was purified by flash filtration to give an off-white solid C104 (50 mg, 51.5% yield). LCMS: [M+H] + =938. 1 H NMR(400MHz,DMSO-d6) δ 11.14(d,2H),8.48(s,1H),8.06(d,2H),7.96(t,1H),7.87(d,1H),7.70(d,1H),7.56-7.49(m,1H),7.39(d,1H),7. 34(t,1H),7.09(t,1H),6.63(d,1H),6.47(dd,1H),5.14(dd,1H),3.76(s,3H),3.72(d,4H),3.51(s,2H),2.89(dt, 1H),2.66(t,3H),2.39(s,1H),2.10-1.96(m,2H),1.83(d,2H),1.79-1.73(m,9H),1.55-1.50(m,3H),1.24(m,3H).

[0273] Preparation of 4-((1-((4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)methyl)cyclopropyl)methoxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (C106) [ka]

[0274] Step 1: Compound C106-1 (or A2-1) (274 mg, 1 mmol), compound C106-2 (102 mg, 1 mmol), and triphenylphosphine (393 mg, 1.5 mmol) were added to a 50 mL three-neck flask, and anhydrous tetrahydrofuran (5 mL) was added. The atmosphere was replaced with nitrogen gas to remove oxygen. Under nitrogen gas protection, the mixture was cooled to 0 °C with stirring, and DIAD (303 mg, 1.5 mmol) was added dropwise. The mixture was then warmed to room temperature and reacted with stirring for 3 hours. LCMS analysis showed that the starting materials were almost completely converted to the product. The reaction mixture was concentrated under reduced pressure to obtain the crude product. Separation by column chromatography afforded 210 mg of the desired product C106-3. Yield: 58.6%. LCMS: [M+H] + =359.

[0275] Step 2: Compound C106-3 (100 mg, 0.28 mmol) was added to a 50 mL single-neck flask and dissolved in dichloromethane (15 mL). Dess-Martin reagent (305 mg, 0.72 mmol) was added and the mixture was stirred overnight at room temperature. The reaction was monitored by LCMS, revealing that the starting material was almost completely consumed and the desired product was produced. 5 mL of saturated sodium bicarbonate solution and saturated sodium thiosulfate solution were added sequentially to the reaction mixture, and the mixture was stirred for 10 minutes. After the mixture became clear, the layers were separated. The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give an off-white solid. Further separation by prep-TLC afforded 45 mg of a pale white solid, C106-4. Yield: 45%. LCMS: [M+H] + =357.

[0276] Step 3: Compound C106-4 (41 mg, 0.115 mmol) and compound A1-4 (66 mg, 0.115 mmol) were added to a 50 mL single-neck flask, dissolved in dichloromethane (3 mL), and acetic acid (0.05 mL) was added. The mixture was stirred at room temperature for 0.5 hours. Sodium cyanoborohydride (22 mg, 0.345 mmol) was then added, and the mixture was allowed to react overnight. The reaction was monitored by LCMS; most of the starting material was consumed, and the desired product was produced. Saturated ammonium chloride solution (3 mL) was added to the reaction mixture, and the mixture was stirred for 5 minutes. The organic phase was dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product. Further separation by prep-HPLC afforded 10 mg of C106 as a white powder. Yield: 9.6%. LCMS: [M+H] + =910.

[0277] Preparation of 2-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)acetic acid (1-(((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)methyl)cyclopropyl)methyl ester (C107) [ka]

[0278] Compound C106-3 (28.5 mg, 0.08 mmol), compound A6-5 (50 mg, 0.08 mmol), DCC (20 mg, 0.096 mmol), and DMAP (10 mg, 0.08 mmol) were added to a 50 mL single-neck flask, dissolved in DMF (3 mL), and reacted overnight at room temperature with stirring. The reaction was monitored by LCMS, and when the starting material was almost consumed, the reaction was stopped. The reaction solution was concentrated under reduced pressure to obtain the crude product. Separation by prep-TLC yielded a pale yellow solid. Further separation by prep-HPLC yielded 10 mg of white powder C107. Yield: 12.98%. LCMS: [M+H] + =968.

[0279] Preparation of 4-(((S)-1-(2-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)acetyl)pyrrolidin-2-yl)methoxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (C109) [ka]

[0280] Step 1: C109-1 (or A2-1) (82.2 mg, 0.3 mmol), C109-2 (66.3 mg, 0.33 mmol), and PPh3 (94.3 mg, 0.36 mmol) were dispersed in 7.0 mL of anhydrous THF, and DIAD (78.8 mg, 0.39 mmol) was added dropwise under nitrogen gas protection. After the addition was completed, the reaction was carried out at room temperature for 5.0 h. The reaction solution was concentrated under reduced pressure to obtain the crude product. The crude product was purified by prep-HPLC to obtain 85 mg of product C109-3 as a white solid. Yield: 70.0%. LCMS: [M+H] + =408.

[0281] Step 2: C109-3 (85 mg, 0.186 mmol) was dissolved in 4.0 mL of anhydrous DCM, and 2.0 mL of 4.0 M HCl / dioxane solution was added. The mixture was sealed at room temperature and reacted for 20 h. LCMS showed the reaction was complete. The reaction solution was concentrated under reduced pressure to give 100 mg of crude product C109-4 as a white solid. The yield was 100%, and the crude product was used directly in the next reaction. LCMS: [M+H] + =358.

[0282] Step 3: C109-4 (42.8 mg, 0.12 mmol) and A6-5 (62.7 mg, 0.1 mmol) were dispersed in 4.0 mL of anhydrous DCM, and T3P (127.2 mg, 0.2 mmol) and DIPEA (64.5 mg, 0.5 mmol) were added sequentially. The reaction was allowed to proceed at room temperature for 2 h. LCMS showed no remaining starting material. The reaction mixture was concentrated under reduced pressure to give the crude product. The crude product was purified by prep-HPLC to give 18 mg of pure product C109 as a pale yellow solid. Yield: 18.6%. LCMS: [M+H] + =967. 1 H-NMR:(400MHz,DMSO-d6)δ 11.160(s,1H),11.093(d,J=3.6Hz,1H),8.476(s,1H),8.062(d,J=13.2Hz,2H),7.861-7.788 (m,1H),7.577-7.320(m,5H),7.112(t,J=7.2Hz,1H),6.622(d,J=2.8Hz,1H),6.476(t,J=2.0, 1H),5.135-5.079(m,1H),4.411-4.238(m,3H),3.761(s,3H),3.707(d,J=12.0Hz,3H),3.550(d,J=5.2Hz,1H),3.179-3.122(m, 1H),3.005-2.858(m,2H),2.674-2.615(m,3H),2.424-2.202(m,9H),1.997(s,4H),1.813-1.745(m,10H),1.509-1.453(m,2H).

[0283] Preparation of (2S)-1-(2-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)acetyl)-N-(2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolin-4-yl)-4,4-difluoropyrrolidine-2-carboxamide (C110) [ka]

[0284] Step 1: C110-1 (or A12-3) (130 mg, 0.5 mmol) and C110-2 (125.5 mg, 0.5 mmol) were dispersed in a mixture of 6.0 mL of anhydrous DCM and 1.2 mL of anhydrous DMF. Under N2 gas protection, T3P (636 mg, 1.0 mmol) and DIPEA (258 mg, 2.0 mmol) were added sequentially and the reaction mixture was allowed to react at room temperature for 2 h. LCMS showed no remaining starting material. The reaction mixture was concentrated under reduced pressure to remove the DCM. After dilution, the residue was diluted with 50 mL of ethyl acetate and washed sequentially with saturated NH4Cl solution (20 mL x 1), HO (20 mL x 3), and saturated brine (20 mL x 1). The organic layer was dried over anhydrous Na2SO4, filtered under vacuum, and the filtrate was concentrated under reduced pressure to give the crude product. Purification by prep-TLC afforded 100 mg of the pale yellow oily product C110-3. Yield: 40.7%. 1 H-NMR:(400MHz,DMSO-d6)δ 11.021(s,1H),10.080(s,1H),7.781-7.726(m,1H),7.575-7.523(m,2H),5.182-5.136(m,1H),4.574-4.255(m,2H),3.853 (m,2H),2.962-2.890(m,2H),2.639-2.585(m,1H),2.341-2.253(m,1H),2.051-2.028(m,1H),1.416(s,3H),1.344(s,6H).

[0285] Step 2: C110-3 (100 mg, 0.203 mmol) was dissolved in a mixed solvent of 4.0 mL of anhydrous DCM, 2.0 mL of anhydrous THF, and 1.0 mL of anhydrous 1,4-dioxane, and 3.0 mL of 4.0 M HCl / dioxane solution was added. The mixture was sealed at room temperature and reacted for 2 h. LCMS showed the reaction was complete. The reaction solution was concentrated under reduced pressure to give 130 mg of crude product C110-4 as a white solid. The yield was 100%, and the crude product was used directly in the next reaction. LCMS: [M+H] + =393.

[0286] Step 3: A6-5 (51.3 mg, 0.0818 mmol) and C110-4 (35 mg, 0.0818 mmol) were dispersed in a mixture of 5.0 mL of anhydrous DCM and 1.0 mL of anhydrous DMF. Under N2 gas protection, T3P (104 mg, 0.1636 mmol) and DIPEA (63.3 mg, 0.4908 mmol) were added sequentially and the reaction was allowed to proceed at room temperature for 2 h. LCMS showed no remaining starting material. The reaction mixture was concentrated under reduced pressure to give the crude product. The crude product was purified by prep-HPLC to give 25 mg of pure product C110 as a white solid. Yield: 30.6%. LCMS: [M+H] + =1002. 1 H-NMR:(400MHz,DMSO-d6) δ 11.164(s,1H),11.037(s,1H),10.052(s,1H),8.477(s,1H),8.155-8.043(m,2H),7.776(t,J=6.8Hz,1H),7.56 6-7.499(m,3H),7.391-7.318(m,2H),7.112-7.075(m,2H),6.627-6.373(m,2H),5.201-5.130(m,1H),4.505-4. 059(m,5H),3.773-3.703(m,5H),3.530(s,1H),3.286-3.275(m,2H),3.095-2.810(m,10H),2.640-2.598(m,1H) ,2.291-2.180(m,4H),2.008-1.838(m,3H),1.782-1.748(m,1H),1.741(d,J=12.0Hz,6H),1.538-1.445(m,3H).

[0287] 2-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)-N -( Preparation of (2S)-1-((2-(2,6-dioxopiperidin-3-yl)-1,3-dioxoisoindolin-4-yl)oxy)-3,3-dimethyl-2-yl)acetamide (C112) [ka]

[0288] Step 1: Compound C112-1 (or A2-1) (274 mg, 1 mmol), compound C112-2 (217 mg, 1 mmol), and triphenylphosphine (393 mg, 1.5 mmol) were added to a 50 mL three-neck flask, and anhydrous tetrahydrofuran (5 mL) was added. The atmosphere was replaced with nitrogen gas to remove oxygen, and the mixture was cooled to 0 °C with stirring under nitrogen gas protection. DIAD (303 mg, 1.5 mmol) was added dropwise, and the mixture was warmed to room temperature and reacted with stirring for 3 hours. After completion of the reaction as determined by LCMS, the reaction solution was concentrated under reduced pressure to obtain the crude product. Separation by column chromatography afforded 240 mg of the desired product C112-3. Yield: 50.7%. LCMS: [M+H] + =475.

[0289] Step 2: Compound C112-3 (100 mg, 0.21 mmol) and hydrogen chloride / 1,4-dioxane solution (5 mL, 4 mol / L) were added to a 25 mL single-neck flask and reacted with stirring at room temperature for 2 hours. The reaction was monitored by TLC. After completion, the mixture was concentrated under reduced pressure to remove hydrogen chloride and most of the 1,4-dioxane. The mixture was dissolved in dichloromethane (20 mL) and adjusted to pH 8-9 with sodium bicarbonate solution. The mixture was separated, the dichloromethane solution was dried over anhydrous magnesium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give 40 mg of a pale yellow solid, C112-4. Yield: 51%. LCMS: [M+H] + =374.

[0290] Step 3: Compounds C112-4 (40 mg, 0.107 mmol) and A6-5 (67 mg, 0.107 mmol) were added to a 50 mL single-neck flask and dissolved in dichloromethane (3 mL). T3P (136 mg, 0.214 mmol) was added and the mixture was stirred at room temperature for 3 hours. The reaction was monitored by LCMS. After completion of the reaction, dichloromethane (10 mL) was added to the reaction mixture, which was washed with water (5 mL). The organic phase was separated, dried over anhydrous magnesium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product. Purification by prep-TLC yielded a pale yellow solid. Further separation by prep-HPLC yielded 34 mg of pale white powder, C112. Yield: 32.3%. LCMS: [M+H] + =983.

[0291] Preparation of 3-(4-(6-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)hex-1-yn-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (C116) [ka]

[0292] Step 1: C116-1 (or C1-1) (500 mg, 1.553 mmol), CuI (59 mg, 0.3106 mmol), and Pd(dppf)Cl2 (454 mg, 0.6212 mmol) were dispersed in 25 mL of anhydrous DMF. Under N2 gas protection, 5-alkynyl-1-hexanol (380 mg, 3.883 mmol) and triethanolamine (470 mg, 4.659 mmol) were sequentially added. The mixture was heated to 70 °C and reacted for 20 h. LCMS showed the reaction was complete. The reaction mixture was cooled to room temperature and diluted with 150 mL of ethyl acetate. The mixture was washed sequentially with saturated ammonium chloride (2 x 50 mL), HO (2 x 50 mL), and saturated brine (2 x 50 mL). The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give the crude product. Purification by RP-Flash gave the product C116-2 (255 mg, 48.3%) as a pale yellow solid. LCMS: [M+H] + =341.

[0293] Step 2: C116-2 (90 mg, 0.265 mmol) was dispersed in 18.0 mL of anhydrous DCM and heated to 40 °C to clarify the reaction mixture. Under N2 gas protection, Dess-Martin reagent (168.5 mg, 0.3975 mmol) was added, and the mixture was heated to 50 °C and refluxed for 2.0 h. TLC showed the reaction was complete. After cooling to room temperature, 10 mL of saturated NaHCO3 solution and 10 mL of saturated Na2S2O3 solution were added to the reaction mixture and stirred vigorously at room temperature for 5 min. The organic layer was separated, dried over anhydrous sodium sulfate, and suction filtered. The filtrate was concentrated under reduced pressure to obtain the crude product. This crude product was purified by prep-TLC to obtain the product C116-3 (35 mg, 39.1%) as a pale yellow solid. LCMS: [M+H] + =339.

[0294] Step 3: C116-3 (30 mg, 0.0888 mmol) and A1-4 (45.5 mg, 0.0799 mmol) were dissolved in a mixture of 4.0 mL of anhydrous DCM and 0.4 mL of anhydrous methanol. Under nitrogen gas protection, CH3COOH (5.3 mg, 0.0888 mmol, dissolved in 0.5 mL of DCM) was added and stirred at room temperature for 0.5 h. Solid NaBH3CN (8.36 mg, 0.1332 mmol) was then added to the reaction mixture, and the mixture was allowed to react at room temperature for an additional 2 h. LCMS and TLC confirmed the completion of the reaction. Purification by prep-HPLC afforded 25 mg of product C116 as a white solid. Yield: 31.6%. LCMS: [M+H] + =892. 1 H-NMR:(400MHz,DMSO-d6)δ 12.683(s,1H),11.119(s,1H),8.869(dd,J=2.0Hz,9.2Hz,3H),8.281(s,1H),8.263(s,1H),7.721(d,J=6 .8Hz,1H),7.646(d,J=0.8Hz,1H),7.643(d,J=6.8Hz,1H),7.539(d,J=7.6Hz,1H),7.321(s,1H),6.809(s, 1H),5.188(dd,J=5.2Hz,13.6Hz,1H),4.477(d,J=17.6Hz,1H),4.325(d,J=17.6Hz,1H),3.784(s,3H),2.5 13-2.495(m,10H),2.494-2.103(m,6H),2.075(s,3H),2.040(s,3H),2.004(s,3H),1.557-1.429(m,18H).

[0295] Preparation of 3-(4-(5-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)pent-1-yn-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (C126) [ka]

[0296] Step 1: C126-1 (or C1-1) (322 mg, 1.0 mmol), CuI (19 mg, 0.1 mmol), and Pd(dppf)Cl2 (73.1 mg, 0.1 mmol) were dispersed in 10.0 mL of anhydrous DMF. Under N2 gas protection, 4-alkynyl-1-pentanol (210 mg, 2.5 mmol) and TEA (303 mg, 3.0 mmol) were added sequentially. The mixture was heated to 70 °C and reacted for 20 h. LCMS showed the reaction was complete. The reaction mixture was cooled to room temperature and purified by RP-Flash to give the crude product C126-2 (410 mg, 94.1% yield) as a white solid. LCMS: [M+H] + =327.

[0297] Step 2: C126-2 (400 mg, 0.920 mmol) was dissolved in a mixed solvent of 150 mL of anhydrous DCM and 10 mL of anhydrous THF. Under N2 gas protection, Dess-Martin reagent (1.04 g, 2.454 mmol) was added, and the mixture was heated to 50 °C and refluxed for 2.0 h. TLC showed the reaction was complete. After cooling to room temperature, 20 mL of saturated NaHCO3 solution and 20 mL of saturated Na2S2O3 solution were added and stirred vigorously at room temperature for 5 min. The organic layer was separated, dried over anhydrous sodium sulfate, and suction filtered. The filtrate was concentrated under reduced pressure to obtain the crude product. This crude product was purified by flash filtration to obtain the product C126-3 (280 mg, 93.3%) as a pale yellow solid. LCMS: [M+H] + =325.

[0298] Step 3: C126-3 (48.6 mg, 0.15 mmol) and A1-4 (76.8 mg, 0.135 mmol) were dissolved in a mixture of 5.0 mL of anhydrous DCM and 0.5 mL of anhydrous MeOH. Under nitrogen gas protection, CH3COOH (13.5 mg, 0.225 mmol) was added and the mixture was stirred at room temperature for 0.5 h. Solid NaBH3CN (14.1 mg, 0.225 mmol) was then added to the reaction mixture, and the mixture was allowed to react at room temperature for an additional 2 h. LCMS and TLC confirmed the reaction was complete. Purification by prep-HPLC afforded the pure product C126 (35 mg, 26.7% yield) as a white solid. LCMS: [M+H] + =878.

[0299] Preparation of 4-(7-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)hept-1-yn-1-yl)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (C148) [ka]

[0300] Step 1: Compound C148-1 (or A1-1) (330 mg, 0.98 mmol), compound C148-2 (220 mg, 1.96 mmol), copper(I) iodide (38 mg, 0.20 mmol), Pd(PPh3)2Cl2 (274 mg, 0.39 mmol), and triethylamine (297 mg, 2.94 mmol) were dissolved in dry DMF (10 ml) and stirred overnight at 70 °C under nitrogen gas protection. After cooling to room temperature, the solvent was evaporated under reduced pressure, and the crude product was separated by column chromatography to give compound C148-3 (90 mg, 24.9% yield). LCMS: [M+H] + =369.

[0301] Step 2: Compound C148-3 (60 mg, 0.163 mmol) and carbon tetrabromide (108 mg, 0.326 mmol) were dissolved in dichloromethane (20 ml) and stirred at room temperature for 2 hours. The mixture was cooled to 0 °C, and a solution of triphenylphosphine (86 mg, 0.326 mmol) in dichloromethane (2 ml) was added dropwise. The mixture was allowed to warm to room temperature and reacted at 55 °C for 2 hours with stirring. The solvent was removed under reduced pressure, and the crude product was separated by column chromatography to obtain compound C148-4 (40 mg, 57.1%). LCMS: [M+H] + =431,433.

[0302] Step 3: Compound C148-4 (40 mg, 0.093 mmol), compound A1-4 (58 mg, 0.102 mmol), and DIEA (60 mg, 0.465 mmol) were dissolved in 2 ml of DMF and stirred at 80 °C for 5 hours under nitrogen gas protection. LCMS monitoring showed the reaction was complete. The solvent was evaporated under reduced pressure at 40 °C, and the crude product was purified by flash filtration to give C148 (22 mg, 25.9% yield). LCMS: [M+H] + =920. 1 H NMR (400 MHz, DMSO-d6) δ 11.13(d,2H),8.47(s,1H),8.04(d,2H),7.87(dd,3H),7.52(dd,1H),7.36(dd,2 H),7.09(t,1H),6.62(d,1H),6.46(dd,1H),5.75(s,1H),5.14(dd,1H),3.76(s, 3H),3.71(d,2H),3.26(s,1H),2.92-2.83(m,1H),2.69-2.60(m,4H),2.55(d,4H) ),2.34(d,5H),2.03(m,2H),1.84(d,2H),1.76(d,6H),1.60(m,3H),1.47(s,6H).

[0303] Preparation of 4-(3-((7-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)heptyl)oxy)azetidin-1-yl)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (C150) [ka]

[0304] Step 1: Compound C150-1 (470 mg, 2.72 mmol) was placed in a 100 mL three-neck flask and dissolved in anhydrous tetrahydrofuran (6 mL). Under nitrogen gas protection, the mixture was cooled to 0 °C, sodium hydride (120 mg, 2.98 mmol) was added, and the mixture was warmed to room temperature and stirred for 30 minutes. The mixture was then cooled to 0 °C, and compound C150-2 (842 mg, 3.26 mmol) was added. The mixture was then allowed to react at room temperature for 3 hours. The reaction was monitored by TLC, and the reaction was stopped when the starting material was almost completely consumed. Ice water (3 g) was added to the reaction mixture, and the mixture was extracted twice with ethyl acetate (10 mL each time). The organic phases were combined, washed with saturated brine (5 mL x 2), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product. Separation by column chromatography afforded 100 mg of a pale yellow solid, C150-3, in a 10.6% yield.

[0305] Step 2: Compound C150-3 (35 mg, 0.1 mmol), compound A1-4 (57 mg, 0.1 mmol), and DIPEA (38.7 mg, 0.3 mmol) were added to a 50 mL single-neck flask, dissolved in DMF (2 mL), heated to 70 ° C, and reacted for 2 hours. LCMS detection showed the reaction was complete. After cooling, ethyl acetate (10 mL) and water (5 mL) were added to the reaction mixture, and the mixture was separated. The water-containing layerAfter extraction with ethyl acetate once, the organic layers were combined, washed with saturated brine (5 mL x 2), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give the crude product. Separation by prep-TLC afforded 35 mg of a pale white solid, C150-4, in a yield of 41.7%.

[0306] Step 3: Compound C150-4 (30 mg, 0.035 mmol) and hydrogen chloride / 1,4-dioxane solution (5 mL, 4 mol / L) were added to a 25 mL single-neck flask and reacted for 2 hours with stirring at room temperature. The reaction was monitored by TLC. After completion of the reaction, the solvent was concentrated under reduced pressure, dissolved in dichloromethane (20 mL), and the pH was adjusted to 8-9 with sodium bicarbonate solution. After separation, the dichloromethane solution was dried over anhydrous magnesium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give 25 mg of a pale yellow solid, C150-5. Yield: 99%. LCMS: [M+H] + =739.

[0307] Step 4: Compound C150-5 (20 mg, 0.027 mmol), C150-6 (or A6-1) (8.8 mg, 0.032 mmol), DIPEA (10.4 mg, 0.081 mmol), and NMP (2 mL) were added to a 25 mL single-neck flask and heated to 90°C under nitrogen gas protection for 3 hours. The reaction was monitored by LCMS, revealing the production of a small amount of product. The reaction mixture was directly separated by prep-HPLC to obtain 0.7 mg of C150 as a pale white powder. Yield: 2.6%. LCMS: [M+H] + =995.

[0308] Preparation of 3-(4-((7-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)heptyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (C153) [ka]

[0309] Step 1: C153-1 (or A12-3) (2.59 g, 10.0 mmol) and bis(pinacolato)diboron (2.794 g, 11.0 mmol) were dispersed in 80.0 mL of anhydrous MeCN, and tert-butyl nitrite (1.545 g, 15.0 mmol) was added dropwise under nitrogen gas protection. After the addition was complete, the reaction was allowed to proceed at room temperature for 4.0 h. The reaction mixture was diluted with 80 mL of ethyl acetate, stirred for 5 minutes, suction filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product. Purification by flash chromatography afforded the product C153-2 (2.1 g, 56.7%) as a pale yellow solid. LCMS: [M+H] + =371.

[0310] Step 2: C153-2 (2.1 g, 5.68 mmol) was dispersed in 63.0% H2O2 (30%), and TBAB (548 mg, 1.70 mmol) was added with stirring. The mixture was allowed to react in air for 1 h. LCMS showed the reaction was complete. The reaction mixture was diluted with 150 mL of ethyl acetate and stirred for 5 minutes. The organic layer was separated, the aqueous phase was extracted once, the organic layers were combined, washed with saturated brine (50 mL x 2), dried over anhydrous Na2SO4, and filtered by suction to remove the drying agent. The filtrate was concentrated under reduced pressure to give the crude product. Purification by flash chromatography gave the product C153-3 (0.71 g, 48.2%) as a pale yellow solid. LCMS: [M+H] + =261.

[0311] Step 3: C153-3 (130 mg, 0.5 mmol), K2CO3 (103.5 mg, 0.75 mmol), and KI (41.5 mg, 0.25 mmol) were dispersed in 13.0 mL of anhydrous MeCN, and 7-bromo-1-heptanol (195 mg, 1.0 mmol) was added. The mixture was reacted at 85 °C for 1.5 h. The reaction mixture was cooled to room temperature, filtered under suction, and the solid residue was removed. The filtrate was concentrated under reduced pressure to obtain the crude product. This crude product was purified by prep-TLC to obtain the product C153-4 (115 mg, 61.5%) as a pale yellow solid. LCMS: [M+H] + =375.

[0312] Step 4: C153-4 (75 mg, 0.2 mmol) was dissolved in 10.0 mL of anhydrous DCM, and Dess-Martin reagent (127.5 mg, 0.3 mmol) was added. The mixture was refluxed at 50 °C for 2 h. The reaction mixture was cooled to room temperature and diluted with 10 mL of DCM. 5 mL of saturated NaHCO3 solution and 5 mL of saturated Na2S2O3 solution were added and stirred for 5 min. The organic layer was washed with saturated NaCl solution (10 mL x 1), dried over anhydrous Na2SO4, and filtered by suction to remove the drying agent. The filtrate was concentrated under reduced pressure to obtain the crude product. Purification by prep-TLC gave the product C153-5 (40 mg, 53%) as a pale yellow solid. LCMS: [M+H] + =373.

[0313] Step 5: C153-5 (40 mg, 0.1075 mmol) and A1-4 (55.1 mg, 0.0968 mmol) were dissolved in 8.0 mL of anhydrous DCM. Under nitrogen gas protection, CH3COOH (6.45 mg, 0.1075 mmol) was added dropwise and the mixture was stirred at room temperature for 30 min. NaBH3CN (62.8 mg, 0.1613 mmol) was then added and the mixture was stirred at room temperature for 2 h. The reaction mixture was diluted with 30 mL of DCM and washed sequentially with saturated NH4Cl solution (15 mL x 1) and saturated NaCl solution (10 mL x 1). The organic layer was dried over anhydrous Na2SO4, filtered by suction to remove the drying agent, and the filtrate was concentrated under reduced pressure to give the crude product. Purification by prep-HPLC afforded the pure product C153 (16 mg, 16.2% yield) as a white solid. LCMS: [M+H] + =926. 1 H-NMR:(400MHz,DMSO-d6) δ 11.163(s,1H),10.962(s,1H),8.480(brs, 1H),8.061(d,J=13.2Hz,1H),7.534-7.492(m,2H),7.473-7.292(m,3H),7.241-7.221(m,1H),7.110(t,J=7.2Hz,1H ),6.623(d,J=2.4Hz,1H),6.477(dd,J=2.4,8.8Hz,1H),5.127(dd,J=5.2,13.6Hz,1H),4.390(d,J=17.6Hz,1H),4.24 4(d,J=17.2Hz,1H),4.128(t,J=6.4Hz,2H),3.758(s,3H),3.720-3.690(m,2H),3.300-3.277(m,1H),2.954-2.864( m,1H),2.690-2.558(m,4H),2.328-2.204(m,7H),2.010-1.974(m,2H),1.855-1.745(m,10H),1.549-1.237(m,12H).

[0314] Preparation of 4-((7-(4-(1-(4-((5-bromo-4-((5-(dimethylphosphoryl)quinoxalin-6-yl)amino)pyrimidin-2-yl)amino)-5-methoxy-2-methylphenyl)piperidin-4-yl)piperazin-1-yl)heptyl)oxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (C158) [ka]

[0315] A10-2 (46.3 mg, 0.12 mmol) and C158-1 (67.9 mg, 0.1 mmol) were dissolved in 10.0 mL of anhydrous DCM. Under nitrogen gas protection, CH3COOH (6.0 mg, 0.1 mmol, dissolved in 0.5 mL of DCM) was added and stirred at room temperature for 1 h. Solid NaBH3CN (15.7 mg, 0.25 mmol) was then added to the reaction mixture and the mixture was allowed to react at room temperature for an additional 2 h. LCMS showed the reaction was complete. The reaction mixture was diluted with 20 mL of DCM and washed sequentially with saturated NH4Cl (1 x 15 mL) and saturated brine (1 x 15 mL). The organic layer was dried over anhydrous Na2SO4, filtered under suction, and the filtrate was concentrated under reduced pressure to give the crude product. This crude product was purified by prep-HPLC to give 36 mg of pure product C158 as a yellow solid. Yield: 34.3%. LCMS: [M+H] + =1050. 1H-NMR:(400MHz,DMSO-d6) δ 11.749(s,1H),11.096(s,1H),8.887-8.849(m,3H),8.341(s,1H),8.288(s,1H),7.948(d,J=9.6Hz,1H),7. 841(t,J=7.2Hz,1H),7.531(d,J=8.8Hz,1H),7.467(d,J=7.2Hz,1H),7.406(s,1H),6.767(s,1H),5.102(dd, J=5.2,12.8Hz,1H),4.583(s,6H),4.236(t,J=6.4Hz,3H),3.789(s,3H),3.198-2.700(m,9H),2.625-32.532 (m,3H),2.111(s,3H),2.049(s,4H),2.013(s,3H),1.800-1.647(m,5H),1.495-1.376(m,6H),1.238(s,2H).

[0316] Preparation of 3-(4-(1-(5-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)pentyl)-1H-pyrazol-4-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (C162) [ka]

[0317] Step 1: Compound C162-1 (or C1-1) (300 mg, 1 mmol), compound C162-2 (440 mg, 1.5 mmol), Pd(dppf)Cl2 (73.1 mg, 0.1 mmol), and anhydrous sodium carbonate (414 mg, 3 mmol) were added to a 50 mL single-neck flask. DMF (10 mL) and water (2 mL) were added, and the atmosphere was replaced with nitrogen gas to remove oxygen. The mixture was heated to 90 °C under nitrogen gas protection and subjected to a microwave reaction for 1 h. After cooling, water (30 mL) was added and the mixture was extracted with ethyl acetate three times (20 mL each time). The combined organic phases were washed with brine (25 mL x 3), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product. The crude product was separated by column chromatography to obtain 140 mg of a pale white solid, C162-3. Yield: 34%.

[0318] Step 2: Compound C162-3 (70 mg, 0.17 mmol) and dichloromethane (3 mL) were added to a 25 mL single-neck flask and stirred to dissolve. Trifluoroacetic acid (2 mL) was added and the mixture was stirred at room temperature for 1 hour. The reaction was monitored by TLC. After completion of the reaction, the mixture was concentrated under reduced pressure to remove dichloromethane and most of the trifluoroacetic acid. The mixture was dissolved in dichloromethane (10 mL), and the pH was adjusted to 8-9 with sodium bicarbonate solution. The mixture was separated, the dichloromethane solution was dried over anhydrous magnesium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give 51 mg of a pale yellow solid, C162-4. Yield: 96%. LCMS: [M+H] + =311.

[0319] Step 3: Compound C162-4 (50 mg, 0.16 mmol), compound C162-5 (36.8 mg, 0.16 mmol), and potassium carbonate (66.24 mg, 0.48 mmol) were added to a 25 mL single-neck flask, and the mixture was heated to 45°C with stirring and reacted overnight. LCMS showed the reaction was complete. The reaction mixture was cooled, water (10 mL) was added, and the mixture was extracted with ethyl acetate three times (5 mL each time). The organic phases were combined, washed with brine (5 mL x 3), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product. The crude product was separated by preparative thin-layer chromatography to obtain 22 mg of a pale yellow waxy solid, C162-6. Yield: 30.1%. LCMS: [M+H] + =459,461.

[0320] Step 4: Compound C162-6 (20 mg, 0.053 mmol), compound A1-4 (30.5 mg, 0.053 mmol), and diisopropylethylamine (20.5 mg, 0.159 mmol) were added to a 25 mL single-neck flask, and DMF (2 mL) was added. The mixture was stirred to dissolve, heated to 70°C, and reacted for 2 hours. The reaction was monitored by LCMS. After completion of the reaction, the reaction solution was cooled and concentrated under reduced pressure to obtain the crude product. The crude product was separated by preparative high-performance liquid chromatography to obtain a white solid. C162, 9 mg, yield: 17.9%. LCMS: [M+H] + =948.

[0321] Preparation of 3-(5-(7-(4-(1-(4-((5-bromo-4-((5-(dimethylphosphoryl)quinoxalin-6-yl)amino)pyrimidin-2-yl)amino)-5-methoxy-2-methylphenyl)piperidin-4-yl)piperazin-1-yl)hept-1-yn-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (C163) [ka]

[0322] Step 1: Compound C163-1 (5 g, 16.35 mmol), compound C163-2 (3.49 g, 21.25 mmol), and triethylamine (2.15 g, 21.25 mmol) were dissolved in 80 mL of acetonitrile and stirred overnight at 80 °C under nitrogen gas protection. After cooling to room temperature and filtration, the solid was rinsed with acetonitrile. The mother liquor was concentrated and washed with a small amount of acetonitrile. The solid was combined and dried to give compound C163-3 (7.03 g, 84.4% yield) as a white solid. This was used directly in the next step. LCMS: [M+H] + =323,325.

[0323] Step 2: Compound C163-3 (322 mg, 1 mmol), compound C163-4 (280 mg, 2.5 mmol), copper(I) iodide (38 mg, 0.2 mmol), Pd(dppf)Cl (280 mg, 0.4 mmol), and triethylamine (30.3 mg, 3 mmol) were dissolved in 10 mL of anhydrous DMF and reacted overnight at 70 °C under nitrogen gas protection with stirring. The solvent was removed under reduced pressure, and the crude product was purified by thin layer chromatography to give compound C163-5 (135 mg, 38.1% yield) as an off-white solid. LCMS: [M+H] + =355.

[0324] Step 3: Compound C163-5 (45 mg, 0.127 mmol) and Dess-Martin reagent (162 mg, mmol) were dissolved in 20 mL of dichloromethane and stirred at 50 °C for 2 hours. After cooling to room temperature and quenching with saturated aqueous sodium bicarbonate, the organic phase was separated, and the aqueous phase was extracted with dichloromethane three times. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was purified by TLC to give compound C163-6 (26.7 mg, 60.7% yield) as a white solid. LCMS: [M+H] + =353.

[0325] Step 4: Compounds C163-6 (26.7 mg, 0.076 mmol) and C163-7 (or C158-1) (51.5 mg, 0.076 mmol) were dissolved in 3 mL of dichloromethane / methanol (2 / 1), and one drop of glacial acetic acid was added dropwise. The mixture was stirred at room temperature for 1 hour under nitrogen gas protection. Sodium cyanoborohydride (4.8 mg, 0.076 mmol) was then added and stirred for another hour. The solvent was removed under reduced pressure at 40°C or less, and the crude product was purified by flash filtration to give an off-white solid compound C163 (15 mg, 19.5% yield). LCMS: [M+H] + =1016,1018.

[0326] Preparation of 4-((7-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)heptyl-7,7-dideuterium)oxy)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (C164) [ka]

[0327] Step 1: A1-4 (100 mg, 0.176 mmol) and C164-1 (30.8 mg, 0.211 mmol) were dissolved in 10.0 mL of anhydrous DCM. Under nitrogen gas protection, T3P (224 mg, 0.352 mmol) and DIPEA (90.8 mg, 0.704 mmol) were added sequentially and the reaction was allowed to proceed at room temperature for 2 h. The reaction mixture was diluted with 20 mL of dichloromethane and washed sequentially with saturated NH4Cl (10 mL x 1) and saturated NaCl (10 mL x 1). The organic layer was dried over anhydrous MgSO4, filtered with suction, and the filtrate was concentrated under reduced pressure to give the crude product. This crude product was purified by prep-TLC to give the yellow solid product C164-2 (45 mg, 36.7%). LCMS: [M+H] + =698.

[0328] Step 2: C164-2 (45 mg, 0.065 mmol) was dissolved in 10.0 mL of anhydrous THF, and LiAlD4 (27.1 mg, 0.65 mmol) was added under nitrogen gas protection. The reaction was allowed to proceed at 70 °C for 2.0 h. LCMS showed the reaction was complete. The reaction mixture was cooled to 0 °C and quenched with 1.0 mL of HO. Five drops of 1 mol / L NaOH solution were added to the mixture, and the mixture was stirred for 5 min. The organic layer was separated and concentrated under reduced pressure to give crude product C164-3 (35 mg, 77.7%). This crude product was used directly in the next reaction. LCMS: [M+H] + =686.

[0329] Step 3: C164-3 (35 mg, 0.051 mmol), C164-4 (or A2-1) (15.4 mg, 0.056 mmol), and PPh3 (20 mg, 0.077 mmol) were dissolved in 6.0 mL of anhydrous THF. Under nitrogen gas protection, DIAD (15.4 mg, 0.077 mmol) was added and the reaction was allowed to proceed at room temperature for 2 h. LCMS showed the reaction was complete. The reaction solution was concentrated under reduced pressure to obtain the crude product. This crude product was purified by prep-HPLC to obtain the product C164 (10 mg, 20.8% yield) as a pale yellow solid. LCMS: [M+H] + =942.

[0330] Preparation of 3-(4-(7-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)hept-1-yn-1-yl)-5-fluoro-1-oxoisoindolin-2-yl)piperidine-2,6-dione (C166) [ka]

[0331] Step 1: Compound C166-1 (10 g, 64.87 mmol) was added to a 500 mL single-neck flask, and sulfuric acid (200 mL) was added and stirred to dissolve. NBS (10.4 g, 58.44 mmol) was added and the reaction was allowed to proceed at room temperature with stirring for 5 hours. The reaction was monitored by LCMS. After completion of the reaction, the reaction solution was poured into ice water (1000 g) to quench the reaction. A white solid precipitated and was collected by filtration. The filter cake was washed three times with water (200 mL each time) to obtain a white solid containing water. The mixture was dried at 50 °C under vacuum to obtain 12 g of a white powder, C166-2. This was used directly in the next step.

[0332] Step 2: Compound C166-2 (6 g, 25.75 mmol) was added to a 250 mL single-neck flask and dissolved in methanol (100 mL). The mixture was cooled to 0 °C, and thionyl chloride (7.67 g, 64.37 mmol) was added dropwise. The mixture was then heated and refluxed for 2 hours. The reaction was monitored by TLC, and when the starting material was almost consumed, the reaction was stopped. The reaction mixture was concentrated under reduced pressure to remove most of the solvent and thionyl chloride. Ice water was added to the concentrated solution, and the mixture was extracted with ethyl acetate (100 mL x 3). The organic phases were combined, washed sequentially with saturated sodium bicarbonate solution, water, and brine (50 mL x 2), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to give 5.2 g of a pale yellow oil. Yield: 81.7%. The product was used directly in the next step.

[0333] Step 3: A 250 mL single-neck flask was charged with the compound C166-3 mixture (3 g, 12.1 mmol) and dissolved in chloroform (100 mL). NBS (2.16 g, 12.1 mmol) and AIBN (196.8 mg, 1.21 mmol) were added in sequence, and the mixture was heated to reflux with stirring for 5 hours. The reaction was monitored by TLC, and the reaction was stopped once most of the starting material was converted to the product. After cooling, the reaction mixture was filtered to remove insoluble matter. The mother liquor was washed three times with water (20 mL each time), dried over anhydrous magnesium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product. The crude product was separated by column chromatography to obtain 2.2 g of a colorless oil, C166-4.

[0334] Step 4: Compound C166-4 (2 g, 12.24 mmol) and compound C166-5 (4 g, 12.24 mmol) were added to a 250 mL single-neck flask in this order, followed by acetonitrile (100 mL). Triethylamine (2.56 mL, 36.72 mmol) was then added, and the mixture was heated to reflux and reacted overnight. After cooling the reaction mixture, a solid precipitated and crystallized for another 5 hours. This was then filtered to obtain a pale white solid. The solid was washed with acetonitrile (20 mL x 2) and dried under vacuum at 40 °C to obtain 700 mg of pale white powder, C166-6. Yield: 16.8%. LCMS: [M+H] + =341,343.

[0335] Step 5: Compound C166-6 (700 mg, 2.05 mmol), hept-6-yn-1-ol (392 mg, 3.5 mmol), Pd(PPh3)2Cl2 (490 mg, 0.35 mmol), copper(I) iodide (66.8 mg, 0.35 mmol), and triethylamine (530 mg, 5.25 mmol) were added to a 100 mL three-neck flask and dissolved in DMF (20 mL). The mixture was heated to 70 °C under nitrogen gas protection and reacted for 5 hours. The reaction was monitored by LCMS. After completion of the reaction, the reaction mixture was cooled and concentrated under reduced pressure to obtain the crude product. Separation by column chromatography afforded 170 mg of a pale yellow solid, C166-7. Yield: 22.3%. LCMS: [M+H] + =373.2.

[0336] Step 6: Compound C166-7 (170 mg, 0.46 mmol) was added to a three-necked flask equipped with a 50 mL condenser, dissolved in THF (3 mL), and phosphorus oxybromide (170 mg, 0.59 mmol) was added. The mixture was heated to 70 °C and reacted for 2 hours. The reaction was monitored by LCMS. After completion of the reaction, the mixture was cooled, ethyl acetate (10 mL) was added to the reaction mixture, washed twice with saturated sodium bicarbonate solution (5 mL each time), and then washed with brine (5 mL × 2), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product. The crude product was separated by preparative thin-layer chromatography to obtain 39 mg of a pale white solid, C166-8. Yield: 19.5%. LCMS: [M+H] + =435,437.

[0337] Step 7: Compound C166-8 (40 mg, 0.11 mmol), A1-4 (61.2 mg, 0.11 mmol), diisopropylethylamine (41.7 mg, 0.33 mmol), and DMF (2 mL) were added to a 25 mL single-neck flask equipped with a condenser, and the mixture was heated to 70°C for 3 hours. The reaction was monitored by LCMS, and when the starting material was almost consumed, the reaction was stopped. After cooling, the reaction mixture was concentrated under reduced pressure to obtain the crude product. Separation by prep-HPLC afforded 10 mg of C166 as a white powder. Yield: 10%. LCMS: [M+H] + =924.

[0338] Preparation of 3-(4-(7-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)hept-1-yn-1-yl)-6-fluoro-1-oxoisoindolin-2-yl)piperidine-2,6-dione (C167) [ka]

[0339] Step 1: C167-1 (1.0 g, 4.06 mmol) was dissolved in 10.0 mL of CCl4, and NBS (1.1 g, 6.1 mmol) and AIBN (266.5 mg, 1.624 mmol) were added under nitrogen gas protection. The mixture was heated to 90 °C, refluxed, and reacted for 20 h. LCMS showed no remaining starting material. After cooling to room temperature, the reaction mixture was suction filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product. Purification by flash chromatography yielded 1.2 g of a pale yellow oily product, C167-2, which solidified upon standing.

[0340] Step 2: C167-2 (1.2 g, 3.69 mmol) and 3-aminopiperidine-2,6-dione hydrochloride (787 mg, 4.80 mmol) were dispersed in 25.0 mL of anhydrous MeCN, and TEA (485 mg, 4.80 mmol) was added. The mixture was heated to 80 °C and refluxed for 16 h. LCMS showed the reaction was complete. After cooling to room temperature, the reaction mixture was suction filtered, and the filter cake was washed three times with MeCN. The solid was dried to give product C167-3 (1.0 g, 80% yield). LCMS: [M+H] + =341,343.

[0341] Step 3: C167-3 (340 mg, 1.0 mmol), CuI (38 mg, 0.2 mmol), and Pd(dppf)Cl (292.4 mg, 0.4 mmol) were dispersed in 17.0 mL of anhydrous DMF. Under N gas protection, hept-6-yn-1-ol (281 mg, 2.5 mmol) and triethanolamine (303 mg, 3.0 mmol) were sequentially added. The mixture was heated to 70 °C and reacted for 16 h. LCMS showed the reaction was complete. The reaction mixture was cooled to room temperature and diluted with 80 mL of ethyl acetate. The mixture was washed sequentially with saturated ammonium chloride (2 x 40 mL), HO (2 x 40 mL), and saturated brine (2 x 40 mL). The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give the crude product. Purification by RP-Flash gave the product C167-4 (95 mg, 25.5%) as a pale yellow solid. LCMS: [M+H] + =373.

[0342] Step 4: C167-4 (90 mg, 0.242 mmol) was dissolved in 25.0 mL of anhydrous DCM, and Dess-Martin reagent (154 mg, 0.363 mmol) was added under N2 gas protection. The mixture was heated to 50 °C and refluxed for 2.0 h. TLC showed the reaction was complete. After cooling to room temperature, 10 mL of saturated NaHCO3 solution and 10 mL of saturated Na2S2O3 solution were added and stirred at room temperature for 5 min. The organic layer was separated, dried over anhydrous sodium sulfate, and suction filtered. The filtrate was concentrated under reduced pressure to obtain the crude product. This crude product was purified by prep-TLC to obtain the product C167-5 (55 mg, 60%) as a pale yellow solid. LCMS: [M+H] + =371.

[0343] Step 5: C167-5 (30.0 mg, 0.081 mmol) and A1-4 (46.1 mg, 0.081 mmol) were dissolved in 5.5 mL of anhydrous DCM. Under nitrogen gas protection, CH3COOH (4.86 mg, 0.081 mmol, dissolved in 0.5 mL of DCM) was added and stirred at room temperature for 0.5 h. Solid NaBH3CN (10.2 mg, 0.162 mmol) was then added to the reaction mixture and the mixture was allowed to react at room temperature for an additional 2 h. LCMS and TLC confirmed the reaction was complete. The reaction mixture was diluted with 20 mL of DCM and washed sequentially with saturated NH4Cl (1 x 15 mL) and saturated brine (1 x 15 mL). The organic layer was dried over anhydrous Na2SO4, filtered under suction, and the filtrate was concentrated under reduced pressure to give the crude product. Purification by prep-HPLC afforded 25 mg of the pure product as a white solid. Yield: 33.5%. LCMS: [M+H] + =924. 1H-NMR:(400MHz,DMSO-d6) δ 11.190(s,1H),11.051(s,1H),8.490(br s,1H),8.098(s,1H),8.066(s,1H),7.563-7.507(m,3H),7.397-7.315(m,2H),7.110(t,J=6.4Hz,1H),6.628( d,J=2.4Hz,1H),6.479(dd,J=2.4Hz,8.4Hz,1H),5.182(dd,J=5.2Hz,13.2Hz,1H),4.462(dd,J=17.2Hz,60.0H z,2H),3.758(s,3H),3.725(d,J=12.8Hz,2H),2.967-2.876(m,2H),2.672-2.503(m,3H),2.501-2.397(m,6H) ,2.398-2.247(m,3H),2.032-1.974(m,1H),1.832-1.748(m,12H),1.5615-1.527(m,2H),1.498-1.436(m,6H).

[0344] Preparation of 3-(4-(3-(2-(4-(1-(4-((5-bromo-4-((5-(dimethylphosphoryl)quinoxalin-6-yl)amino)pyrimidin-2-yl)amino)-5-methoxy-2-methylphenyl)piperidin-4-yl)piperazin-1-yl)ethoxy)prop-1-yn-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (C169) [ka]

[0345] Step 1: Compound C169-1 (or C1-1) (309 mg, 1 mmol), compound C169-2 (200 mg, 2 mmol), Pd(dppf)Cl2 (280 mg, 0.4 mmol), copper(I) iodide (38.2 mg, 0.2 mmol), and triethylamine (303 mg, 3 mmol) were added to a 100 mL single-neck flask, and DMF (20 mL) was added to dissolve the mixture. The atmosphere was replaced with nitrogen gas three times to remove oxygen, and the mixture was heated to 70 °C under nitrogen gas protection and reacted for 5 hours. The reaction was monitored by LCMS. After completion of the reaction, the mixture was cooled and concentrated under reduced pressure to obtain the crude product. Separation by column chromatography afforded 70 mg of a pale yellow solid, C169-3. Yield: 20.3%. LCMS: [M+H] + =343.

[0346] Step 2: Compound C169-3 (70 mg, 0.2 mmol) was added to a three-neck flask equipped with a 50 mL condenser, dissolved in THF (2 mL), and phosphorus oxybromide (170 mg, 0.59 mmol) was added. The mixture was heated to 70 °C and reacted for 2 hours. The reaction was monitored by LCMS. After completion of the reaction, the mixture was cooled, ethyl acetate (10 mL) was added to the reaction mixture, washed with saturated sodium bicarbonate solution (5 mL x 2), washed with brine (5 mL x 2), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain the crude product. The crude product was separated by preparative thin-layer chromatography to obtain 24 mg of a pale white solid, C169-4. Yield: 29.7%. LCMS: [M+H] + =405,407.

[0347] Step 3: Compound C169-4 (12 mg, 0.029 mmol), compound C169-5 (or C158-1) (19.3 mg, 0.029 mmol), diisopropylethylamine (11.2 mg, 0.087 mmol), and DMF (1 mL) were added to a 25 mL single-neck flask equipped with a condenser, and the mixture was heated to 70° C. and reacted for 3 hours. The reaction was monitored by LCMS. After completion of the reaction, the mixture was cooled and concentrated under reduced pressure to obtain the crude product. Separation by prep-HPLC afforded 10 mg of C169 as a white powder. Yield: 34.5%. LCMS: [M+H] + =1004.

[0348] Preparation of 4-(7-(9-(4-((5-bromo-4-((5-(dimethylphosphoryl)quinoxalin-6-yl)amino)pyrimidin-2-yl)amino)-5-methoxy-2-methylphenyl)-3,9-diazaspiro[5.5]undecan-3-yl)hept-1-yn-1-yl)-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione (C171) [ka]

[0349] Step 1: Compound C171-1 (or C148-3) (56.6 mg, 0.154 mmol) and Dess-Martin reagent (196 mg, 0.461 mmol) were dissolved in dichloromethane (20 ml) and reacted at 50 °C with stirring for 2 hours. After cooling to room temperature, the reaction was quenched with saturated aqueous sodium bicarbonate solution, the layers were separated, and the aqueous phase was extracted three times with dichloromethane. The organic phases were combined, washed with saturated brine (15 mL x 2), dried over anhydrous sodium sulfate, filtered, and the solvent was removed under reduced pressure. The crude product was separated by column chromatography to give compound C171-2 (45 mg, 80.4% yield). LCMS: [M+H] + =367.

[0350] Step 2: Compound C171-2 (45 mg, 0.12 mmol) and compound C47-1 (82 mg, 0.12 mmol) were dissolved in dichloromethane and methanol (2 / 1) (3 ml), and one drop of glacial acetic acid was added. The mixture was stirred at room temperature for 1 hour under nitrogen gas protection. Sodium cyanoborohydride (7.8 mg, 0.12 mmol) was then added and stirred for 1 hour. The mixture was concentrated to remove the solvent, and the crude product was purified by flash filtration to give compound C171 (15 mg, 14.7% yield). LCMS: [M+H] + =1015,1017.

[0351] Preparation of 3-(4-(8-(9-(4-((5-bromo-4-((5-(dimethylphosphoryl)quinoxalin-6-yl)amino)pyrimidin-2-yl)amino)-5-methoxy-2-methylphenyl)-3,9-diazaspiro[5.5]undecan-3-yl)oct-1-yn-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (C172) [ka]

[0352] Step 1: Compound C172-1 (or C1-1) (309 mg, 1 mmol), compound C172-2 (252 mg, 2 mmol), bis(triphenylphosphine)palladium dichloride (280 mg, 0.4 mmol), copper(I) iodide (38.4 mg, 0.2 mmol), and triethylamine (303 mg, 3 mmol) were added to a 100 mL single-neck flask, and DMF (20 mL) was added to dissolve the mixture. The atmosphere was replaced with nitrogen gas three times to remove oxygen, and the mixture was heated to 70 °C under nitrogen gas protection and reacted for 5 hours. The reaction was monitored by LCMS. After completion of the reaction, the reaction mixture was cooled and concentrated under reduced pressure to obtain the crude product. Separation by column chromatography afforded 200 mg of a pale yellow solid, C172-3. Yield: 54.3%. LCMS: [M+H] + =369.4.

[0353] Step 2: Compound C172-3 (200 mg, 0.543 mmol) and dichloromethane (40 mmol) were added to a 100 mL single-neck flask and dissolved by stirring. Dess-Martin reagent (345 mg, 0.814 mmol) was added and the mixture was heated to 40°C and reacted for 2 hours. The reaction was monitored by LCMS. After the raw materials were mostly converted to the product, the reaction was stopped. The reaction mixture was cooled to 0-5°C in an ice bath, and saturated sodium bicarbonate solution (10 mL) and sodium thiosulfate solution (10 mL) were added in that order. The mixture was stirred for about 10 minutes, and the layers were separated. The water-containing layer Extracted twice with dichloromethane (20 mL each time), the organic phases were combined, washed with saturated brine (10 mL x 2), dried over anhydrous sodium sulfate, and concentrated under reduced pressure to give 180 mg of a white sticky solid, C172-4, which was used directly in the next step. LCMS: [M+H] + =367.2.

[0354] Step 3: Compound C172-4 (40 mg, 0.11 mmol) and compound C47-1 (59.7 mg, 0.09 mmol) were added to a 25 mL single-neck flask and dissolved in dichloromethane (5 mL). Acetic acid (10 mg, 0.16 mmol) was added and the mixture was stirred at room temperature for 30 minutes. Sodium cyanoborohydride (9.5 mg, 0.15 mmol) was added and the mixture was stirred at room temperature for 3 hours. The reaction was monitored by LCMS, and after most of the raw materials were converted to the product, the reaction was stopped. Saturated ammonium chloride (5 mL) was added to the reaction system, and the mixture was stirred for 5 minutes, followed by separation. The water-containing layer Extracted twice with dichloromethane (10 mL each time), the organic phases were combined, washed with saturated brine (5 mL x 2), dried over anhydrous sodium sulfate, concentrated under reduced pressure, and separated by Prep-HPLC to give 20 mg of yellow powder C172. Yield 18%. LCMS: [M+H] + =1001.

[0355] Preparation of 3-(4-(9-(9-(4-((5-bromo-4-((5-(dimethylphosphoryl)quinoxalin-6-yl)amino)pyrimidin-2-yl)amino)-5-methoxy-2-methylphenyl)-3,9-diazaspiro[5.5]undecan-3-yl)non-1-yn-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (C173) [ka]

[0356] Step 1: C173-1 (or C1-1) (644 mg, 2.0 mmol), CuI (76 mg, 0.4 mmol), and Pd(dppf)Cl2 (585 mg, 0.8 mmol) were dispersed in 34 mL of anhydrous DMF. Under N2 gas protection, 8-alkynyl-1-nonanol (700 mg, 5.0 mmol) and triethanolamine (606 mg, 6.0 mmol) were sequentially added. The mixture was heated to 70 °C and reacted for 20 h. LCMS showed the reaction was complete. The mixture was cooled to room temperature and diluted with 150 mL of EA. The mixture was washed sequentially with saturated ammonium chloride (2 x 50 mL), HO (2 x 50 mL), and saturated brine (2 x 50 mL). The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give the crude product. Purification by RP-Flash gave the product C173-2 (210 mg, 27.5%) as a pale yellow solid. LCMS: [M+H] + =383.

[0357] Step 2: C173-2 (200 mg, 0.524 mmol) was dissolved in 30.0 mL of anhydrous DCM, and Dess-Martin reagent (333 mg, 0.785 mmol) was added under N2 gas protection. The mixture was heated to 50 °C and refluxed for 2.0 h. TLC showed the reaction was complete. After cooling to room temperature, 10 mL of saturated NaHCO3 solution and 10 mL of saturated Na2S2O3 solution were added and stirred at room temperature for 5 min. The organic layer was separated, dried over anhydrous sodium sulfate, and suction filtered. The filtrate was concentrated under reduced pressure to obtain the crude product. This crude product was purified by prep-TLC to obtain the product C173-3 (150 mg, 75%) as a pale yellow solid. LCMS: [M+H] + =381.

[0358] Step 3: C173-3 (45 mg, 0.1184 mmol) and C47-1 (70.8 mg, 0.1066 mmol) were dissolved in a mixture of 8.0 mL of anhydrous DCM and 0.8 mL of anhydrous methanol. Under nitrogen gas protection, CH3COOH (7.1 mg, 0.1184 mmol, dissolved in 0.5 mL of DCM) was added and stirred at room temperature for 0.5 h. Solid NaBH3CN (11.2 mg, 0.1776 mmol) was then added to the reaction mixture and the mixture was allowed to react at room temperature for an additional 2 h. LCMS and TLC confirmed the reaction was complete. The reaction mixture was diluted with 20 mL of DCM and washed sequentially with saturated NH4Cl (1 x 15 mL) and saturated brine (1 x 15 mL). The organic layer was dried over anhydrous Na2SO4, filtered under vacuum, and the filtrate was concentrated under reduced pressure to give the crude product. Purification by prep-HPLC afforded 45 mg of the pure product as a yellow solid. Yield 40.0%. LCMS:[M+H] + =1029,1031. 1H-NMR:(400MHz,DMSO-d6) δ 12.683(s,1H),11.119(s,1H),8.869(dd,J=2.0Hz,9.2Hz,3H),8.281(s,1H),8.263(s,1H),7.721(d,J=6 .8Hz,1H),7.646(d,J=0.8Hz,1H),7.643(d,J=6.8Hz,1H),7.539(d,J=7.6Hz,1H),7.321(s,1H),6.809(s, 1H),5.188(dd,J=5.2Hz,13.6Hz,1H),4.477(d,J=17.6Hz,1H),4.325(d,J=17.6Hz,1H),3.784(s,3H),2.5 13-2.495(m,10H),2.494-2.103(m,6H),2.075(s,3H),2.040(s,3H),2.004(s,3H),1.557-1.429(m,18H).

[0359] Preparation of 3-(4-(3-(2-(9-(4-((5-bromo-4-((5-(dimethylphosphoryl)quinoxalin-6-yl)amino)pyrimidin-2-yl)amino)-5-methoxy-2-methylphenyl)-3,9-diazaspiro[5.5]undecan-3-yl)ethoxy)prop-1-yn-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (C174) [ka]

[0360] Compound C169-4 (2 mg, 0.029 mmol), compound C47-1 (1 mg, 0.029 mmol), diisopropylethylamine (11.2 mg, 0.087 mmol), and DMF (1 mL) were added to a 25 mL single-neck flask equipped with a condenser, and the mixture was heated to 70° C. and reacted for 3 hours. The reaction was monitored by LCMS. After completion of the reaction, the mixture was cooled and concentrated under reduced pressure to obtain the crude product. Separation by prep-HPLC afforded 9 mg of C174 as a white powder. Yield: 31.2%. LCMS: [M+H] + =989,991.

[0361] Preparation of 3-(4-(3-(2-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)ethoxy)prop-1-yn-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (C176) [ka]

[0362] Step 1: Compound C176-1 (or C1-1) (322 mg, 1.00 mmol), compound C176-2 (200 mg, 2.00 mmol), copper(I) iodide (38 mg, 0.20 mmol), Pd(PPh3)2Cl2 (280 mg, 0.40 mmol), and triethylamine (303 mg, 3.00 mmol) were dissolved in dry DMF (10 ml) and stirred overnight at 70 °C under nitrogen gas protection. After cooling to room temperature, the solvent was evaporated under reduced pressure, and the crude product was separated by column chromatography to obtain compound C176-3 (80 mg, 23.4% yield). LCMS: [M+H] + =343.

[0363] Step 2: Compound C176-3 (52 mg, 0.152 mmol) and carbon tetrabromide (101 mg, 0.305 mmol) were dissolved in dichloromethane (20 ml) and stirred at room temperature for 2 hours. The mixture was cooled to 0 °C, and a solution of PPh3 (80 mg, 0.305 mmol) in dichloromethane (2 ml) was added dropwise. The mixture was allowed to warm to room temperature and reacted at 55 °C with stirring for 2 hours. The solvent was removed under reduced pressure, and the crude product was separated by column chromatography to obtain compound C176-4 (20 mg, yield 32.8%). LCMS: [M+H] + =405,407.

[0364] Step 3: Compound C176-4 (20 mg, 0.050 mmol), compound A1-4 (31 mg, 0.054 mmol), and DIEA (32 mg, 0.248 mmol) were dissolved in 1 ml of DMF and stirred at 80 °C for 5 hours under nitrogen gas protection. LCMS monitoring showed the reaction was complete. The solvent was evaporated under reduced pressure at 40 °C, and the crude product was purified by flash filtration to give C176 (18 mg, 40.9% yield). LCMS: [M+H] + =894. 1 H NMR(400MHz,DMSO-d6) δ 11.17(s,1H),11.01(s,1H),8.48(s,1H),8.05(d,2H),7.75(dd,2H),7.54(dt,2H),7.36(dd, 2H),7.09(t,1H),6.62(d,1H),6.47(dd,1H),5.75(s,1H),5.16(dd,1H),4.50(d,1H),4.35(d, 1H),3.76(s,3H),3.71(d,2H),3.65(t,2H),3.28(s,1H),3.00-2.87(m,2H),2.66(d,4H),2.5 7(s,1H),2.44(d,4H),2.29(s,2H),2.01(p,3H),1.84(d,2H),1.76(d,6H),1.57-1.42(m,3H).

[0365] Preparation of 3-(4-(8-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)oct-1-yn-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (C177) [ka]

[0366] Compounds C172-4 (40 mg, 0.11 mmol) and A1-4 (51.2 mg, 0.09 mmol) were added to a 25 mL single-neck flask and dissolved in dichloromethane (5 mL). Acetic acid (10 mg, 0.16 mmol) was added and the mixture was stirred at room temperature for 30 minutes. Sodium cyanoborohydride (9.5 mg, 0.15 mmol) was then added and the mixture was stirred at room temperature for 3 hours. The reaction was monitored by LCMS. After completion of the reaction, saturated ammonium chloride (5 mL) was added to the reaction mixture, which was stirred for 5 minutes and then separated. The water-containing layer Extraction with dichloromethane (10 mL x 2) was performed, and the combined organic phases were washed with saturated brine (5 mL x 2), dried over anhydrous sodium sulfate, concentrated under reduced pressure, and separated by Prep-HPLC to obtain 18 mg of a yellow powder. Yield: 19.5%. LCMS: [M+H] + =920.

[0367] Preparation of 3-(4-(9-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)non-1-yn-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (C178) [ka]

[0368] C173-3 (48 mg, 0.1263 mmol) and A1-4 (64.7 mg, 0.1137 mmol) were dissolved in a mixture of 8.0 mL of anhydrous DCM and 0.8 mL of anhydrous methanol. Under nitrogen gas protection, CH3COOH (7.6 mg, 0.1263 mmol, dissolved in 0.5 mL of DCM) was added and stirred at room temperature for 0.5 h. Solid NaBH3CN (11.9 mg, 0.1895 mmol) was then added to the reaction mixture and the mixture was allowed to react at room temperature for an additional 2 h. LCMS and TLC confirmed the reaction was complete. The reaction mixture was diluted with 20 mL of DCM and washed sequentially with saturated NH4Cl (1 x 15 mL) and saturated brine (1 x 15 mL). The organic layer was dried over anhydrous Na2SO4, filtered under vacuum, and the filtrate was concentrated under reduced pressure to give the crude product. The crude product was purified by prep-TLC to give 55 mg of crude product. The crude product was further purified by Prep-HPLC to give 35 mg of pure product as a white solid. Yield 29.7%. LCMS: [M+H] + =934. 1 H-NMR:(400MHz,DMSO-d6) δ 11.190(s,1H),11.089(s,1H),8.481(brs, 1H),8.092(d,J=10.0Hz,2H),7.721(d,J=7.6Hz,1H),7.644(d,J=7.6Hz,1H),7.539-7.502(m,2H),7.340(dd,J=8.4Hz,17.2 Hz,2H),7.070(t,J=14.4Hz,1H),6.621(s,1H),6.476(d,J=8.8Hz,1H),5.184(dd,J=4.8Hz,13.2Hz,1H),4.474(d,J=17.6Hz, 1H),4.321(d,J=17.6Hz,1H),3.757-3.694(m,5H),2.932-2.842(m,2H),2.636-2.530(m,3H),2.444-2.380(m,4H),2.357-2 .160(m,7H),1.989-1.933(m,2H),1.809-780(m,2H),1.743(s,3H),1.709(s,3H),1.566-1.355(m,8H),1.319-1.157(m,5H).

[0369] Preparation of 3-(4-(10-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)dec-1-yn-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (C179) [ka]

[0370] Step 1: C179-1 (or C1-1) (322 mg, 1.0 mmol), CuI (38 mg, 0.2 mmol), and Pd(dppf)Cl2 (292.4 mg, 0.4 mmol) were dispersed in 15 mL of anhydrous DMF. 9-Alkynyl-1-decanol (385 mg, 2.5 mmol) and triethanolamine (303 mg, 3.0 mmol) were added sequentially under N2 gas protection. The mixture was heated to 70 °C and reacted for 20 h. LCMS showed the reaction was complete. The reaction mixture was cooled to room temperature, diluted with 80 mL of EA, and washed sequentially with saturated ammonium chloride (2 x 50 mL), HO (2 x 50 mL), and saturated brine (2 x 50 mL). The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give the crude product. Purification by RP-Flash gave the product C179-2 (105 mg, 26.5%) as a pale yellow solid. LCMS: [M+H] + =397.

[0371] Step 2: C179-2 (35 mg, 0.088 mmol) was dissolved in 10.0 mL of anhydrous DCM, and Dess-Martin reagent (75 mg, 0.176 mmol) was added under N2 gas protection. The mixture was heated to 50 °C and refluxed for 2.0 h. TLC showed the reaction was complete. After cooling to room temperature, 10 mL of saturated NaHCO3 solution and 10 mL of saturated Na2S2O3 solution were added and stirred vigorously at room temperature for 5 min. The organic layer was separated, dried over anhydrous sodium sulfate, and suction filtered. The filtrate was concentrated under reduced pressure to obtain the crude product. This crude product was purified by prep-TLC to obtain the product C179-3 (15 mg, 42.8%) as a pale yellow solid. LCMS: [M+H] + =395.

[0372] Step 3: C179-3 (15 mg, 0.0381 mmol) and A1-4 (19.5 mg, 0.0343 mmol) were dissolved in 3.0 mL of anhydrous DCM. Under nitrogen gas protection, CH3COOH (2.3 mg, 0.0381 mmol, dissolved in 0.5 mL of DCM) was added and stirred at room temperature for 0.5 h. Solid NaBH3CN (3.59 mg, 0.0572 mmol) was then added to the reaction mixture, and the mixture was allowed to react at room temperature for an additional 2 h. LCMS and TLC confirmed the reaction was complete. The reaction mixture was directly purified by prep-TLC to give 15 mg of crude product. This crude product was further purified by prep-HPLC to give the pure product C179 (7.0 mg, 19.5% yield) as a white solid. LCMS: [M+H] + =948.

[0373] 3-(4-(3-(3-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)propoxy)prop-1-yn-1-yl)-1-oxoisoindolin-2-yl ) Preparation of piperidine-2,6-dione (C181) [ka]

[0374] Step 1: At 0 °C, potassium hydroxide (3.75 g, 66.8 mmol) was added in batches to a toluene solution of a mixture of compound C181-1 (3.68 g, 25.0 mmol) and compound C181-2 (1.99 g, 26.2 mmol), stirred vigorously, and then warmed to room temperature and stirred for an additional 1 h. The reaction mixture was diluted with water and extracted with 100 mL of ethyl acetate. The organic phase was dried over anhydrous sodium sulfate, filtered, and the solvent was removed under reduced pressure. The crude product was separated by column chromatography to obtain 1.2 g of a liquid. Yield: 42.9%.

[0375] Step 2: Compound C181-4 (or C1-1) (200 mg, 0.62 mmol), compound C181-3 (566 mg, 4.97 mmol), copper(I) iodide (24 mg, 0.12 mmol), Pd(dppf)Cl2 (174 mg, 0.25 mmol), and triethylamine (188 mg, 1.86 mmol) were dissolved in 5 mL of anhydrous DMF and reacted under nitrogen gas protection at 70 °C for 5 hours with stirring. The solvent was removed under reduced pressure, and the crude product was purified by thin layer chromatography to give compound C181-4 (60 mg, 27.1% yield) as an off-white solid. LCMS: [M+H] + =357.

[0376] Step 3: Compound C181-4 (20 mg, 0.056 mmol) and Dess-Martin reagent (36 mg, 0.084 mmol) were dissolved in 20 mL of dichloromethane and stirred at 50 ° C. for 2 hours. After cooling to room temperature and quenching with saturated aqueous sodium bicarbonate, the organic phase was separated, the aqueous phase was extracted three times with dichloromethane, the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was purified by TLC to give compound C181-5 (18 mg, 90.0% yield) as a white solid. LCMS: [M+H] + =355.

[0377] Step 4: Compound C181-5 (18 mg, 0.051 mmol) and compound A1-4 (32 mg, 0.056 mmol) were dissolved in 3 mL of dichloromethane / methanol (2 / 1, v / v), and one drop of glacial acetic acid was added. The mixture was stirred at room temperature under nitrogen gas protection for 1 hour. Sodium cyanoborohydride (3.2 mg, 0.051 mmol) was then added and stirred for another hour. The solvent was removed under reduced pressure at 40°C or less, and the crude product was purified by flash filtration to give compound C181 (15 mg, 32.6% yield) as an off-white solid. LCMS: [M+H] + =908. 1 H NMR(400MHz,DMSO-d6) δ 11.15(s,1H),11.00(s,1H),8.50(dr, 1H),8.04(d,2H),7.71(dd,1H),7.63(d,1H),7.57-7.44(m,2H),7.36(m,2 H),7.06(d,1H),6.64(s,1H),6.43(d,1H),5.29(t,1H),5.13(dd,1H),4.4 6(d,1H),4.38(s,2H),4.31(d,1H),3.72(s,3H),3.67(d,2H),3.53(t,2H) ,2.98(m,1H),2.67(m,4H),2.59(m,3H),2.25(m,4H),2.02(m,2H),1.96(q, 2H), 1.69 (s, 3H), 1.68 (s, 3H), 1.45 (s, 2H), 1.21 (d, 4H).

[0378] 3-(4-(3-(4-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino ) Preparation of (3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)butoxy)prop-1-yn-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (C182) [ka]

[0379] Step 1: Potassium hydroxide (3.75 g, 66.8 mmol) was added in batches to a toluene solution of a mixture of compound C182-1 (3.68 g, 25.0 mmol) and compound C182-2 (2.36 g, 26.2 mmol) at 0 °C, stirred vigorously, warmed to room temperature, and stirred for an additional 1 h. The reaction mixture was diluted with water and extracted with 100 mL of ethyl acetate. The organic phase was dried over anhydrous sodium sulfate, filtered, and the solvent was removed under reduced pressure. The crude product was separated by column chromatography to obtain 1.4 g of liquid C182-3. Yield: 45.2%.

[0380] Step 2: Compound C182-4 (or C1-1) (200 mg, 0.62 mmol), compound C182-3 (6366 mg, 4.97 mmol), copper(I) iodide (24 mg, 0.12 mmol), Pd(dppf)Cl2 (174 mg, 0.25 mmol), and triethylamine (188 mg, 1.86 mmol) were dissolved in 5 mL of anhydrous DMF and reacted under nitrogen gas protection at 70 °C for 5 hours with stirring. The solvent was removed under reduced pressure, and the crude product was purified by thin layer chromatography to give compound C182-5 (60 mg, 26.1% yield) as an off-white solid. LCMS: [M+H] + =371.

[0381] Step 3: Compound C182-5 (30 mg, 0.081 mmol) and Dess-Martin reagent (52 mg, 0.1224 mmol) were dissolved in 20 mL of dichloromethane and stirred at 50 ° C. for 2 hours. After cooling to room temperature and quenching with saturated aqueous sodium bicarbonate, the organic phase was separated, the aqueous phase was extracted three times with dichloromethane, the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was purified by TLC to give compound C182-6 (28 mg, 93.3% yield) as a white solid. LCMS: [M+H] + =369.

[0382] Step 4: Compound C182-6 (20 mg, 0.051 mmol) and compound A1-4 (32 mg, 0.056 mmol) were dissolved in 3 mL of dichloromethane / methanol (2 / 1), and one drop of glacial acetic acid was added. The mixture was stirred at room temperature for 1 hour under nitrogen gas protection. Sodium cyanoborohydride (3.2 mg, 0.051 mmol) was then added and the mixture was stirred for another hour. The solvent was removed under reduced pressure at 40°C or less, and the crude product was purified by flash filtration to give compound C182 (10 mg, 20.8% yield) as an off-white solid. LCMS: [M+H] + =948. 1 H NMR(400MHz,DMSO-d6) δ 11.18(s,1H),11.05(s,1H),8.50(dr,1H),8.08(d,2H),7.78(dd,1H),7.72(d,1H),7.56-7.44(m, 2H),7.36(m,2H),7.09(d,1H),6.62(s,1H),6.48(d,1H),5.32(t,1H),5.15(dd,1H),4.53(d,1H), 4.37(s,2H),4.32(d,1H),3.75(s,3H),3.69(d,2H),3.54(t,2H),2.97(m,1H),2.66(m,4H),2.56( m,3H),2.49(m,4H),2.02(m,2H),1.96(q,2H),1.69(s,3H),1.68(s,3H),1.45(s,3H),1.23(d,5H).

[0383] Preparation of 3-(4-(9-(4-(1-(4-((5-bromo-4-((5-(dimethylphosphoryl)quinoxalin-6-yl)amino)pyrimidin-2-yl)amino)-5-methoxy-2-methylphenyl)piperidin-4-yl)piperazin-1-yl)non-1-yn-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (C183) [ka]

[0384] C173-3 (30 mg, 0.079 mmol) and C183-1 (or C158-1) (48.2 mg, 0.071 mmol) were dissolved in a mixture of 4.0 mL of anhydrous DCM and 0.4 mL of anhydrous methanol. Under nitrogen gas protection, CH3COOH (4.74 mg, 0.079 mmol, dissolved in 0.5 mL of DCM) was added and stirred at room temperature for 0.5 h. Solid NaBH3CN (7.44 mg, 0.1185 mmol) was then added to the reaction mixture and the mixture was allowed to react at room temperature for an additional 2 h. LCMS and TLC confirmed the reaction was complete. The reaction mixture was diluted with 20 mL of DCM and washed sequentially with saturated NH4Cl (1 x 15 mL) and saturated brine (1 x 15 mL). The organic layer was dried over anhydrous Na2SO4, filtered under vacuum, and the filtrate was concentrated under reduced pressure to give the crude product. Purification by Prep-HPLC gave 25 mg of pure product as a yellow solid. Yield 30.4%. LCMS: [M+H] + =1044,1046. 1 H-NMR:(400MHz,DMSO-d6) δ 12.696(s,1H),11.089(s,1H),8.876(dd,J=2.0Hz,7.6Hz,3H),8.272(d,J=1.6Hz,2H),7.722(d,J=7.6Hz,1H ),7.646(d,J=6.8Hz,1H),7.629(t,J=0.8Hz,1H),7.347(s,1H),6.748(s,1H),5.187(dd,J=5.2Hz,13.2Hz,1H ),4.478(d,J=17.6Hz,1H),4.325(d,J=17.6Hz,1H),3.775(s,3H),3.345-2.831(m,4H),2.522-2.469(m,4H) ,2.468-2.185(m,9H),2.087(s,3H),2.043(s,3H),2.007(s,3H),1.574-1.560(m,2H),1.432-1.230(m,16H).

[0385] Preparation of 3-(4-(3-(2-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)ethoxy)prop-1-yn-1-yl)-6-fluoro-1-oxoisoindolin-2-yl)piperidine-2,6-dione (C184) [ka]

[0386] Step 1: C167-3 (340 mg, 1.0 mmol), CuI (19.0 mg, 0.10 mmol), and Pd(dppf)Cl2 (73.1 mg, 0.10 mmol) were dispersed in 17.0 mL of anhydrous DMF. C184-1 (200.2 mg, 2.0 mmol) and TEA (303 mg, 3.0 mmol) were added sequentially under N2 gas protection. The mixture was heated to 70 °C and reacted for 20 h. LCMS showed the reaction was complete. The reaction mixture was cooled to room temperature, diluted with 100 mL of ethyl acetate, and washed sequentially with saturated ammonium chloride (2 x 50 mL), HO (2 x 50 mL), and saturated brine (2 x 50 mL). The organic layer was dried over anhydrous sodium sulfate, filtered, and concentrated under reduced pressure to give the crude product. Purification by RP-Flash gave the product C184-2 (175 mg, 48.6%) as a white solid. LCMS: [M+H] + =361.

[0387] Step 2: C184-2 (70 mg, 0.195 mmol) was dissolved in 14.0 mL of anhydrous DCM, and Dess-Martin reagent (124 mg, 0.293 mmol) was added under N2 gas protection. The mixture was heated to 50 °C and refluxed for 2.0 h. TLC showed the reaction was complete. After cooling to room temperature, 10 mL of saturated NaHCO3 solution and 10 mL of saturated Na2S2O3 solution were added and the mixture was stirred vigorously at room temperature for 5 min. The organic layer was separated, dried over anhydrous sodium sulfate, and suction filtered. The filtrate was concentrated under reduced pressure to obtain the crude product. This crude product was purified by prep-TLC to obtain the product C184-3 (40 mg, 57.2%) as a pale yellow solid. LCMS: [M+H] + =359.

[0388] Step 3: C184-3 (40 mg, 0.112 mmol) and A1-4 (51 mg, 0.0896 mmol) were dissolved in a mixture of 5.0 mL of anhydrous DCM and 0.5 mL of anhydrous methanol. Under nitrogen gas protection, CH3COOH (10.08 mg, 0.168 mmol) was added and the mixture was stirred at room temperature for 0.5 h. Solid NaBH3CN (14.1 mg, 0.224 mmol) was then added to the reaction mixture, and the mixture was allowed to react at room temperature for an additional 2 h. LCMS and TLC confirmed the reaction was complete. Purification by prep-HPLC afforded the pure product C184 (20 mg, 19.6% yield) as a white solid. LCMS: [M+H] + =912.

[0389] Preparation of 3-(4-(7-(9-(4-((5-bromo-4-((5-(dimethylphosphoryl)quinoxalin-6-yl)amino)pyrimidin-2-yl)amino)-5-methoxy-2-methylphenyl)-3,9-diazaspiro[5.5]undecan-3-yl)hept-1-yn-1-yl)-6-fluoro-1-oxoisoindolin-2-yl)piperidine-2,6-dione (C185) [ka]

[0390] Step 1: C167-5 (18.0 mg, 0.0486 mmol) and C47-1 (32.3 mg, 0.0486 mmol) were dissolved in 4.0 mL of anhydrous DCM. Under nitrogen gas protection, CH3COOH (2.9 mg, 0.0486 mmol, dissolved in 0.5 mL of DCM) was added and the mixture was stirred at room temperature for 0.5 h. Solid NaBH3CN (6.1 mg, 0.0972 mmol) was then added to the reaction mixture and the mixture was allowed to react at room temperature for an additional 2 h. LCMS and TLC confirmed the reaction was complete. The reaction mixture was diluted with 20 mL of DCM and washed sequentially with saturated NH4Cl (1 x 15 mL) and saturated brine (1 x 15 mL). The organic layer was dried over anhydrous Na2SO4, filtered under suction, and the filtrate was concentrated under reduced pressure to give the crude product. Purification by prep-HPLC afforded 13 mg of the pure product as a yellow solid. Yield: 26.3%. LCMS: [M+H] + =1019,1021. 1 H-NMR:(400MHz,DMSO-d6)δ 11.688(s,1H),11.051(s,1H),8.877(dd,J=2.0Hz,11.2Hz,3H),8.307(s,1H),8.272(d,J=2.0H z,1H),7.936(d,J=7.6Hz,1H),7.586-7.541(m,2H),7.328(s,1H),6.820(s,1H),5.191(dd,J=5 .2Hz,13.2Hz,1H),4.474(dd,J=18.8Hz,60.0Hz,2H),3.787(s,3H),3.505(s,1H),3.347(s,3H) ,2.942-2.619(m,6H),2.570(s,4H),2.081-2.004(m,9H),1.639-1.432(m,11H),1.232(s,5H).

[0391] Preparation of 3-(4-(6-(4-(1-(4-((5-bromo-4-((5-(dimethylphosphoryl)quinoxalin-6-yl)amino)pyrimidin-2-yl)amino)-5-methoxy-2-methylphenyl)piperidin-4-yl)piperazin-1-yl)hex-1-yn-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (C186) [ka]

[0392] C116-3 (25 mg, 0.0740 mmol) and C183-1 (or C158-1) (50.2 mg, 0.0740 mmol) were dissolved in a mixture of 4.0 mL of anhydrous DCM and 0.4 mL of anhydrous methanol. Under nitrogen gas protection, CH3COOH (4.44 mg, 0.0740 mmol, dissolved in 0.5 mL of DCM) was added and stirred at room temperature for 0.5 h. Solid NaBH3CN (6.97 mg, 0.1110 mmol) was then added to the reaction mixture and the mixture was allowed to react at room temperature for an additional 2 h. LCMS and TLC confirmed the completion of the reaction. Purification by prep-HPLC afforded 23 mg of the product C186 as a yellow solid. Yield: 31.0%. LCMS: [M+H] + =1002,1004. 1 H-NMR:(400MHz,DMSO-d6) δ 11.027(s,1H),8.874-8.850(m,4H),8.271-8.255(m,2H),7.937(d,J=9.6Hz,1H),7.728(d,J=1.2Hz,1H) ,7.709(d,J=1.2Hz,1H),7.655-7.634(m,1H),7.357(s,1H),6.752(s,1H),5.181(dd,J=4.0Hz,13.6Hz,1H ),4.484(d,J=17.6Hz,1H),4.335(d,J=17.6Hz,1H),3.776(s,3H),3.328-3.107(m,2H),2.967-2.892(m,1 H),2.682-2.334(m,13H),2.091-2.007(m,12H),1.884-1.855(m,2H),1.600-1.567(m,6H),1.236(s,2H).

[0393] Preparation of 3-(4-(6-(9-(4-((5-bromo-4-((5-(dimethylphosphoryl)quinoxalin-6-yl)amino)pyrimidin-2-yl)amino)-5-methoxy-2-methylphenyl)-3,9-diazaspiro[5.5]undecan-3-yl)hex-1-yn-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (C187) [ka]

[0394] C116-3 (25 mg, 0.0740 mmol) and C47-1 (49.1 mg, 0.0740 mmol) were dissolved in a mixture of 4.0 mL of anhydrous DCM and 0.4 mL of anhydrous methanol. Under nitrogen gas protection, CH3COOH (4.44 mg, 0.0740 mmol, dissolved in 0.5 mL of DCM) was added and stirred at room temperature for 0.5 h. Solid NaBH3CN (6.97 mg, 0.1110 mmol) was then added to the reaction mixture and the mixture was allowed to react at room temperature for an additional 2 h. LCMS and TLC confirmed the reaction was complete. Purification by prep-HPLC afforded 30 mg of pure product C187 as a yellow solid. Yield: 41.1%. LCMS: [M+H] + =987,989. 1H-NMR:(400MHz,DMSO-d6) δ 11.026(s,1H),8.864(dd,J=2.0Hz,9.6Hz,4H),8.265(s,2H),7.940(d,J=11.2Hz,1H),7.723(dd,J=1.2Hz,7. 6Hz,1H),7.653(dd,J=1.2Hz,7.6Hz,1H),7.544(t,J=7.6Hz,1H),7.327(s,1H),6.815(s,1H),5.181-5.135(m, 1H),4.483(d,J=16.8Hz,1H),4.334(d,J=17.2Hz,1H),3.783(s,3H),2.933-2.821(m,1H),2.807-2.797(m,4H) ),2.621-2.577(m,3H),2.503-2.335(m,6H),2.081(s,3H),2.040(s,4H),2.004(s,4H),1.600-1.528(m,12H).

[0395] Preparation of 3-(4-(10-(4-(1-(4-((5-bromo-4-((5-(dimethylphosphoryl)quinoxalin-6-yl)amino)pyrimidin-2-yl)amino)-5-methoxy-2-methylphenyl)piperidin-4-yl)piperazin-1-yl)dec-1-yn-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (C188) [ka]

[0396] C179-3 (30 mg, 0.076 mmol) and C183-1 (or C158-1) (43.9 mg, 0.0647 mmol) were dissolved in 8.0 mL of anhydrous DCM. Under nitrogen gas protection, CH3COOH (4.56 mg, 0.076 mmol, dissolved in 0.5 mL of DCM) was added and stirred at room temperature for 0.5 h. Solid NaBH3CN (7.16 mg, 0.114 mmol) was then added to the reaction mixture and the mixture was allowed to react at room temperature for an additional 2 h. LCMS and TLC confirmed the reaction was complete. The reaction mixture was diluted with 20 mL of DCM and washed sequentially with saturated ammonium chloride (1 x 10 mL) and saturated brine (1 x 10 mL). The organic layer was dried over anhydrous sodium sulfate, filtered under suction, and the filtrate was concentrated under reduced pressure to give the crude product. Purification by prep-HPLC afforded 4,4-dimethyl-2,4-dichloro-1,4-dichloro-2 ... Pure product C188 (19.5 mg, 24.4% yield) as a yellow solid. LCMS: [M+H] + =1058,1060.

[0397] Preparation of 3-(4-(10-(9-(4-((5-bromo-4-((5-(dimethylphosphoryl)quinoxalin-6-yl)amino)pyrimidin-2-yl)amino)-5-methoxy-2-methylphenyl)-3,9-diazaspiro[5.5]undecan-3-yl)dec-1-yn-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (C189) [ka]

[0398] C179-3 (30 mg, 0.076 mmol) and C47-1 (40.4 mg, 0.0608 mmol) were dissolved in 5.0 mL of anhydrous DCM. Under nitrogen gas protection, CH3COOH (4.56 mg, 0.076 mmol, dissolved in 0.5 mL of DCM) was added and stirred at room temperature for 0.5 h. Solid NaBH3CN (7.16 mg, 0.114 mmol) was then added to the reaction mixture, and the mixture was allowed to react at room temperature for an additional 2 h. LCMS and TLC confirmed the reaction was complete. Purification by prep-HPLC afforded the pure product C189 (25 mg, 31.5% yield) as a yellow solid. LCMS: [M+H] + =1043,1045.

[0399] Preparation of 3-(5-(7-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)hept-1-yn-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (C190) [ka]

[0400] Compound C163-6 (35 mg, 0.099 mmol) and compound A1-4 (62 mg, 0.109 mmol) were dissolved in 3 mL of dichloromethane / methanol (2 / 1), and one drop of glacial acetic acid was added. The mixture was stirred at room temperature for 1 hour under nitrogen gas protection. Sodium cyanoborohydride (6.2 mg, 0.099 mmol) was then added and stirred for another hour. The solvent was removed under reduced pressure at 40°C or less, and the crude product was purified by flash filtration to give compound C190 (15 mg, 16.7% yield) as an off-white solid. LCMS: [M+H] + =906.

[0401] Preparation of 3-(5-(7-(9-(4-((5-bromo-4-((5-(dimethylphosphoryl)quinoxalin-6-yl)amino)pyrimidin-2-yl)amino)-5-methoxy-2-methylphenyl)-3,9-diazaspiro[5.5]undecan-3-yl)hept-1-yn-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (C191) [ka]

[0402] Compound C163-6 (35 mg, 0.099 mmol) and compound C47-1 (73 mg, 0.109 mmol) were dissolved in 3 mL of dichloromethane / methanol (2 / 1), and one drop of glacial acetic acid was added dropwise. The mixture was stirred at room temperature for 1 hour under nitrogen gas protection. Sodium cyanoborohydride (6.2 mg, 0.099 mmol) was then added and stirred for another hour. The solvent was removed under reduced pressure at 40°C or less, and the crude product was purified by flash filtration to give compound C191 (20 mg, 20.2% yield) as a yellow solid. LCMS: [M+H] + =1001,1003.

[0403] Preparation of 3-(5-(6-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)hex-1-yn-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (C192) [ka]

[0404] Step 1: Compound C192-1 (100 mg, 0.31 mmol), compound C192-2 (76 mg, 0.78 mmol), copper(I) iodide (12 mg, 0.06 mmol), Pd(dppf)Cl (87 mg, 0.12 mmol), and triethylamine (94 mg, 0.93 mmol) were dissolved in 4 mL of anhydrous DMF and reacted under nitrogen gas protection at 70 °C for 5 hours with stirring. The solvent was removed under reduced pressure, and the crude product was purified by thin layer chromatography to give compound C192-3 (78 mg, 72.2% yield) as an off-white solid. LCMS: [M+H] + =341.

[0405] Step 2: Compound C192-3 (39 mg, 0.115 mmol) and Dess-Martin reagent (73 mg, 0.172 mmol) were dissolved in 15 mL of dichloromethane and stirred at 50 ° C. for 2 hours. After cooling to room temperature and quenching with saturated aqueous sodium bicarbonate, the organic phase was separated, the aqueous phase was extracted three times with dichloromethane, the organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was purified by TLC to give compound C192-4 (30 mg, 77.5% yield) as a white solid. LCMS: [M+H] + =339.

[0406] Step 3: Compound C192-4 (26.6 mg, 0.079 mmol) and compound A1-4 (49 mg, 0.087 mmol) were dissolved in 3 mL of dichloromethane / methanol (2 / 1), and one drop of glacial acetic acid was added. The mixture was stirred at room temperature for 1 hour under nitrogen gas protection. Sodium cyanoborohydride (5 mg, 0.079 mmol) was then added and stirred for another hour. The solvent was removed under reduced pressure at 40°C or less, and the crude product was purified by flash filtration to give compound C192 (10 mg, 14.3% yield) as an off-white solid. LCMS: [M+H] + =892.

[0407] 3-(5-(3-(2-(4-(1-(4-((5-chloro-4-((2 -(Preparation of dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)ethoxy)prop-1-yn-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (C193) [ka]

[0408] Step 1: Compound C193-1 (or C192-1) (100 mg, 0.31 mmol), compound C193-2 (78 mg, 0.78 mmol), copper(I) iodide (12 mg, 0.06 mmol), Pd(dppf)Cl2 (87 mg, 0.12 mmol), and triethylamine (94 mg, 0.93 mmol) were dissolved in 4 mL of anhydrous DMF and reacted under nitrogen gas protection at 70 °C with stirring for 5 hours. The solvent was removed under reduced pressure, and the crude product was purified by thin layer chromatography to obtain an off-white solid compound C193-3 (70 mg, 66.0% yield). LCMS: [M+H] + =343.

[0409] Step 2: Compound C193-3 (23.2 mg, 0.068 mmol) and Dess-Martin reagent (43.1 mg, 0.102 mmol) were dissolved in 15 mL of dichloromethane and stirred at 50 °C for 2 hours. After cooling to room temperature and quenching with saturated aqueous sodium bicarbonate, the organic phase was separated, and the aqueous phase was extracted three times with dichloromethane. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was purified by TLC to give compound C193-4 (20 mg, 87.0% yield) as a white solid. LCMS: [M+H] + =341.

[0410] Step 3: Compound C193-4 (20 mg, 0.059 mmol) and compound A1-4 (37 mg, 0.065 mmol) were dissolved in 3 mL of dichloromethane / methanol (2 / 1), and one drop of glacial acetic acid was added dropwise. The mixture was stirred at room temperature for 1 hour under nitrogen gas protection. Sodium cyanoborohydride (3.7 mg, 0.059 mmol) was then added and stirred for another hour. The solvent was removed under reduced pressure at 40°C or less, and the crude product was purified by flash filtration to give compound C193 (15 mg, 28.8% yield) as an off-white solid. LCMS: [M+H] + =894.

[0411] Preparation of 3-(5-(8-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)oct-1-yn-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (C194) [ka]

[0412] Step 1: Compound C194-1 (or C192-1) (100 mg, 0.31 mmol), compound C194-2 (98 mg, 0.78 mmol), copper(I) iodide (12 mg, 0.06 mmol), Pd(dppf)Cl2 (87 mg, 0.12 mmol), and triethylamine (94 mg, 0.93 mmol) were dissolved in 4 mL of anhydrous DMF and reacted under nitrogen gas protection at 70 °C for 5 hours with stirring. The solvent was removed under reduced pressure, and the crude product was purified by thin layer chromatography to give compound C194-3 (68 mg, 59.6% yield) as an off-white solid. LCMS: [M+H] + =369.

[0413] Step 2: Compound C194-3 (27 mg, 0.073 mmol) and Dess-Martin reagent (46.7 mg, 0.110 mmol) were dissolved in 16 mL of dichloromethane and stirred at 50 °C for 2 hours. After cooling to room temperature and quenching with saturated aqueous sodium bicarbonate, the organic phase was separated, and the aqueous phase was extracted three times with dichloromethane. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was purified by TLC to give compound C194-4 (20.6 mg, 76.6% yield) as a white solid. LCMS: [M+H] + =367.

[0414] Step 3: Compound C194-4 (20.6 mg, 0.056 mmol) and compound A1-4 (35 mg, 0.062 mmol) were dissolved in 3 mL of dichloromethane / methanol (2 / 1), and one drop of glacial acetic acid was added. The mixture was stirred at room temperature for 1 hour under nitrogen gas protection. Sodium cyanoborohydride (3.5 mg, 0.056 mmol) was then added and stirred for another hour. The solvent was removed under reduced pressure at 40°C or less, and the crude product was purified by flash filtration to give compound C194 (15 mg, 29.0% yield) as an off-white solid. LCMS: [M+H] + =920.

[0415] Preparation of 3-(5-(9-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)non-1-yn-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (C195) [ka]

[0416] Step 1: Compound C195-1 (or C192-1) (100 mg, 0.31 mmol), compound C195-2 (109 mg, 0.78 mmol), copper(I) iodide (12 mg, 0.06 mmol), Pd(dppf)Cl2 (87 mg, 0.12 mmol), and triethylamine (94 mg, 0.93 mmol) were dissolved in 4 mL of anhydrous DMF and reacted under nitrogen gas protection at 70 °C for 5 hours with stirring. The solvent was removed under reduced pressure, and the crude product was purified by thin layer chromatography to give compound C195-3 (72 mg, 61.0% yield) as an off-white solid. LCMS: [M+H] + =383.

[0417] Step 2: Compound C195-3 (23 mg, 0.060 mmol) and Dess-Martin reagent (38.3 mg, 0.090 mmol) were dissolved in 16 mL of dichloromethane and stirred at 50 ° C. for 2 hours. After cooling to room temperature and quenching with saturated aqueous sodium bicarbonate, the organic phase was separated, and the aqueous phase was extracted three times with dichloromethane. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was purified by TLC to give compound C195-4 (20 mg, 87.0% yield) as a white solid. LCMS: [M+H] + =381.

[0418] Step 3: Compound C195-4 (20 mg, 0.053 mmol) and A1-4 (33 mg, 0.058 mmol) were dissolved in 3 mL of dichloromethane / methanol (2 / 1), and one drop of glacial acetic acid was added. The mixture was stirred at room temperature for 1 hour under nitrogen gas protection. Sodium cyanoborohydride (3.5 mg, 0.053 mmol) was then added and the mixture was stirred for another hour. The solvent was removed under reduced pressure at below 40 °C, and the crude product was purified by flash filtration to give compound C195 (15 mg, 30.6% yield) as an off-white solid. LCMS: [M+H] + =934.

[0419] Preparation of 3-(5-(10-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)dec-1-yn-1-yl)-1-oxoisoindolin-2-yl)piperidine-2,6-dione (C196) [ka]

[0420] Step 1: Compound C196-1 (or C192-1) (100 mg, 0.31 mmol), compound C196-2 (120 mg, 0.78 mmol), copper(I) iodide (12 mg, 0.06 mmol), Pd(dppf)Cl2 (87 mg, 0.12 mmol), and triethylamine (94 mg, 0.93 mmol) were dissolved in 4 mL of anhydrous DMF and reacted under nitrogen gas protection at 70 °C with stirring for 5 hours. The solvent was removed under reduced pressure, and the crude product was purified by thin layer chromatography to give compound C196-3 (65 mg, 52.8% yield) as an off-white solid. LCMS: [M+H] + =397.

[0421] Step 2: Compound C195-3 (23.9 mg, 0.060 mmol) and Dess-Martin reagent (38.4 mg, 0.090 mmol) were dissolved in 15 mL of dichloromethane and stirred at 50 °C for 2 hours. After cooling to room temperature and quenching with saturated aqueous sodium bicarbonate, the organic phase was separated, and the aqueous phase was extracted three times with dichloromethane. The organic phases were combined, dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was purified by TLC to give compound C196-4 (20 mg, 84.0% yield) as a white solid. LCMS: [M+H] + =395.

[0422] Step 3: Compound C196-4 (20 mg, 0.051 mmol) and compound A1-4 (32 mg, 0.056 mmol) were dissolved in 3 mL of dichloromethane / methanol (2 / 1), and one drop of glacial acetic acid was added. The mixture was stirred at room temperature for 1 hour under nitrogen gas protection. Sodium cyanoborohydride (3.2 mg, 0.051 mmol) was then added and stirred for another hour. The solvent was removed under reduced pressure at 40°C or less, and the crude product was purified by flash filtration to give compound C196 (10 mg, 20.8% yield) as an off-white solid. LCMS: [M+H] + =948.

[0423] Preparation of 3-(4-(3-(2-(4-(1-(4-((5-chloro-4-((2-(dimethylphosphoryl)phenyl)amino)pyrimidin-2-yl)amino)-3-methoxyphenyl)piperidin-4-yl)piperazin-1-yl)ethoxy)prop-1-yn-1-yl)-1-oxo-6-(trifluoromethyl)isoindolin-2-yl)piperidine-2,6-dione (C200) [ka]

[0424] Step 1: Compound C200-1 (2 g, 9.8 mmol) and NBS (1.63 g, 9.16 mmol) were added in batches to concentrated sulfuric acid (20 mL) while stirring at 0 °C. The mixture was stirred for 3 hours while maintaining the temperature under nitrogen gas protection. The temperature was raised to room temperature and the mixture was stirred overnight. The reaction mixture was slowly poured into ice water, and the mixture was extracted three times with ethyl acetate. The organic phases were combined, washed once with 0.5 M hydrochloric acid and once with saturated brine, dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was purified by flash filtration to give compound C200-2 (1.3 g, 47.1% yield). LCMS: [M+H] + =283,285.

[0425] Step 2: To a solution of compound C200-2 (1.3 g, 4.61 mmol) in 20 mL of methanol was added thionyl chloride (2 mL, 25.57 mmol) dropwise at 0° C., followed by heating and stirring at 70° C. overnight. After cooling to room temperature and concentrating under reduced pressure, the crude product was purified by flash filtration to give compound C200-3 (1.25 g, yield 91.9%).

[0426] Step 3: Compound C200-3 (1.25 g, 4.22 mmol), NBS (857 mg, 4.81 mmol), and AIBN (69 mg, 0.42 mmol) were dissolved in 20 mL of chloroform and refluxed overnight at 95 °C under nitrogen gas protection. The solvent was removed under reduced pressure, and the crude product was purified by flash filtration to give compound C200-4 (1.3 g, 82.3% yield) as a white solid.

[0427] Step 4: Compound C200-4 (1.33 g, 3.56 mmol), 3-aminopiperidine-2,6-dione hydrochloride (759 mg, 4.62 mmol), and triethylamine (467 mg, 4.62 mmol) were dissolved in 15 mL of acetonitrile and stirred overnight at 80 °C under nitrogen gas protection. After cooling to room temperature, the solvent was removed under reduced pressure, and the crude product was purified by flash filtration to give compound C200-5 (790 mg, 56.9% yield) as a white solid. LCMS: [M+H] = 391,393.

[0428] Step 5: Compound C200-5 (100 mg, 0.256 mmol), compound C169-2 (64 mg, 0.641 mmol), copper(I) iodide (4.9 mg, 0.026 mmol), Pd(dppf)Cl (18.8 mg, 0.026 mmol), and triethylamine (77.7 mg, 0.769 mmol) were dissolved in 3 mL of anhydrous DMF and stirred overnight at 70 °C under nitrogen gas protection. The solvent was removed under reduced pressure, and the crude product was purified by thin layer chromatography to give compound C200-6 (100 mg, 95.2% yield). LCMS: [M+H] + =411.

[0429] Step 6: Compound C200-6 (126 mg, 0.307 mmol) and Dess-Martin reagent (261 mg, 0.615 mmol) were dissolved in 10 mL of dichloromethane and stirred at 50 °C for 2 hours. After cooling to room temperature, saturated aqueous sodium bicarbonate and saturated aqueous sodium thiosulfate were added sequentially, each time stirring for 5 minutes, to quench the reaction. The organic phase was separated, and the aqueous phase was extracted three times with dichloromethane. The combined organic phases were dried over anhydrous sodium sulfate, filtered, and concentrated. The crude product was purified by TLC to give compound C200-7 (44 mg, 35.2% yield) as a white solid. LCMS: [M+H] + =409.

[0430] Step 7: Compound C200-7 (22 mg, 0.054 mmol) and compound A1-4 (21.5 mg, 0.038 mmol) were dissolved in 1.5 mL of dichloromethane / methanol (2 / 1, v / v), and glacial acetic acid (3.2 mg, 0.054 mmol) was added dropwise. The mixture was stirred at room temperature for 1 hour under nitrogen gas protection. Sodium cyanoborohydride (2.4 mg, 0.038 mmol) was then added and the mixture was stirred for another hour. The solvent was removed under reduced pressure at 40°C o...

Claims

1. A compound represented by general formula (X), its pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, solvate, hydrate, or isotopic variant, and mixtures thereof, 【Chemistry 1】 however, Ring A is an optionally substituted group as follows: 3-7 Cycloalkyl, 4-8 membered heterocyclyl, C 6-10 aryl, or 5-10 membered heteroaryl, wherein said substituents are halogen, —CN, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 3-7 Cycloalkyl, 4-8 membered heterocyclyl, -P(O)(C 1-6 Alkyl) 2 , -P(O)(C 2-6 alkenyl) 2 , -O-C 1-6 Alkyl, —O—C 1-6 Haloalkyl, —O—C 2-6 Alkenyl, —O—C 3-7 Cycloalkyl, -O-4 to 8 membered heterocyclyl, -NH-C 1-6 Alkyl, -NH-C 2-6 Alkenyl, -NH-C 3-7 Cycloalkyl, -NH-4 to 8 membered heterocyclyl, -C(O)-C 1-6 Alkyl, —C(O)—C 2-6 Alkenyl, —C(O)—C 3-7 Cycloalkyl, -C(O)-4 to 8 membered heterocyclyl, -S(O) 2 -C 1-6 Alkyl, -S(O) 2 -C 2-6 Alkenyl, -S(O) 2 -C 3-7 Cycloalkyl, -S(O) 2 -4 to 8 membered heterocyclyl, -NHC(O)-C 1-6 Alkyl, -NHC(O)-C 2-6 Alkenyl, -NHC(O)-C 3-7 Cycloalkyl, -NHC(O)-4 to 8 membered heterocyclyl, -NHS(O) 2 -C 1-6 Alkyl, -NHS(O) 2 -C 2-6 Alkenyl, -NHS(O) 2 -C 3-7 Cycloalkyl, or -NHS(O) 2 - selected from the group consisting of 4- to 8-membered heterocyclyl; Ring B is 【Chemistry 2】 and 【Chemistry 3】 represents a single or double bond; 【Chemistry 4】 indicates that the site of attachment to the remainder of the molecule may be located at any available site on the ring; Z 1 is one or two R Z1 an O, S, N or C atom optionally substituted with 1 does not exist, so Z 4 But, Z 1 A C atom of an aromatic ring to which 2 Or Z 3 and connected to Z 1 Z bonded to 2 and the C atoms of the aromatic ring are R W or Z 1 , Z 2 and Z 3 Since none of these exist, Z 4 But, Z 1 Or Z 3 is connected to one of the C atoms of the aromatic ring to which is bonded, and another C atom of the aromatic ring is connected to R W connected to; Z 2 is one or two R Z2 is an O, S, N or C atom optionally substituted with Z 3 is one or two R Z3 an O, S, N or C atom optionally substituted with 【Chemistry 5】 When represents a double bond, Z 2 is a N or C atom, Z 3 is a N or C atom; Z 4 is N or CR Z4 and Z 5 is N or CR Z5 and R a , R b and R c are independently H, halogen, -(CH 2 ) 0-5 -OR'', -(CH 2 ) 0-5 -NR''R'''',C 1-6 Alkyl, or C 1-6 haloalkyl; or R a , R b and together with the C atom to which they are attached, C=O, C 3-7 forms a cycloalkyl or a 4- to 8-membered heterocyclyl; or R a , R c and together with the C atoms to which they are attached, C 3-7 forms a cycloalkyl or a 4- to 8-membered heterocyclyl; or R a and R c forms a chemical bond; R N1 is H, C 1-6 Alkyl, or C 1-6 haloalkyl; R Z1 is absent or is H, CN, halogen, -(CH 2 ) 0-5 -OR'', -(CH 2 ) 0-5 -NR''R'''',C 1-6 Alkyl, C 1-6 Haloalkyl, -(CH 2 ) 0-5 -C 3-7 Cycloalkyl, or -(CH 2 ) 0-5 -4- to 8-membered heterocyclyl; or two R Z1 Z 1 Together with C=O, C 3-7 forming a cycloalkyl or a 4-8 membered heterocyclyl; R Z2 is absent or is H, CN, halogen, -(CH 2 ) 0-5 -OR'', -(CH 2 ) 0-5 -NR''R'''',C 1-6 Alkyl, C 1-6 Haloalkyl, -(CH 2 ) 0-5 -C 3-7 Cycloalkyl, or -(CH 2 ) 0-5 -4- to 8-membered heterocyclyl; or two R Z2 Z 2 Together with C=O, C 3-7 forming a cycloalkyl or a 4-8 membered heterocyclyl; R Z3 is absent or is H, CN, halogen, -(CH 2 ) 0-5 -OR'', -(CH 2 ) 0-5 -NR''R'''',C 1-6 Alkyl, C 1-6 Haloalkyl, -(CH 2 ) 0-5 -C 3-7 Cycloalkyl, or -(CH 2 ) 0-5 -4- to 8-membered heterocyclyl; or two R Z3 Z 3 Together with C=O, C 3-7 forming a cycloalkyl or a 4-8 membered heterocyclyl; R Z4 is H, CN, halogen, -(CH 2 ) 0-5 -OR'', -(CH 2 ) 0-5 -NR''R'''',C 1-6 Alkyl, or C 1-6 haloalkyl; R Z5 is H, CN, halogen, -(CH 2 ) 0-5 -OR'', -(CH 2 ) 0-5 -NR''R'''',C 1-6 Alkyl, C 1-6 Haloalkyl, -(CH 2 ) 0-5 -C 3-7 Cycloalkyl, or -(CH 2 ) 0-5 - 4 to 8 membered heterocyclyl; Or Z. 4 is not present; Here, R w is H, CN, halogen, -(CH 2 ) 0-5 -OR'', -(CH 2 ) 0-5 -NR''R'''', -C 1-6 Alkyl, C 1-6 Haloalkyl, -(CH 2 ) 0-5 -C 3-7 Cycloalkyl, -(CH 2 ) 0-5 -4 to 8 membered heterocyclyl, C 2-6 Alkenyl, C 2-6 Alkynyl, -(CH 2 ) 0-5 -C 3-10 Halocycloalkyl, -(CH 2 ) 0-5 -C 6-10 Aryl, or -(CH 2 ) 0-5 - 5 to 14 membered heteroaryl; R'' is H, C 1-6 Alkyl, C 1-6 Haloalkyl, or -(CH 2 ) 0-5 -C 3-7 is cycloalkyl; R''' is H, C 1-6 Alkyl, or C 1-6 haloalkyl; L 1 is -C≡C-; L 2 is a chemical bond, -O-, -S(O) p -, -S(O)(=NR * ) -, -NR # -, -CR # R # '-,-C a R # R # '-C b R # R # '-,-N=S(O)(R * )-, or -S(O)(R * )=N-; Here, C a R # R # ' or C b R # R # ' is O, S(O) p , S(O)(=NR * ) or N.R. # and C a R # R # ' or C b R # R # ' is O, S or NR # When replaced with a R # R # ' or C b R # R # ' and the other one is S(O) q can be replaced by; E is independently a chemical bond, -C c R # R # '-C d R # R # '-C e R # R # ', 【Chemistry 6】 selected from the group consisting of: Here, C c R # R # ', C d R # R # ' or C e R # R # ' or C c R # R # ' and C e R # R # ' both O,S(O) p , S(O)(=NR * ) or N.R. # and C c R # R # ', C d R # R # ' or C e R # R # ' is O, S or NR # If replaced by one or two adjacent C c R # R # ', C d R # R # ' or C e R # R # ', but S(O) q can be replaced by; Alternatively, two E units are -CH 2 CH 2 OCH 2 CH 2 --, --OCH 2 CH 2 CH 2 CH 2 --, --CH 2 CH 2 CH 2 CH 2 O-, 【Chemistry 7】 can be formed; Where: 【Chemistry 8】 L 1 Or L 2 represents the connection site to; H 1 and H 2 is a N or C atom, H 3 is an O, S, N or C atom, and H 1 and H 3 , H 2 and H 3 is not a heteroatom at the same time; H 4 and H 5 is a N or C atom; H 6 , H 7 , H 8 and H 9 is a C or N atom; p is 0, 1 or 2; q is 1 or 2; R * is H, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Cycloalkyl, C 3-10 Halocycloalkyl, 3-10 membered heterocyclyl, C 6-10 aryl, or 5-14 membered heteroaryl; R # is H, halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Cycloalkyl, C 3-10 Halocycloalkyl, 3-10 membered heterocyclyl, C 6-10 aryl, or 5-14 membered heteroaryl; R # ' is H, halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Cycloalkyl, C 3-10 Halocycloalkyl, 3-10 membered heterocyclyl, C 6-10 aryl, or 5-14 membered heteroaryl; Alternatively, R on an adjacent atom # and R # can form a chemical bond, R on adjacent atoms # ' and R # ' is capable of forming a chemical bond; Alternatively, R on the same or different atoms # and R # ' is both, =O, C 3-7 Cycloalkyl, 4-8 membered heterocyclyl, C 6-10 aryl or 5-6 membered heteroaryl, where C 3-7 Cycloalkyl, 4-8 membered heterocyclyl, C 6-10 Aryl or 5- to 6-membered heteroaryl is R x may be substituted with, and the R x H, CN, halogen, C 1-6 Alkyl, or C 1-6 haloalkyl; m is 0, 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10; R s1 is H, CN, halogen, -(CH 2 ) 0-5 -OR'', -(CH 2 ) 0-5 -NR''R'''',C 1-6 Alkyl, C 1-6 Haloalkyl, -(CH 2 ) 0-5 -4 to 8 membered heterocyclyl, C 2-6 Alkenyl, C 2-6 Alkynyl, -(CH 2 ) 0-5 -C 3-7 Cycloalkyl, -(CH 2 ) 0-5 -C 3-10 Halocycloalkyl, -(CH 2 ) 0-5 -C 6-10 Aryl, -(CH 2 ) 0-5 -5 to 14 membered heteroaryl, -C(O)R W , -S(O)R W Or -S(O) 2 R W selected from the group consisting of: s1 is 0, 1, 2 or 3; R' is H, -C(O)-C 1-6 Alkyl, —C(O)—C 1-6 Haloalkyl, —C(O)—C 2-6 alkenyl, or -C(O)-C 6-10 aryl; L is a chemical bond, -O- or -NR-; where R is H or C 1-6 is alkyl; Z is -N= or -C(R 4 ) =; T is a chemical bond, C 2-6 selected from the group consisting of heteroalkylene, 4- to 12-membered heterocyclylene, or 5- to 6-membered heterocyclylene substituted with 5- to 6-membered heterocyclylene; R 1 is H, halogen, cyano, C 1-6 Alkyl, C 3-7 Cycloalkyl, 4-8 membered heterocyclyl, C 1-6 Haloalkyl, C 2-6 Alkenyl or C 2-6 alkynyl; Alternatively, when L is -NR-, R 1 and R together with the atom to which they are attached form an optionally substituted 5- to 6-membered heterocyclyl, where the substituents are halogen, oxo, C 1-6 Alkyl, C 1-6 Haloalkyl, C mono- or poly-substituted with halogen 6-10 aryl; R 2 is H, halogen, hydroxyl, amino, C 1-6 Alkyl, or C 1-6 haloalkyl; Or, R 1 , R 2 together with the atom to which they are attached form a 5- to 6-membered heterocyclyl or a 5- to 6-membered heteroaryl; R 3 is H, -O-C 1-6 Alkyl or -O-C 1-6 haloalkyl; R 4 is H, halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, -NHC(O)-C 1-6 Alkyl, or -NHC(O)-C 2-6 alkenyl; When each of said groups is H or a H-containing group, one or more of said H atoms may be replaced with a D atom; the alkyl, alkylene, haloalkyl, alkenyl, alkynyl, cycloalkyl, halocycloalkyl, heterocyclyl, aryl, heteroaryl, or L 1 , E., L. 2 and OH, NH, NH in T 2 , C.H., C.H. 2 , C.H. 3 Each group containing one, two, three or more R s and isotopic variants thereof, s are independently halogen, hydroxyl, amino, cyano, nitro, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-10 Cycloalkyl, C 3-10 Halocycloalkyl, 3-10 membered heterocyclyl, C 6-10 Aryl, 5-14 membered heteroaryl, C 6-12 Aralkyl, -OR a’ , -OC(O)R a’ , -C(O)R a’ , -C(O)OR a’ , -C(O)NR a’ R b’ , -S(O) n R a’ , -S(O) n OR a’ , -S(O) n N.R. a’ R b’ , -NR a’ R b’ , -NR a’ C(O)R b’ , -NR a’ -C(O)OR b’ , -NR a’ -S (O) n -R b’ , -NR a’ C(O)NR a’ R b’ , -C 1-6 Alkylene-R a’ , -C 1-6 Alkylene-OR a’ , -C 1-6 Alkylene -OC(O)R a’ , -C 1-6 Alkylene -C(O)OR a’ , -C 1-6 Alkylene-S(O) n R a’ , -C 1-6 Alkylene-S(O) n OR a’ , -C 1-6 Alkylene -OC(O)NR a’ R b’ , -C 1-6 Alkylene-C(O)NR a’ R b’ , -C 1-6 Alkylene -NR a’ -C(O)NR a’ R b’ , -C 1-6 Alkylene-OS(O) n R a’ , -C 1-6 Alkylene-S(O) n N.R. a’ R b’ , -C 1-6 Alkylene -NR a’ -S (O) n N.R. a’ R b’ , -C 1-6 Alkylene -NR a’ R b’ and -O-C 1-6 Alkylene -NR a’ R b’ wherein the substituent R s The hydroxyl, amino, alkyl, alkylene, cycloalkyl, heterocyclyl, aryl, heteroaryl and aralkyl described above are independently halogen, OH, amino, cyano, nitro, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkyl hydroxyl, C 3-6 Cycloalkyl, 3- to 10-membered heterocyclyl, C 6-10 Aryl, 5- to 14-membered heteroaryl and C 6-12 aryl, arylalkyl, arylsulfonyl ... n is independently 1 or 2; R a’ and R b’ are each independently H, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkyl-O-, C 1-6 Alkyl-S-, C 3-10 Cycloalkyl, 3- to 10-membered heterocyclyl, C 6-10 Aryl, 5- to 14-membered heteroaryl and C 6-12 aralkyl; However, the following compounds 【Chemistry 9】 【Chemistry 10】 【Chemistry 11】 Does not include A compound represented by the general formula (X), its pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, solvate, hydrate, or isotopic variant, and mixtures thereof.

2. Ring A is 【Chemistry 12】 and Where: R 7 But, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 3-7 Cycloalkyl, -P(O)(C 1-6 Alkyl) 2 or -P(O)(C 2-6 alkenyl) 2 selected from the group consisting of: R 8 H, -NH-C 1-6 Alkyl, -NH-C 2-6 Alkenyl, -NH-C 3-7 Cycloalkyl, -NH-4 to 8 membered heterocyclyl, -NHC(O)-C 1-6 Alkyl, -NHC(O)-C 2-6 Alkenyl, -NHC(O)-C 3-7 Cycloalkyl, -NHC(O)-4 to 8 membered heterocyclyl, -NHS(O) 2 -C 1-6 Alkyl, or -NHS(O) 2 -C 3-7 cycloalkyl; R 9 H, halogen, C 1-6 Alkyl, -CN, C 1-6 Haloalkyl, —O—C 1-6 Alkyl, —O—C 1-6 Haloalkyl, C 3-7 Cycloalkyl, —O—C 3-7 Cycloalkyl, -NH-C 1-6 Alkyl, -NH-C 2-6 Alkenyl, -NH-C 3-7 Cycloalkyl, -NH-4 to 8 membered heterocyclyl, -NHC(O)-C 1-6 Alkyl, -NHC(O)-C 2-6 Alkenyl, -NHC(O)-C 3-7 Cycloalkyl, -NHC(O)-4 to 8 membered heterocyclyl, -NHS(O) 2 -C 1-6 Alkyl, or -NHS(O) 2 -C 3-7 cycloalkyl; X is -C(R x )= or -N=; Here, R x is H, or R x and R 8 together with the C atom to which they are attached form a 5- to 6-membered heterocyclyl or a 5- to 6-membered heteroaryl; X 1 is -CH(R X1 )- or -N(R X1 )—wherein X 2 is -CH(R X2 )- or -N(R X2 )—wherein Here, R X1 But, H, C 1-6 Alkyl, C 3-7 Cycloalkyl, —O—C 1-6 Alkyl, —O—C 3-7 Cycloalkyl, -NH-C 1-6 Alkyl, -NH-C 3-7 Cycloalkyl, -S(O) 2 -C 1-6 Alkyl, -S(O) 2 -C 3-7 Cycloalkyl, -NHS(O) 2 -C 1-6 Alkyl, -NHS(O) 2 -C 3-7 Cycloalkyl, —C(O)—C 1-6 Alkyl, —C(O)—C 2-6 Alkenyl, —C(O)—C 3-7 Cycloalkyl, -NHC(O)-C 1-6 Alkyl, -NHC(O)-C 3-7 cycloalkyl, or —C(O)-4- to 8-membered heterocyclyl; R X2 But, H, C 1-6 Alkyl, C 3-7 Cycloalkyl, —O—C 1-6 Alkyl, —O—C 3-7 Cycloalkyl, -NH-C 1-6 Alkyl, -NH-C 3-7 Cycloalkyl, —C(O)—C 1-6 Alkyl, —C(O)—C 3-7 Cycloalkyl, -C(O)-4 to 8 membered heterocyclyl, -S(O) 2 -C 1-6 Alkyl, -S(O) 2 -C 3-7 Cycloalkyl, -NHS(O) 2 -C 1-6 Alkyl, -NHS(O) 2 -C 3-7 Cycloalkyl, -NHC(O)-C 1-6 Alkyl, -NHC(O)-C 2-6 Alkenyl, -NHC(O)-C 3-7 cycloalkyl, or -NHC(O)-4- to 8-membered heterocyclyl; 【Chemistry 13】 represents the attachment site to L, A compound represented by the general formula (X) according to claim 1, its pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, solvate, hydrate, or isotopic variant, and mixtures thereof.

3. T is a chemical bond, 【Chemistry 14】 and Where: R 5 is H or C 1-6 is alkyl; R 6 is H or C 1-6 is alkyl; Or, R 5 and R 6 Combined to form C 1-6 Forming an alkylene; 【Chemistry 15】 is the mother nucleus or L 2 represents the connection site to A compound represented by the general formula (X) according to claim 1, its pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, solvate, hydrate, or isotopic variant, and mixtures thereof.

4. When L is -NR-, R 1 and R are both -C(O)N(R N )C(O)-, or -C(C 1-6 alkyl)=C(R N ) forming C(O)—; Where: R N But, C 1-6 Alkyl, or 【Chemistry 16】 selected from the group consisting of: R 11 is H or a halogen; R 12 is H or a halogen; R 13 is H or a halogen; 【Chemistry 17】 represents the connection site, A compound represented by the general formula (X) according to any one of claims 1 to 3, its pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, solvate, hydrate, or isotopic variant, and mixtures thereof.

5. R 1 , R 2 together with the atom to which they are attached form a 5-6 membered heteroaryl; A compound represented by the general formula (X) according to any one of claims 1 to 4, its pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, solvate, hydrate, or isotopic variant, and mixtures thereof.

6. Ring A is 【Chemistry 18】 and Where: R 7 is -Me, cyclopropyl or -P(O)Me 2 selected from the group consisting of: R 8 H, -NHMe, -NHC(O)CH 2 CH 3 or -NH-cyclopropyl; R 9 is H, -F, -Cl, -Br, -Me, -CF 3 , -OMe, -OCF 3 , -CN, -NHC(O)CH 2 CH 3 , -NHS(O) 2 CH 2 CH 3 , -NHC(O)CH=CH 2 or -NH-cyclopropyl; X is -C(R x )= or -N=; Here, R x is H, or R x and R 8 together with the C atom to which they are attached form a 5- to 6-membered heterocyclyl or a 5- to 6-membered heteroaryl; X 1 But -CH 2 - or -N(R X1 )—wherein X 2 is -CH(R X2 )- or -N(R X2 )—wherein Here, R X1 is -C(O)CH 2 CH 3 or -C(O)CH=CH 2 and R X2 is H, -Me, -OMe, -NHMe, -C(O)CH 2 CH 3 , -NHS(O) 2 CH 2 CH 3 or -NHC(O)CH 2 CH 3 and 【Chemistry 19】 represents the site of attachment to L; T, 【Chemistry 20】 and Where: R 5 is -Me; R 6 is -Me; Or, R 5 and R 6 is bonded to -CH 2 CH 2 - forming; 【Chemistry 21】 is the mother nucleus or L 2 represents the connection site to; R 1 is H, -Cl, -Br, -CH 3 , C.F. 3 , cyclopropyl, or -CH=CH 2 selected from the group consisting of: Alternatively, when L is -NR-, R 1 R together with the atoms to which they are attached form an optionally substituted 5-6 membered heterocyclyl, where said substituents are selected from the group consisting of halogen, oxo, -iPr, -Et, phenyl mono- or polysubstituted with halogen; R 2 is H; Or, R 1 , R 2 together with the atom to which they are attached form a 5- to 6-membered heterocyclyl or a 5- to 6-membered heteroaryl; R 3 is selected from the group consisting of H or -OMe; R 4 is H, -F, -Me, -CF 3 or -NHC(O)CH=CH 2 selected from the group consisting of: the other radicals are as defined in claim 1 or 2. A compound represented by the general formula (X) according to claim 1 or 2, its pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, solvate, hydrate, or isotopic variant, and mixtures thereof.

7. L is -NR-, R 1 and R are both -C(O)N(R N )C(O)-, or -C(CH 3 ) = C(R N ) forming C(O)—; Where: R N is -iPr, -Et or 【Chemical 22】 Selected from: R 11 is -Cl, or -Br; R 12 is H or -F; R 13 is H or -F; 【Chemistry 23】 A compound represented by the general formula (X) according to claim 6, wherein represents a connecting site, its pharma- ceutically acceptable salts, enantiomers, diastereomers, racemates, solvates, hydrates, or isotopic variants, and mixtures thereof.

8. The compound represented by the general formula (X) 【Chemistry 24】 【Chemistry 25】 【Chemistry 26】 【Chemical 27】 【Chemistry 28】 【Chemical 29】 【Chemistry 30】 【Chemistry 31】 【Chemistry 32】 【Chemical 33】 【Chemical Formula 34】 【Chemistry 35】 【Chemical 36】 【Chemical 37】 【Chemical Formula 38】 【Chemical Formula 39】 【Chemistry 40】 【Chemistry 41】 【Chemistry 42】 【Chemistry 43】 【Chemistry 44】 【Chemistry 45】 【Chemistry 46】 【Chemistry 47】 having a structure selected from the group consisting of: Here, Y is Z 1 and other radicals are as defined in claims 1 to 7. A compound represented by the general formula (X) according to any one of claims 1 to 7, its pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, solvate, hydrate, or isotopic variant, and mixtures thereof.

9. The compound represented by the general formula (X) is a compound represented by the general formula (I-1), (I-1-A), (I-1-B), (I-1-C), (I-1-D), (I-1-E), (I-1-F), (I-1-G), (I-1-H) or (I-1-I), Where: R 1 is -Cl, -Br, -CF 3 or -CH=CH 2 selected from the group consisting of: R 4 is H or -Me; R 8 H, -NHMe, -NHC(O)CH 2 CH 3 or -NH-cyclopropyl; R 9 is H, -F, -Cl, -Br, -Me, -CF 3 , -OMe, -OCF 3 , -CN, -NHC(O)CH 2 CH 3 , -NHS(O) 2 CH 2 CH 3 or -NHC(O)CH=CH 2 and X is -C(R x )= or -N=; R x is H, or R x and R 8 together with the C atom to which they are attached form pyrazinyl; The other radicals are as defined in claims 1 to 7. A compound represented by the general formula (X) according to claim 8, its pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, solvate, hydrate, or isotopic variant, and mixtures thereof.

10. The compound represented by general formula (X) is a compound represented by general formula (IG), 【Chemistry 48】 Where: Ring A is 【Chemistry 49】 and Where: R 7 -P(O)(C 1-6 Alkyl) 2 and R 8 is H; R 9 H, halogen, C 1-6 Alkyl, -CN or C 1-6 haloalkyl; X is -C(R x ) =; Here, R x is H, or R x and R 8 together with the C atom to which they are attached form a 5-6 membered heteroaryl; R with 1 or 2 Ys Z1 is a C atom optionally substituted with, where R Z1 is H, CN, or halogen; or two R Z1 forms C=O together with Y; L 1 is -C≡C-; L 2 is a chemical bond, -CR # R # '- or -C a R # R # '-C b R # R # '- selected from the group consisting of; Here, C a R # R # ' or C b R # R # ' is O, S(O) p Or N.R. # can be replaced by; E is independently a chemical bond or -C c R # R # '-C d R # R # '-C e R # R # ' selected from the group consisting of; Here, C c R # R # ', C d R # R # ' or C e R # R # ' or C c R # R # ' and C e R # R # ' both O,S(O) p Or N.R. # can be replaced by; p is 0, 1 or 2; R # H, halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl or C 2-6 alkynyl; R # ' is H, halogen, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl or C 2-6 alkynyl; Alternatively, R on an adjacent atom # and R # can form a chemical bond, R on adjacent atoms # ' and R # ' is capable of forming a chemical bond; Alternatively, R on the same or different atoms # and R # ' together form =O; m is 0, 1, 2, 3, 4 or 5; R s1 H, CN, halogens, OH, NH 2 , C 2-6 Alkenyl, C 2-6 Alkynyl, —O—C 1-6 Alkyl, —O—C 1-6 Haloalkyl, -NH-C 1-6 Alkyl, C 1-6 Alkyl, or C 1-6 haloalkyl; s1 is 0, 1, 2 or 3; L is -NR-; where R is H or C 1-6 is alkyl; Z is -C(R 4 ) =; T 【Chemistry 50】 and R 1 H, halogen, cyano, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl or C 2-6 alkynyl; R 2 H, halogen, hydroxyl, amino, C 1-6 Alkyl, or C 1-6 haloalkyl; R 3 H, -O-C 1-6 Alkyl or -O-C 1-6 haloalkyl; R 4 H, halogen, C 1-6 Alkyl, or C 1-6 haloalkyl; When each of said groups is H or a H-containing group, one or more of said H atoms may be replaced by a D atom; A compound represented by the general formula (X) according to claim 8, its pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, solvate, hydrate, or isotopic variant, and mixtures thereof.

11. The compound represented by the general formula (X) is a compound represented by the general formula (I-1-G), (I-1-H), (I-1-H'), or (I-1-H''); 【Chemistry 51】 Where: X is -CH=; R with 1 or 2 Ys Z1 is a C atom optionally substituted with, where R Z1 is H, CN, or halogen; or two R Z1 forms C=O together with Y; R 1 H, halogen, cyano, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl or C 2-6 alkynyl; R 4 H, halogen, C 1-6 Alkyl, or C 1-6 haloalkyl; R 8 is H; R 9 H, halogen, C 1-6 Alkyl, -CN or C 1-6 haloalkyl; L 1 is -C≡C-; L 2 is a chemical bond, -CH 2 - or -CH 2 CH 2 -, wherein one or more H atoms in said groups may be replaced by D atoms; E is -CH 2 CH 2 CH 2 --, --CH 2 CH 2 O-, -CH 2 OCH 2 --, --OCH 2 CH 2 --, --CH 2 CH 2 S-, -CH 2 SCH 2 -or- SCH 2 CH 2 -, and one or more H atoms in said group may be replaced by D atoms; m is 0, 1, 2 or 3, or -L 1 -(E) m -L 2 - chain length is 4-12 bond length; R s1 H, CN, halogens, OH, NH 2 , C 2-6 Alkenyl, C 2-6 Alkynyl, —O—C 1-6 Alkyl, —O—C 1-6 Haloalkyl, -NH-C 1-6 Alkyl, C 1-6 Alkyl, or C 1-6 haloalkyl; s1 is 0, 1 or 2; A compound represented by the general formula (X) according to claim 8, its pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, solvate, hydrate, or isotopic variant, and mixtures thereof.

12. The compound represented by the general formula (X) is a compound represented by the general formula (I-1-G), (I-1-H), (I-1-H'), or (I-1-H''); 【Chemistry 52】 Where: X is -CH=; Y is CH 2 or C=O; R 1 is a halogen; R 4 is H; R 8 is H; R 9 is H; L 1 is -C≡C-; L 2 is a chemical bond, -CH 2 - or -CH 2 CH 2 -, wherein one or more H atoms in said groups may be replaced by D atoms; E is -CH 2 CH 2 CH 2 --, --CH 2 CH 2 O-, -CH 2 OCH 2 --, --OCH 2 CH 2 --, --CH 2 CH 2 S-, -CH 2 SCH 2 -or- SCH 2 CH 2 -, and one or more H atoms in said group may be replaced by D atoms; m is 1, 2 or 3, or -L 1 -(E) m -L 2 - chain length is 5-10 bond lengths; R s1 is H or a halogen; s1 is 0, 1 or 2; A compound represented by the general formula (X) according to claim 8, its pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, solvate, hydrate, or isotopic variant, and mixtures thereof.

13. The compound represented by the general formula (X) is a compound represented by the general formula (I-1-I), (I-1-I'), (I-1-I''), or (I-1-I'''), 【Chemistry 53】 Where: R with 1 or 2 Ys Z1 is a C atom optionally substituted with, where R Z1 is H, CN, or halogen; or two R Z1 and Y together form C=O; 1 H, halogen, cyano, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl or C 2-6 alkynyl; R 4 H, halogen, C 1-6 Alkyl, or C 1-6 haloalkyl; R 9 H, halogen, C 1-6 Alkyl, -CN or C 1-6 haloalkyl; L 1 is -C≡C-; L 2 is a chemical bond, -CH 2 - or -CH 2 CH 2 - selected from the group consisting of; E is -CH 2 CH 2 CH 2 --, --CH 2 CH 2 O-, -CH 2 OCH 2 --, --OCH 2 CH 2 --, --CH 2 CH 2 S-, -CH 2 SCH 2 -or- SCH 2 CH 2 - selected from the group consisting of; m is 1 or 2, or -L 1 -(E) m -L 2 - chain length is 4-14 bond lengths; R s1 H, CN, halogens, OH, NH 2 , C 2-6 Alkenyl, C 2-6 Alkynyl, —O—C 1-6 Alkyl, —O—C 1-6 Haloalkyl, -NH-C 1-6 Alkyl, C 1-6 Alkyl, or C 1-6 haloalkyl; s1 is 0, 1 or 2; A compound represented by the general formula (X) according to claim 8, its pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, solvate, hydrate, or isotopic variant, and mixtures thereof.

14. The compound represented by the general formula (X) is a compound represented by the general formula (I-1-I), (I-1-I'), (I-1-I''), or (I-1-I'''), 【Chemical 54】 Where: Y is CH 2 and R 1 is a halogen; R 4 But, C 1-6 Alkyl, or C 1-6 haloalkyl; R 9 is H; L 1 is -C≡C-; L 2 is a chemical bond, -CH 2 - or -CH 2 CH 2 - selected from the group consisting of; E is -CH 2 CH 2 CH 2 - and m is 1 or 2, or -L 1 -(E) m -L 2 - the chain length is less than 10 bond lengths; R s1 is H or a halogen; s1 is 0, 1 or 2; A compound represented by the general formula (X) according to claim 8, its pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, solvate, hydrate, or isotopic variant, and mixtures thereof.

15. The compound represented by the general formula (X) is a compound represented by the general formula (I-2-I), (I-2-I'), (I-2-I''), or (I-2-I'''), 【Chemistry 55】 Where: R with 1 or 2 Ys Z1 is a C atom optionally substituted with, where R Z1 is H, CN, or halogen; or two R Z1 and Y together form C=O; 1 H, halogen, cyano, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl or C 2-6 alkynyl; R 4 H, halogen, C 1-6 Alkyl, or C 1-6 haloalkyl; R 9 H, halogen, C 1-6 Alkyl, -CN or C 1-6 haloalkyl; L 1 is -C≡C-; L 2 is a chemical bond, -CH 2 - or -CH 2 CH 2 - selected from the group consisting of; E is -CH 2 CH 2 CH 2 --, --CH 2 CH 2 O-, -CH 2 OCH 2 --, --OCH 2 CH 2 --, --CH 2 CH 2 S-, -CH 2 SCH 2 -or- SCH 2 CH 2 - and m is 1 or 2, or -L 1 -(E) m -L 2 - the chain length is less than 10 bond lengths; R s1 H, CN, halogens, OH, NH 2 , C 2-6 Alkenyl, C 2-6 Alkynyl, —O—C 1-6 Alkyl, —O—C 1-6 Haloalkyl, -NH-C 1-6 Alkyl, C 1-6 Alkyl, or C 1-6 haloalkyl; s1 is 0, 1 or 2; A compound represented by the general formula (X) according to claim 8, its pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, solvate, hydrate, or isotopic variant, and mixtures thereof.

16. The compound represented by the general formula (X) is a compound represented by the general formula (I-2), (I-2-A), (I-2-B), (I-2-C), (I-2-D), (I-2-E), (I-2-F), (I-2-G), (I-2-H) or (I-2-I), Where: R 1 is -Cl, -Br or -CH=CH 2 and R 4 is H or -Me; R 8 H, -NHMe, -NHC(O)CH 2 CH 3 or -NH-cyclopropyl; R 9 is H, -F, -Cl, -Br, -Me, -CF 3 , -OMe, -OCF 3 , -CN, -NHC(O)CH 2 CH 3 , -NHS(O) 2 CH 2 CH 3 or -NHC(O)CH=CH 2 and X is -C(R x ) =; R x is H, or R x and R 8 together with the C atom to which they are attached form pyrazinyl; The other radicals are as defined in claims 1 to 7. A compound represented by the general formula (X) according to claim 8, its pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, solvate, hydrate, or isotopic variant, and mixtures thereof.

17. The compound represented by the general formula (X) is a compound represented by the general formula (I-3), (I-3-A), (I-3-B), (I-3-C), (I-3-D), (I-3-E), (I-3-F), (I-3-G) or (I-3-H), Where: R 1 is H, -Cl or -CH=CH 2 and R 4 -NHC(O)CH=CH 2 and R 5 is -Me; R 6 is -Me; Or, R 5 and R 6 is bonded to -CH 2 CH 2 - forming; R 7 is -Me or cyclopropyl; The other radicals are as defined in claims 1 to 7. A compound represented by the general formula (X) according to claim 8, its pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, solvate, hydrate, or isotopic variant, and mixtures thereof.

18. The compound represented by the general formula (X) is a compound represented by the general formula (I-4), (I-4-A), (I-4-B), (I-4-C), (I-4-D), (I-4-E), (I-4-F), (I-4-G) or (I-4-H), Where: R 1 Ga-CF 3 and R 9 is H, -F, -Cl, -Br, -Me, -CF 3 , -OMe, -OCF 3 , -CN, -NHC(O)CH=CH 2 or -NH-cyclopropyl; The other radicals are as defined in claims 1 to 7. A compound represented by the general formula (X) according to claim 8, its pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, solvate, hydrate, or isotopic variant, and mixtures thereof.

19. The compound represented by the general formula (X) is a compound represented by the general formula (I-6), (I-6-A), (I-6-B), (I-6-C), (I-6-D), (I-6-E), (I-6-F), (I-6-G) or (I-6-H), Where: L is -O- or -NH-; R 3 is H or -OMe; R 4 is H or -F; R 9 Ga-CF 3 , -OMe, -OCF 3 , -CN, -NHC(O)CH 2 CH 3 or -NHC(O)CH=CH 2 and The other radicals are as defined in claims 1 to 7. A compound represented by the general formula (X) according to claim 8, its pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, solvate, hydrate, or isotopic variant, and mixtures thereof.

20. The compound represented by the general formula (X) is a compound represented by the general formula (I-5), (I-5-A), (I-5-B), (I-5-C), (I-5-D), (I-5-E), (I-5-F), (I-5-G) or (I-5-H), Where: Ring A is an optionally substituted group as follows: 3-7 Cycloalkyl or C 6-10 aryl, where the substituents are -F, -Cl, -Br, -Me, -OMe, -CF 3 , -OCF 3 , -CN, -NHMe, -P(O)Me 2 , -NHC(O)CH 2 CH 3 , -C(O)CH=CH 2 , -NHS(O) 2 CH 2 CH 3 , -NH-cyclopropyl, -NHC(O)CH=CH 2 or -C(O)CH 2 CH 3 or Ring A is selected from the group consisting of: 【Chemistry 56】 and Where: R 9 is H, -F, -Cl, -Br, -Me, -CF 3 , -OMe, -OCF 3 , -CN, -NHC(O)CH 2 CH 3 , -NHS(O) 2 CH 2 CH 3 or -NHC(O)CH=CH 2 and X 1 But -CH 2 - or -N(R X1 )—wherein X 2 is -CH(R X2 )- or -N(R X2 )—wherein Where: R X1 is -C(O)CH 2 CH 3 or -C(O)CH=CH 2 and R X2 H, -Me, -OMe, -NHMe, -NHS(O) 2 CH 2 CH 3 , -C(O)CH 2 CH 3 or -NHC(O)CH 2 CH 3 and 【Chemistry 57】 represents the connection site; R 1 R together with the atoms to which they are attached form an optionally substituted 5-6 membered heterocyclyl, where said substituents are selected from the group consisting of halogen, oxo, -iPr, -Et, phenyl mono- or polysubstituted with halogen; R 3 is H or -OMe; R 4 is H or -Me; The other radicals are as defined in claims 1 to 7. A compound represented by the general formula (X) according to claim 8, its pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, solvate, hydrate, or isotopic variant, and mixtures thereof.

21. R 1 and R are both -C(O)N(R N )C(O)-, or -C(CH 3 ) = C(R N ) forming C(O)—; Where: R N is -iPr, -Et or 【Chemistry 58】 selected from the group consisting of: R 11 is -Cl, -Br; R 12 is H or -F; R 13 is H or -F; 【Chemical Formula 59】 represents the connection site, A compound represented by the general formula (X) according to claim 20, its pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, solvate, hydrate, or isotopic variant, and mixtures thereof.

22. The compound represented by the general formula (X) is a compound represented by the general formula (I-5-1) or (I'-5-1), 【Chemistry 60】 Where: R 9 -NHC(O)CH 2 CH 3 or -NHC(O)CH=CH 2 and R N is -iPr or -Et; The other radicals are as defined in claims 1 to 7. A compound represented by the general formula (X) according to claim 8, its pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, solvate, hydrate, or isotopic variant, and mixtures thereof.

23. The compound represented by the general formula (X) is a compound represented by the general formula (I-5-2) or (I'-5-2), 【Chemistry 61】 Where: R 3 is H or -OMe; R 4 is H or -Me; The other radicals are as defined in claims 1 to 7. A compound represented by the general formula (X) according to claim 8, its pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, solvate, hydrate, or isotopic variant, and mixtures thereof.

24. The compound represented by the general formula (X) is a compound represented by the general formula (I-5-3) or (I'-5-3), 【Chemistry 62】 Where: X 1 But -CH 2 - or -N(R X1 )—wherein X 2 is -CH(R X2 )- or -N(R X2 )—wherein Where: R X1 -C(O)CH 2 CH 3 and R X2 is H, -Me, -OMe, -NHMe, -C(O)CH 2 CH 3 , -NHS(O) 2 CH 2 CH 3 or -NHC(O)CH 2 CH 3 and R 11 is -Cl or -Br; R 12 is H or -F; R 13 is H or -F; The other radicals are as defined in claims 1 to 7. A compound represented by the general formula (X) according to claim 8, its pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, solvate, hydrate, or isotopic variant, and mixtures thereof.

25. 【Chemical 63】 but 【Chemistry 64】 【Chemistry 65】 selected from the group consisting of: One or more H atoms in the above groups may be replaced by D atoms; A compound represented by the general formula (X) according to any one of claims 1 to 7, its pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, solvate, hydrate, or isotopic variant, and mixtures thereof.

26. L 2 are independently a chemical bond, -O-, -S-, -S(O)-, -S(O) 2 -, -S(O)(=NH)-, -S(O)(=NMe)-, 【Chemistry 66】 -NH-, -N(Me)-, 【Chemistry 67】 -N(CF 3 )-、-CH 2 -、-CH(OMe)-、-CH(Cl)-、-CH(F)-、-CF 2 -、-CH(CF 3 )-、-C(O)-、-CH 2 CH 2 -、-CH=CH-、-C≡C-、-OCH 2 -、-CH 2 O-、-SCH 2 -、-CH 2 S-、-S(O)CH 2 -、-CH 2 S(O)-、-S(O) 2 CH 2 -、-CH 2 S(O) 2 -、-NHCH 2 -、-N(Me)CH 2 -、-CH 2 H 2 N(Me)-、-C(O)CH 2 -、-CH 2 C(O)-、-C(O)CMe 2 -、-CMe 2 C(O)-、-OC(O)-、-C(O)O-、-SC(O)-、 -C(O)S-、-NHC(O)-、-N(Me)C(O)-、-C (O)NH-、-C(O)N(Me)-、-S(O)=NH-、- NH=S(O)-、-N=S(O)Me-、-S(O)Me=N-、 【Chemistry 68】 selected from the group consisting of: One or more H atoms in the above groups may be replaced by D atoms; A compound represented by the general formula (X) according to any one of claims 1 to 7, its pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, solvate, hydrate, or isotopic variant, and mixtures thereof.

27. E is a chemical bond, -CH 2 CH 2 CH 2 -, -CH 2 CH=CH-, -CH=CHCH 2 -, -CH 2 C≡C-, -C≡CCH 2 -, -CH 2 CH 2 C(O)-, -CH 2 C(O)CH 2 -, -C(O)CH 2 CH 2 -, -CH 2 CH 2 S(O) 2 -, -CH 2 S(O) 2 CH 2 -, -S(O) 2 CH 2 CH 2 -, -C(O)CH=CH-, -C(O)C≡C-, -CH 2 CH 2 O-, -CH 2 OCH 2 -, -OCH 2 CH 2 -, -CH 2 CH 2 S-, -CH 2 SCH 2 -, -SCH 2 CH 2 -, -C(O)CH 2 O-, -OCH 2 C(O)-, -CH 2 C(O)O-, -C(O)CH 2 S-, -SCH 2 C(O)-, -CH 2 C(O)S-, -OC(O)CH 2 -, -C(O)OCH 2 -, -CH 2 OC(O)-, -SC(O)CH 2 -, -C(O)SCH 2 -, -CH 2 SC(O)-, -CH 2 CH 2 NH-, -CH 2 NHCH 2 -, -NHCH 2 CH 2 -、-CH 2 CH 2 NMe-、-CH 2 NMeCH 2 -、-NMeCH 2 CH 2 -、-C(O)CH 2 NH-、-NHCH 2 C(O)-、-CH 2 C(O)NH-、-NHC(O)CH 2 -、-C(O)NXCH 2 -、-CH 2 NXC(O)-、 【Chemistry 69】 selected from the group consisting of: Alternatively, two E units or two E' units are -CH 2 CH 2 OCH 2 CH 2 --, --OCH 2 CH 2 CH 2 CH 2 --, --CH 2 CH 2 CH 2 CH 2 O-, 【Chemistry 70】 can be formed; One or more H atoms in the above groups may be replaced by D atoms; A compound represented by the general formula (X) according to any one of claims 1 to 7, its pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, solvate, hydrate, or isotopic variant, and mixtures thereof.

28. General formulas (I-2-I), (I-2-I'), (I-2-I''), and (I-2-I''') 【Chemistry 71】 [In the formula, R with 1 or 2 Ys Z1 is a C atom optionally substituted with, where R Z1 is H, CN, or halogen; or two R Z1 and Y together form C=O; R 1 H, halogen, cyano, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl or C 2-6 alkynyl; R 4 H, halogen, C 1-6 Alkyl, or C 1-6 haloalkyl; R 9 H, halogen, C 1-6 Alkyl, -CN or C 1-6 haloalkyl; L 1 But -CH 2 CH 2 -, -CH=CH-, -C≡C-, or -OCH 2 - selected from the group consisting of; L 2 is a chemical bond, -CH 2 - or -CH 2 CH 2 - selected from the group consisting of; E is -CH 2 CH 2 CH 2 --, --CH 2 CH 2 O-, -CH 2 OCH 2 --, --OCH 2 CH 2 --, --CH 2 CH 2 S-, -CH 2 SCH 2 -or- SCH 2 CH 2 - and m is 1 or 2, or -L 1 -(E) m -L 2 - the chain length is less than 10 bond lengths; R s1 H, CN, halogens, OH, NH 2 , C 2-6 Alkenyl, C 2-6 Alkynyl, —O—C 1-6 Alkyl, —O—C 1-6 Haloalkyl, -NH-C 1-6 Alkyl, C 1-6 Alkyl, or C 1-6 haloalkyl; s1 is 0, 1 or 2. Compounds of the formula (I) and their pharma- ceutically acceptable salts, enantiomers, diastereomers, racemates, solvates, hydrates, or isotopic variants, and mixtures thereof.

29. The compound is 【Chemical Formula 72】 【Chemical 73】 【Chemical 74】 【Chemistry 75】 【Chemical 76】 【Chemical 77】 【Chemical Formula 78】 【Chemical 79】 【Chemistry 80】 【Chemistry 81】 【Chemistry 82】 【Chemistry 83】 【Chemistry 84】 【Chemistry 85】 【Chemistry 86】 【Chemistry 87】 【Chemistry 88】 【Chemistry 89】 A compound selected from: its pharma- ceutically acceptable salts, enantiomers, diastereomers, racemates, solvates, hydrates, or isotopic variants, and mixtures thereof.

30. A compound according to any one of claims 1 to 29, or a pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, solvate, hydrate, or isotopic variant thereof; and a pharma- ceutically acceptable excipient; A pharmaceutical composition which may optionally further comprise other therapeutic agents.

31. 30. A pharmaceutical composition comprising a compound according to any one of claims 1 to 29, or a pharma- ceutically acceptable salt, enantiomer, diastereomer, racemate, solvate, hydrate, or isotopic variant thereof, for treating and / or preventing a disease mediated by EGFR and / or ALK kinase.

32. 32. The pharmaceutical composition of claim 31 , wherein the disease mediated by EGFR and / or ALK kinase comprises cancer.

33. 33. The pharmaceutical composition of claim 32, wherein the cancer is selected from ovarian cancer, cervical cancer, colorectal cancer, breast cancer, pancreatic cancer, glioma, glioblastoma, melanoma, prostate cancer, leukemia, lymphoma, non-Hodgkin's lymphoma, gastric cancer, lung cancer, hepatocellular carcinoma, gastric cancer, gastrointestinal stromal tumor (GIST), thyroid cancer, cholangiocarcinoma, endometrial cancer, renal cancer, anaplastic large cell lymphoma, acute myeloid leukemia (AML), multiple myeloma, melanoma, and mesothelioma.

Citation Information

Patent Citations

  • Pyrimido pyrimidine dione derivative as EGFR inhibitor and application thereof

    CN105985342A

  • Compound for inhibiting and degrading tyrosine protein kinase ALK

    CN109422733A

  • ALK (anaplastic lymphoma kinase) protein degradation agent and anti-tumor application thereof

    CN109912655A

  • Compound for targeted ubiquitin degradation of EGFR protein as well as pharmaceutical composition and application thereof

    CN109928956A

  • ALK-targeted PROTAC and application thereof

    CN110684015A